

Chemical Aspects of Human and Environmental Overload with Fluorine

Jianlin Han, Loránd Kiss,* Haibo Mei, Attila Márió Remete, Maja Ponikvar-Svet,* Daniel Mark Sedgwick, Raquel Roman, Santos Fustero,* Hiroki Moriwaki, and Vadim A. Soloshonok*



Cite This: *Chem. Rev.* 2021, 121, 4678–4742



Read Online

ACCESS |

Metrics & More

Article Recommendations

ABSTRACT: Over the last 100–120 years, due to the ever-increasing importance of fluorine-containing compounds in modern technology and daily life, the explosive development of the fluorochemical industry led to an enormous increase of emission of fluoride ions into the biosphere. This made it more and more important to understand the biological activities, metabolism, degradation, and possible environmental hazards of such substances. This comprehensive and critical review focuses on the effects of fluoride ions and organofluorine compounds (mainly pharmaceuticals and agrochemicals) on human health and the environment. To give a better overview, various connected topics are also discussed: reasons and trends of the advance of fluorine-containing pharmaceuticals and agrochemicals, metabolism of fluorinated drugs, withdrawn fluorinated drugs, natural sources of organic and inorganic fluorine compounds in the environment (including the biosphere), sources of fluoride intake, and finally biomarkers of fluoride exposure.



CONTENTS

1. Introduction	4679	3.1.6. Fluorination- and Mechanism-Based Inhibitors. Highlighted: 5-Fluorouracil and Trifluridine	4692
2. Fluorine in Biosphere	4680	3.2. Agrochemicals	4693
2.1. General Properties of Fluorine and Its Xenobiotic Nature	4680	3.2.1. Fluorination and Degradation	4693
2.2. Fluoroacetate	4681	3.2.2. Fluorination and Activity	4693
2.3. (2 <i>R</i> ,3 <i>R</i>)-Fluorocitrate	4682	3.2.3. Fluorination and Lipophilicity	4694
2.4. ω -Fluorinated Fatty Acids	4684	3.3. Observable Trends Related to Fluorinated Bioactive Compounds	4694
2.5. (2 <i>S</i> ,3 <i>S</i>)-4-Fluorothreonine	4684	3.3.1. Pharmaceuticals	4694
2.6. (2 <i>R</i> ,3 <i>S</i> ,4 <i>S</i>)-5-Fluoro-2,3,4-trihydroxypentanoic Acid	4684	3.3.2. Agrochemicals	4701
2.7. Nucleocidin and Related Fluoroorganic Compounds	4685	4. Fluorine in the Environment	4701
2.8. Miscellaneous Information	4686	4.1. Fluorine in the Lithosphere, Air, and Water	4701
3. Current Trends in Fluorine-Containing Pharmaceuticals and Agrochemicals	4687	4.1.1. Lithosphere	4701
3.1. Advantages of Fluorinated Drug Molecules	4687	4.1.2. Air	4702
3.1.1. Fluorination and Metabolism. Highlighted: Ezetimibe, Celecoxib, and Alpelisib	4687	4.1.3. Water	4702
3.1.2. Fluorination and Potency. Highlighted: Type 2 Statins, Sitagliptin and Alpelisib	4688	4.2. Fluorine in Drinking Water, Food, and Beverages and Dietary Fluoride Supplements and Dental Products	4702
3.1.3. Fluorination and Bioavailability. Highlighted: Sitagliptin	4689	4.2.1. Drinking Water	4702
3.1.4. Isosteric Replacement by Fluorine or Fluorinated Moieties. Highlighted: Odanacatib	4691	4.2.2. Food and Beverages	4702
3.1.5. Conformational Changes Triggered by Fluorine Incorporation	4691	4.2.3. Salt, Milk, and Dietary Supplements	4703

Received: November 29, 2020

Published: March 16, 2021



4.2.4. Dental Products	4703
4.3. Adequate Intake of Fluoride/Fluorine	4703
4.4. Daily Intake of Fluorine	4703
4.4.1. Fluorine Intake in Children	4704
4.4.2. Fluorine Intake in Adults	4704
5. Metabolism of Fluorine-Containing Drugs	4705
5.1. Metabolic Differences between Fluorinated and Nonfluorinated Compounds	4705
5.2. Loss of Fluoride and the Formation of Toxic Metabolites	4706
5.2.1. Via Conjugation and Enzymatic Transformations	4706
5.2.2. Organophosphorus Compounds	4709
5.2.3. Fluorinated Anesthetics	4710
5.3. Environmental Factors and Bioaccumulation of Fluorine-Containing Compounds	4711
5.3.1. Chlorofluorocarbons (CFCs) and Hydrofluorocarbons (HFCs)	4712
5.3.2. Perfluoroalkyl Substances (PFASs)	4712
6. Fluorine-Containing Pharmaceuticals Withdrawn from the Market	4713
6.1. Aromatic Substitution	4713
6.1.1. Aromatic Fluoro-Substituted Compounds	4713
6.1.2. Aromatic Trifluoromethyl-Substituted Compounds	4718
6.2. Aliphatic Substitution	4719
6.2.1. Odanacatib	4719
6.2.2. Begacestat	4720
7. Fluoride Toxicity	4721
7.1. Digestion and Absorption, Distribution, and Elimination of Fluoride	4721
7.1.1. Fluoride Absorption	4721
7.1.2. Fluoride in Plasma	4721
7.1.3. Distribution and Elimination	4721
7.2. Mechanisms of Fluoride Cytotoxicity	4721
7.3. Toxicity in Relation to the Exposure to Fluoride	4722
7.3.1. Acute Toxicity	4722
7.3.2. Chronic Toxicity	4722
7.4. Mitigation of Fluoride Toxicity	4725
8. Biomarkers of Fluoride Exposure and Their Status	4725
8.1. Contemporary Biomarkers	4725
8.2. Recent Biomarkers	4726
8.3. Historic Biomarkers	4726
9. Conclusion	4726
Author Information	4727
Corresponding Authors	4727
Authors	4727
Notes	4728
Biographies	4728
Acknowledgments	4728
Abbreviations	4729
References	4729

1. INTRODUCTION

The aim of the current review is to give a comprehensive, authoritative, critical, and highly appealing account of general interest to the chemistry community. Namely, it deals with the emerging issues of a high socioeconomic impact—the rapidly growing number of fluorine-containing pharmaceuticals and

agrochemicals and their effects on human health and the environment.

The fluorochemical industry has greatly expanded in the last 100–150 years because numerous fluorinated products have shown their decisive importance in many areas linked to our daily life.^{1–4} Hydrogen fluoride, the key intermediate, is prepared from fluorospar (CaF₂) via treatment with sulfuric acid, and it is mainly used to synthesize cryolite (for aluminum production) and fluorocarbons (mainly used as refrigerants). Within fluorocarbons, initially, production of chlorofluorocarbons (CFCs) was the most prominent. However, the discovery of the detrimental effect of CFCs on the ozone layer led to their phase out (Montreal Protocol, 1987), and they were replaced with hydrochlorofluorocarbons (HCFCs) and hydrofluorocarbons (HFCs). The former are mainly temporary CFC replacements, while the latter are seen as long-term alternatives (although their greenhouse effects also raised concerns).¹ The synthesis of fluorinating reagents and fluorinated building blocks for organic synthesis as well as the production of elemental fluorine, fluoropolymers (such as Teflon), and perfluorinated compounds are minor but important applications of HF.^{1–5} Furthermore, elemental fluorine is essential for the nuclear industry (enrichment of ²³⁵U is achieved by gas centrifugation of uranium hexafluoride, which is obtained via treatment of UF₄ with F₂ gas).^{6,7} Based on their exceptional optical properties, some inorganic fluorides have small scale but important applications (such as optics for deep ultraviolet photolithography used in the manufacture of microelectronics).⁵

Fluorine-containing organic compounds not only are useful in scientific research^{8–11} but also have high practical importance. Hydrofluorocarbon refrigerants were already mentioned above. Fluorinated liquid crystal monomers are widely used in LCD devices.³ Fluoropolymers have many attractive properties (chemical resistance, thermal and weather stability, flame resistance, good mechanical properties, and high dielectric breakdown voltage) which resulted in their widespread use (e.g., in the electrical, chemical, automotive, and medicinal industry).⁴ Fluorine also plays a critical role in the development of modern pharmaceuticals because introduction of fluorine often enhances the bioactivity and metabolic stability.^{12–14} Currently, fluorine-containing compounds constitute around 25% of small-molecule drugs in the clinic, and 25–30% of newly introduced drugs contain fluorine atom(s).^{13–15} Among the best selling and most prescribed drugs, fluorinated preparations are even more prevalent.^{16,17} The current trend suggests that in the next 10–15 years fluorinated drugs will dominate the pharmaceutical market. An even more profound fluorine trend exists in the agricultural industry since upon “fluorination” different physicochemical properties of active ingredients like lipophilicity, water solubility, and metabolic stability could be fine-tuned.^{18–20} Fluorination of drugs and agrochemicals is well-rationalized, and most definitely, it is very beneficial, providing more potent life-saving medicines and selective crop-protection agents.^{12–14,18} This trend is very welcomed and of critical importance for our aging and overpopulated modern western society. Synthesis of ¹⁸F-containing radiopharmaceuticals is also an emerging area.^{21,22}

However, our meticulous review of the relevant literature has pointed to an inherent potential problem. Although fluorine is the 24th most abundant element in the universe and the 13th most common element in the earth’s crust (0.059% by weight),²³ it is virtually absent from the biosphere.^{24,25} The underlying obvious reasons are as follows: (i) the minerals

fluorspar (CaF_2), fluorapatite [$\text{Ca}_5(\text{PO}_4)_3\text{F}$], and cryolite (Na_3AlF_6), the three richest natural sources of fluorine, are practically insoluble in water and, therefore, are out of the biological realm;²⁶ (ii) the high oxidation potential of fluorine (-3.06 V, much higher than that of the rest of halogens) makes it impossible to form the fluorine analogues of hypohalites or other electrophilic halogen species involved in most of the known enzymatic halogenation processes; and (iii) finally, the high hydration energy of the fluoride ion (490 kJ mol⁻¹) renders it a very poor nucleophile in the aqueous/biological environment, and therefore, it is unsuitable to form organic C–F bonds via typical nucleophilic substitutions.^{24,25}

Thus, fluoride is xenobiotic, and the effects of fluoride and fluoroorganic compounds on the biosphere and on processes essential to human life and health were not thoroughly studied in the past. However, as a consequence of the growth of the fluorochemical industry and the increasing role of fluorine in the development of new pharmaceuticals and agrochemicals, the emission of fluoride and organofluorine compounds greatly increased, and efforts to understand the physiological effects of these substances have been renewed.

Approximately half of the fluoride intake is quickly deposited in calcified tissues like bones and teeth. Its release is a much slower process; that is, fluoride can accumulate in the body.²⁷ It has long been known that excess fluoride intake can result in dental fluorosis in children or skeletal fluorosis in children and adults alike.²⁷ More recent studies uncovered that fluoride can cause numerous other health problems, such as impaired thyroid and endocrine system function or developmental neurotoxicity.²⁸ It is quite unnerving that aluminum(III) fluorocomplexes can activate G-protein-coupled receptors at much lower concentrations than either Al^{3+} or F^- acting alone.²⁹ Important sources of fluoride pollution are the aluminum industry and phosphate fertilizers.^{1,30} The latter often have considerable fluoride content (1–3% in the case of superphosphate), which is released directly into the soil. Although fluoride is strongly bound in soils, it can still endanger grazing livestock.³⁰ Community water fluoridation, which has a high influence on fluoride intake, is one of the most controversial topics in medicine.²⁸

The increased usage of polyfluoroalkyl substances, fluorine-containing drugs, and fluorinated agrochemicals generated new dangers. On one hand, metabolism of fluorinated compounds may produce toxic fluorine-containing metabolites (e.g., fluoride or fluoroacetate), leading to increased concentrations of fluoride in body fluids and tissues. It is a major concern, in particular, because fluorinated drugs are in the most prescribed medications, and an average patient may take several fluorine-containing drugs at the same time. There are documented cases of fluorinated drugs whose side effects are at least partially based on such toxic fluoro-metabolites (for example, α -fluoro- β -alanine and fluoroacetate in the case of the anticancer drug 5-fluorouracil).³¹ Sometimes, these problems resulted in withdrawal or restriction (a good example is the heavily fluorinated anesthetic agent methoxyflurane).³² On the other hand, many fluorinated entities, especially perfluorinated ones, are highly resistant to degradation, leading to their accumulation in the environment.³³ Currently, residues of various fluorinated organic compounds (polyfluoroalkyl substances, drugs, and agrochemicals) can be detected in surface waters and biological samples.^{33–36} The history of various polychlorinated compounds (DDT, γ -hexachlorocyclohexane, polychlorinated bi-

phenyls, etc.) clearly illustrates the dangers of such persistent organic pollutants.³⁷

Until now, environmental and healthcare policies concerning fluorine-containing compounds mainly focused on limiting emissions from the aluminum industry, the ban of ozone-depleting CFCs, and keeping the fluoride content in drinking water below the accepted thresholds.^{1,27} However, with the emergence of organofluorine compounds, efforts should be taken to carefully study the metabolism of various fluorine-containing groups and substances in order to identify derivatives of better biological tolerance (posing no risk to human health and the environment) and those which are problematic. The first steps are already in progress (perfluorooctanesulfonic acid and perfluorooctanoic acid were phased out because of their harmful effects), but there is much work to be done.³³

The goal of this review is to raise these issues and provide a comprehensive discussion of all relevant data available in the literature. Section 2 covers the occurrence and available biosynthetic data of fluorine-containing natural products. Section 3 describes the beneficial effects of fluorine incorporation into drugs and agrochemicals in detail, and it includes a statistical analysis of recent fluorination trends of these compound families. Section 4 focuses on environmental sources of fluorine-containing compounds and their daily intake. Section 5 reviews available data on the metabolism of organofluorine compounds and environmental concerns related to these substances. In Section 6, dangers of fluorine-containing compounds are illustrated using withdrawn fluorinated drugs as examples. Section 7 summarizes the reasons behind the poisonous nature of fluoride and the most common consequences of acute and chronic fluoride toxicity. Finally, Section 8 discusses biomarkers of recent and historic fluoride exposure.


2. FLUORINE IN BIOSPHERE

2.1. General Properties of Fluorine and Its Xenobiotic Nature


Fluorine, the 13th most common element in the earth's crust (0.059% by weight), is the most abundant halogen on Earth. Chlorine is the 19th; bromine is the 49th; and iodine is the 62th on the list.²³ Because of its extreme electronegativity, fluorine is highly reactive and occurs in nature almost exclusively as fluoride salts.^{38,39}

Despite its abundance, fluorine is rarely incorporated into natural products. Among the more than 5000 known naturally produced halogen-substituted compounds, only a handful contain fluorine.^{24,25} Various reasons are responsible for this phenomenon. For example, the amount of bioavailable fluoride is greatly limited (e.g., seawater contains only 1.3 mg L⁻¹ of F^- in contrast to 19 g L⁻¹ of Cl^-) because the most common fluoride sources, fluorite (CaF_2), fluorapatite [$\text{Ca}_5(\text{PO}_4)_3\text{F}$], and cryolite (Na_3AlF_6), are insoluble in water.²⁶ It is also important to note that the high electronegativity of fluorine prohibits oxidation of fluoride ions under biological conditions, excluding radical or electrophilic fluorination pathways. The only remaining possibility, nucleophilic fluorination, is hindered by the very strong hydration of F^- , which greatly reduces its nucleophilicity.^{24,25}

Despite the above difficulties, some organisms still found ways to produce fluorinated molecules. This section will discuss these compounds, their biological activity, and information available about their biosynthesis.

Scheme 1. Biosynthesis of Fluoroacetate in *Streptomyces cattleya*

Scheme 2. Structure of the Fluorinase Enzyme (Left) and Its Active Site (Right)





2.2. Fluoroacetate

Fluoroacetate (6, Scheme 1) was first isolated in 1943 from *Dichapetalum cymosum*, a poisonous plant found in South Africa. Its leaves contain up to 250 mg kg⁻¹ of fluoroacetate, which is the main component responsible for its toxicity. Since that time, more than 40 plant species were found with high fluoroacetate content. These include numerous *Dichapetalum* species, several *Amorima* species, *Palicourea marcgravii* and *P. aeneofusca*, *Gastrolobium grandiflorum* and *G. parviflorum*, *Arrabidaea bilabiata*, *Spondianthus preussii*, and *Cyamopsis tetragonolobus*. The record is held by *D. braunii* seeds (8000 mg kg⁻¹ of fluoroacetate). These plants grow in tropical and semitropical areas of Africa, Australia, and South America. Their fluoroacetate accumulation is possibly related to a defense strategy against herbivores. Interestingly, nontoxic levels (trace amounts) of fluoroacetate (and the related (2*R*,3*R*)-fluorocitrate, see below) can be found in some edible plants too (for example, tea leaves, soya bean, oatmeal). This suggests that the ability to produce fluoroacetate is widespread among plants, and a limited number of species were capable of greatly amplifying this ability. It is worth mentioning that the mechanism of fluoroacetate production in plants is still unknown.^{26,40}

Furthermore, some microorganisms also produce fluoroacetate. An important example is *Streptomyces cattleya*. Its ability to produce fluoroacetate and (2*S*,3*S*)-4-fluorothreonine was discovered in 1986. The whole biosynthetic pathway was uncovered, supported by full genomic sequencing. The first step in the fluorometabolite synthesis by *S. cattleya* is the reaction of the F⁻ ion with S-adenosylmethionine 1 to produce 5'-fluoro-5'-deoxyadenosine 2.^{24,25} This reaction is catalyzed by the fluorinase enzyme, which was isolated, and its crystal structure was determined. Three monomeric units form a trimer, and two trimers then form the final hexameric structure (Scheme 2). The monomeric unit represented a new protein fold different from any previously solved analogues. Fluorinase increases the nucleophilicity of fluoride by its desolvation (hydrogen bond donor groups of the enzyme replace water molecules around fluoride; see Scheme 2).⁴¹ Isotopic labeling confirmed that the catalyzed nucleophilic fluorination reaction follows an S_N2 mechanism with configurational inversion.⁴² 5'-Fluoro-5'-deoxyadenosine 2 is then converted to 5-fluoro-5-deoxy-D-ribose-1-phosphate 3 by a purine nucleoside phosphorylase. Subsequent enzymatic isomerization produces (3*R*,4*S*)-5-fluoro-5-deoxy-D-ribose-1-phosphate 4, which is then cleaved by an aldolase to produce fluoroacetaldehyde 5 and followed by oxidation with a NAD⁺-dependent aldehyde dehydrogenase to

Scheme 3. Transformation of Fluoroacetate in the Citrate Cycle

Scheme 4. Naturally Produced ω -Fluorinated Fatty Acids

fluoroacetate **6** (Scheme 1). Later, genetic sequencing utilizing *S. cattleya* fluorinase enabled the discovery of five similar fluorinases via genome mining.^{24,25,43}

The high toxicity of fluoroacetate is caused by its metabolism (Scheme 3). Fluoroacetate is transformed into fluoroacetyl-CoA **7**, which reacts with oxaloacetate in the presence of citrate synthase to form (2R,3R)-fluorocitrate **8**, the only toxic 2-fluorocitrate stereoisomer. This compound inhibits citrate transport. In addition, the aconitase enzyme transforms (2R,3R)-fluorocitrate **8** into (R)-4-hydroxy-trans-aconitate **10**, which then inhibits aconitase. Through these actions, fluoroacetate and (2R,3R)-fluorocitrate block the citric acid cycle, impairing oxidative metabolism and causing citrate accumulation in several tissues. The reduction of ionized serum calcium concentrations also contributes to toxicity.^{24,25,40,44}



Organisms producing fluoroacetate have to defend themselves against self-poisoning. *D. cymosum* achieves this by a fluoroacetyl-CoA hydrolase. Of acetyl-CoA and fluoroacetyl-CoA, this enzyme selectively hydrolyzes the latter one, preventing (2R,3R)-fluorocitrate formation. It is also worthwhile to mention that plants producing fluoroacetate seem to be capable of catabolizing fluoroacetate. *S. cattleya* also has a

fluoroacetyl-CoA hydrolase, but this microorganism has an additional defense mechanism: it only starts synthesizing fluorinated metabolites after it stopped its growth, that is, when the citrate cycle is inactive.^{24,25}

Herbivores, living in areas where plants synthesizing fluoroacetate occur, also developed increased resistance to fluoroacetate. It seems that they have a glutathione-dependent fluoroacetate-specific defluorinase enzyme (mostly in their livers), which converts fluoroacetate into *S*-carboxymethylcysteine and a fluoride ion. Various soil microbes are also capable of decomposing fluoroacetate into glycolate and F⁻ utilizing a fluoroacetate dehalogenase enzyme.^{24,25}


2.3. (2R,3R)-Fluorocitrate

(2R,3R)-Fluorocitrate (**8**, Scheme 3) is formed when fluoroacetate enters the citric acid cycle. Since a large number of plants are capable of synthesizing low amounts of fluoroacetate, they also contain traces of its metabolite (2R,3R)-fluorocitrate (e.g., commercial tea can contain up to 30 mg kg⁻¹ on a dry weight basis). As explained in Section 2.2, (2R,3R)-fluorocitrate is the only toxic stereoisomer among 2-fluorocitrates, and it exerts its toxicity via a number of effects (inhibition of citrate transport, reduction of ionized serum

Scheme 5. Plausible Biosynthetic Pathway toward ω -Fluorinated Fatty Acids (ACP = Acyl Carrier Protein)Scheme 6. Final Step of (2*S*,3*S*)-4-Fluorothreonine Biosynthesis^{a,b}

^aSee Scheme 1 for previous steps and their detailed mechanism. ^bPLP = pyridoxal phosphate.

Scheme 7. Major Steps of Salinosporamide-A Biosynthesis



calcium concentration, and inhibition of the citric acid cycle via its metabolite (*R*)-4-hydroxy-*trans*-aconitate).⁴⁰

2.4. ω -Fluorinated Fatty Acids

ω -Fluorinated fatty acids were discovered in the seed oil of the West African plant *Dichapetalum toxicarium*, and their production seems to be restricted to this single species.^{24,25,40} According to a GC/MS study, 12.9% of the total fatty acid content in the seed oil is comprised of ω -fluorinated compounds. The same study showed that 74% of the ω -fluorinated fatty acids is 18-fluorostearic acid **11**; 16% is 18-fluorostearic acid **12**; 6% is 18-fluorolinoleic acid **13**; and 4% is 16-fluoropalmitic acid **14**. Other ω -fluorinated fatty acids (20-fluoroicosanoic acid **15**, (*Z*)-20-fluoroicos-11-enoic acid **16**, (*Z*)-20-fluoroicos-9-enoic acid **17**, (*Z*)-16-fluorohexadec-7-enoic acid **18**, and (*Z*)-16-fluorohexadec-9-enoic acid **19**) were detected in lower amounts.⁴⁵ Other studies found *threo*-18-fluoro-9,10-dihydroxystearic acid **20** and evidence for the presence of 18-fluoro-9,10-epoxyoleic acid (\pm)-**21**.^{46,47} Scheme 4 summarizes these compounds. In 1964, ω -fluorocapric acid and ω -fluoromyristic acid were tentatively identified in the oil on the basis of GC retention time; however, newer studies did not confirm this information.⁴⁶

These compounds, all of them with an even number of carbon atoms, are very toxic because their *in vitro* metabolism leads to fluoroacetate. In stark contrast with fluoroacetate, they are lipophilic and can also be toxic by direct absorption through the skin.^{24,25,40}

Ratios of the ω -fluorinated fatty acids are similar to those of their nonfluorinated counterparts (which are present in 5 to 10 times higher amounts).^{24,25,40,46} This suggests a common origin. The most plausible explanation is that in this plant the first step of fatty acid synthesis, namely, condensation of acetyl-CoA with a malonyl acyl carrier protein or malonyl-ACP, works with fluoroacetyl-CoA too. In contrast, fluoromalonyl-ACP either is not formed or cannot be incorporated to fatty acids in the same manner as malonyl-ACP (Scheme 5).^{24,25,40}


2.5. (2*S*,3*S*)-4-Fluorothreonine

The ability of *Streptomyces cattleya* to produce fluoroacetate **6** and (2*S*,3*S*)-4-fluorothreonine **31** was discovered in 1986. (2*S*,3*S*)-4-Fluorothreonine was noticed because of its mild antibiotic activity. As mentioned in Section 2.2, the *S. cattleya* genome is now fully sequenced, and fluorometabolite biosynthesis of this microorganism is completely understood. Production of (2*S*,3*S*)-4-fluorothreonine **31** follows largely the same pathway as that of fluoroacetate synthesis. The only difference is the final step: fluoroacetaldehyde **5** is subjected to a pyridoxal phosphate (PLP) dependent transaldolase together with *L*-threonine **30** to produce acetaldehyde **32** and (2*S*,3*S*)-4-fluorothreonine **31** (Scheme 6).^{24,25}

2.6. (2*R*,3*S*,4*S*)-5-Fluoro-2,3,4-trihydroxypentanoic Acid

After a fluorinase gene was discovered in the sequenced genome of *Streptomyces* sp. MA37, studies of its fluorometabolite production showed that, apart from fluoroacetate and (2*S*,3*S*)-4-fluorothreonine (which were the main organofluorine products), a range of unidentified fluorinated metabolites were also present. Inspired by the salinosporamide-A synthesis of *Salinispora tropica* (see a simplified version in Scheme 7), where 5-chloro-5-deoxy-D-ribose **35** is an intermediate, 5-fluoro-5-deoxy-D-ribose **37** was added to a cell-free extract of *Streptomyces* sp. MA37. This caused some of the fluorometabolites unidentified previously to become the dominant products, suggesting that they are formed via 5-fluoro-5-deoxy-D-ribose. A homologue search of the *Streptomyces* sp. MA37 showed the presence of genes similar to the ones involved in salinosporamide-A production. One of them, *fdrC*, seemed to code a short-chain dehydrogenase analogous to SalM. It oxidizes 5-chloro-5-deoxy-D-ribose **35** into 5-chloro-5-deoxy-D-ribonolactone **36** and possibly catalyzes subsequent lactone hydrolysis during salinosporamide-A production. Indeed, 5-fluoro-5-deoxy-D-ribose **39** was transformed to (2*R*,3*S*,4*S*)-5-fluoro-2,3,4-trihydroxypentanoic acid **41** *in vitro* in the presence of FdrC and NAD⁺ involving oxidation followed by hydrolysis.¹⁹F NMR

Scheme 8. Fluorinase Pathway: Production of Fluoroacetate (6), (2*S*,3*S*)-4-Fluorothreonine (31), and (2*R*,3*S*,4*S*)-5-Fluoro-2,3,4-trihydroxypentanoic Acid (41)




confirmed that this compound is one of the previously unidentified fluorometabolites of *Streptomyces* sp. MA37.

To sum up, the production of (2*R*,3*S*,4*S*)-5-fluoro-2,3,4-trihydroxypentanoic acid is branching from the fluorinase pathway, with 5-fluoro-5-deoxy-D-ribose-1-phosphate **3** being the last common intermediate. Scheme 8 shows the full fluorinase pathway, including the biosyntheses of (2*R*,3*S*,4*S*)-5-fluoro-2,3,4-trihydroxypentanoic acid **41**, (2*S*,3*S*)-4-fluorothreonine **31**, and fluoroacetate (**6**).^{24,25,48}

2.7. Nucleocidin and Related Fluoroorganic Compounds


Nucleocidin (4'-fluoro-5'-*O*-sulfamoyladenine, **42**, Scheme 9) was isolated in 1957 from *Streptomyces calvus* ATCC 13382, but its fluorinated nature was discovered only in 1969. This compound is a broad-spectrum antibiotic, although it is too toxic for clinical use. The position of the fluorine atom (at C-4 of the ribose moiety) is remarkable because it suggests that nucleocidin is not synthesized from a fluoroacyl molecule. Unfortunately,

Scheme 9. Structure of Nucleocidin and Structurally Related Ascamycin



until 2015, attempts to reisolate nucleocidin from *S. calvus* cultures failed, which seriously hindered the research of its biosynthesis.^{24,25,40}

In *Streptomyces* species, disruption of the regulatory genes results in an unusual "bald" phenotype (no sporulation) and deficiencies in secondary metabolite production. The *S. calvus* ATCC 13382 strain exhibits this bald phenotype, and it was discovered in 2013 that its *bldA* gene (which encodes the tRNA

Scheme 10. Putative Steps of Nucleocidin Production^{a,b}

^aFluorinated compounds **42** and **47a,b** were isolated from the fermentation broth. ^bReaction of **47a** with recombinant NucGS *in vitro* yielded known compound **48**.

for the rare TTA codon) is mutated and nonfunctional. The TTA codon usually concentrates in regulatory and structural biosynthetic genes of *Streptomyces* species; that is, their translation requires a working *bldA*. This explains the loss of nucleocidin production.^{24,25,49}


It was shown in 2015 that providing a functional *bldA* copy to this strain restored both sporulation and nucleocidin synthesis. At that time, the 23-membered gene cluster responsible for the synthesis of ascamycin **43** (which has structural similarities to nucleocidin; see Scheme 9) was already known, and a search in the *S. calvus* ATCC 13382 genome found 16 homologous genes, divided between 2 gene clusters. Supported by gene disruption experiments, these were identified as the nucleocidin biosynthetic cluster.⁴⁹ This identification was confirmed further, when a highly similar gene cluster was revealed in *Streptomyces asterosporus* DSM 41452. This microorganism also had a bald phenotype but for a different reason, namely, because of the presence of the nonfunctional pleiotropic regulator gene *adpA*. Complementation with a working *adpA* sequence restored sporulation and promoted the production of nucleocidin, doubling the number of known nucleocidin-producing organisms.⁵⁰

Armed with the knowledge above, some details of the nucleocidin biosynthesis were already uncovered. Importantly, first *S. calvus* produces two unknown fluorometabolites, which then disappear in parallel with the emergence of nucleocidin. These new metabolites were found to be 3'-*O*- β -glucosylated-4'-

fluoro-adenosine **47a** and 3'-*O*- β -glucosylated nucleocidin **47b**. This directed attention to a glycosyltransferase gene (*nucGT*) and a β -glucosidase gene (*nucGS*) within the biosynthetic cluster. It turned out that NucGS performs the last step of nucleocidin production (deglycosylation of **47b** into nucleocidin), while NucGT is involved in an earlier step (its knockout completely disabled fluorometabolite production). Since 5'-*O*-sulfamoyl-adenosine **44b** is a better substrate of NucGT than adenosine **44a**, it can be assumed that the formation of the sulfamoyl moiety precedes glycosylation. Scheme 10 summarizes related pieces of information.⁵¹ A purine nucleoside phosphorylase, encoded by the *ORF206* gene of *S. calvus*, was also necessary for fluorometabolite production.⁴⁹ According to isotope-labeling experiments, both C5' hydrogens of the ribose ring are derived intact from the *pro-R* CH₂OH group of glycerol. Deuterium labels of the *pro-S* CH₂OH group of glycerol, in turn, are lost, and the secondary carbon of glycerol becomes the C4' of nucleocidin (Scheme 11).^{52,53} This shows that the *pro-R* CH₂OH carbon is not oxidized as glycerol, and it is progressed along the pentose phosphate pathway, incorporating into the ribose moiety of nucleocidin.⁵² Note that the enzyme responsible for fluorine incorporation is still unknown.⁵¹

2.8. Miscellaneous Information

When homogenates of *Acacia georginae* (a known fluoroacetate accumulator) are incubated at 30 °C in the presence of 1 mM fluoride, ATP, and pyruvate, some of the fluoride seemingly

Scheme 11. Results of Isotope-Labeling Experiments^a

^aGlycerol at the left has a virtual labeling pattern, which is a composite of experimentally administered glycerols.

disappeared, suggesting the formation of volatile organofluorine compounds. Passing the volatiles through acidic 2,4-dinitrophenylhydrazine solution resulted in the formation of a fluorine-containing 2,4-dinitrophenylhydrazone. It was originally identified as fluoroacetone-2,4-dinitrophenylhydrazone based on its retention time on paper chromatography. However, this method cannot differentiate between 2,4-dinitrophenylhydrazones of fluoroacetone fluoroacetaldehyde.^{54,55} Taking into account that FCH_2CHO is an intermediate toward FCH_2COO^- in *S. cattleya*, the presence of fluoroacetaldehyde is more plausible than that of fluoroacetone.

In 1960, in an organofluorine-containing oil extracted from *D. cymosum*, a long-chain fatty acid was found with the GC characteristics of ω -fluorooleic acid but without its *in vivo* toxicity. Possibly, reinvestigation of fluoroacetate-accumulating plants with modern analytical methods would be fruitful.⁴⁰

In the marine sponge *Phakellia fusca*, obtained from the South China Sea, five 5-fluorouracil alkaloids were found. However, their natural product nature was debated. Currently, it seems more plausible that they originate from industrial contamination.^{24,25}

3. CURRENT TRENDS IN FLUORINE-CONTAINING PHARMACEUTICALS AND AGROCHEMICALS

As mentioned in Section 2, fluorine-containing organic compounds are rare in nature. In contrast, organofluorine compounds are quite common among pharmaceuticals and agrochemicals. For example, among the drugs accepted by the FDA in 2019, the ratio of the fluorine-containing ones was 31%.

The current section will start with a summary of the main properties and changes associated with fluorination, which are the reasons behind the high abundance of fluorine within man-made bioactive molecules. This part will be illustrated by case studies of drugs. (Note: some compounds benefit more than one effect of fluorine.) Then, fluorinated agrochemicals will be discussed briefly. Finally, current trends in fluorine-containing pharmaceuticals will be studied through statistical analysis of FDA-approved drugs in the 2007–2019 time period.

3.1. Advantages of Fluorinated Drug Molecules

3.1.1. Fluorination and Metabolism. Highlighted: Ezetimibe, Celecoxib, and Alpelisib.

After taking a drug,


the body tries to remove it via deactivation and excretion. Although it is possible to eliminate a drug unchanged, drug molecules are usually subjected to metabolism before elimination. These transformations often result in detoxification (although many exceptions are known) and usually decrease lipophilicity to facilitate clearance. The most important enzymes involved in drug metabolism are cytochrome P450 monooxygenases which are present mainly in the liver, and increasing the stability to oxidation processes mediated by these enzymes is required frequently during drug development.¹² A well-established way to achieve this goal is the replacement of metabolically labile hydrogens with fluorines.¹²

The success of this strategy originates from the unique properties of fluorine and its bond with carbon. First, because of the higher bonding energy of the C–F bond ($\approx 441 \text{ kJ mol}^{-1}$) compared to the C–H bond ($\approx 414 \text{ kJ mol}^{-1}$), hydroxylation of C–H bonds can be blocked by fluorination.^{12,56} Also, the strongly electron-withdrawing nature of fluorine (its Pauling electronegativity is 4, the highest value among the elements on this scale) deactivates fluorinated aromatic rings toward oxidative metabolism.¹² Hydroxyl and amino groups nearby to fluorine are also more resistant to oxidation (the electron withdrawal of F decreases their Lewis basicity).⁵⁶ The bad leaving group ability of fluoride is also important. Thanks to this, fluorinated compounds rarely behave as alkylating agents.^{13,14} (As an exception, electron-deficient (hetero)aryl fluorides can undergo nucleophilic aromatic substitution reactions through the addition–elimination pathway. E1cb elimination reactions of fluoride can lead to reactive intermediates too; see the case of trifluridine in Section 3.1.6.) Finally, the size (van der Waals radius) of a fluorine atom (1.47 Å) is between the sizes of hydrogen (1.20 Å) and oxygen (1.57 Å). As a result, exchanging a H with F often retains the shape of the molecule (for exceptions, see Section 3.1.5), and improvement of metabolic stability can be achieved without compromising binding to the target protein.¹²

A good example is the cholesterol absorption inhibitor ezetimibe, a blockbuster drug. (Vytorin, a combination of ezetimibe and simvastatin, was the 18th best selling drug of 2008 in the USA. Zetia, which contains only ezetimibe, was the 30th on the same list.)¹⁶ During drug development, studying the metabolism of the lead molecule SCH-48461 (49) showed that benzylic hydroxylation and demethylation of the 4-methoxyphenyl group attached to the C-4 atom of the azetidinone ring increase potency, while *para* hydroxylation of the phenyl group and demethylation of the 4-methoxyphenyl group attached to the azetidinone nitrogen were nonproductive. The incorporation of beneficial changes and blocking unwanted metabolism by fluorination resulted in ezetimibe (50), which was 400 times more potent (Scheme 12).¹²


The extent of metabolic stability which can be achieved is illustrated well by the development of celecoxib, a COX-2-selective nonsteroidal anti-inflammatory drug. This compound

Scheme 12. Fluorination Prevents Unwanted Metabolic Changes in the Case of Ezetimibe (50)



was a blockbuster (it was the 20th best selling drug of 2008 in the USA).¹⁶ Here, the lead molecule **51** had a very long plasma half-life. Replacement of the methylsulfone part with a sulfonamide moiety helped somewhat, but to achieve an acceptable half-life, replacement of a fluorine with a methyl group was necessary (Scheme 13).^{57,58}

Scheme 13. Reducing Excessive Half-Life by Fluorine Removal during the Development of Celecoxib




A recent example is alpelisib (**54**, Scheme 14). This compound, an α -selective phosphatidylinositol-3-kinase inhibitor, was approved by the FDA in 2019 for treating HR+, HER2-negative, PIK3CA-mutated advanced, or metastatic breast cancer. During its development, compound **53** (Scheme 14) was synthesized. This molecule was an effective and selective inhibitor of p110 α , the catalytic subunit of phosphatidylinositol-3-kinase α (in biochemical assays, $IC_{50}(p110\alpha) = 0.014$ μ M, $IC_{50}(p110\beta) = 4.4$ μ M, $IC_{50}(p110\delta) = 0.33$ μ M, and $IC_{50}(p110\gamma) = 0.43$ μ M), but it had high clearance (77 μ L min^{-1} mg^{-1} in rat liver microsomes) because of its metabolism (hydrolysis of the CONH₂ moiety and aliphatic hydroxylation of either the *tert*-butyl group or the methyl substituent of the thiazole ring). Replacement of the *t*Bu group with the 1,1,1-trifluoro-2-methylpropan-2-yl substituent to block unwanted aliphatic hydroxylation yielded alpelisib (**54**). Clearance was significantly reduced (29 μ L min^{-1} mg^{-1} in rat liver microsomes), while efficacy and selectivity were not compromised ($IC_{50}(p110\alpha) = 0.005$ μ M, $IC_{50}(p110\beta) = 1.2$ μ M, $IC_{50}(p110\delta) = 0.29$ μ M, and $IC_{50}(p110\gamma) = 0.25$ μ M in biochemical assays). In fact, potency toward p110 α increased (see Section 3.1.2 for details).⁵⁹

Finally, in fluticasone propionate (**55**, Scheme 15), the fluorine at the 9 position increases the acidity of the hydroxyl group at the 11 position, inhibiting undesirable oxidation here.⁵⁶ This compound is a steroidal anti-inflammatory drug which is mainly used to treat asthma. Advair Diskus, which contains fluticasone propionate and salmeterol, was the fourth best selling drug of 2008 in the USA, making compound **55** another blockbuster drug.¹⁶

3.1.2. Fluorination and Potency. Highlighted: Type 2 Statins, Sitagliptin and Alpelisib. In contrast with the apolar C–H bond, the C–F bond is highly polarized thanks to the very

Scheme 15. Structure of Fluticasone Propionate



high electronegativity of fluorine. However, further polarization of C–F bonds is difficult, making the C–F moiety a poor hydrogen bond acceptor. This blocks solvation by water, in contrast to the good hydrogen bond acceptor nature of the fluoride ion. As an overall result, fluorinated organic compounds show polar hydrophobicity and a clear preference for orthogonal multipolar interactions (e.g., C–F \cdots C=O and C–F \cdots H–N) over hydrogen bonding.^{12,56,60}


Since such attractive multipolar interactions are absent when fluorine is replaced with a hydrogen, fluorination often increases potency.^{12,56,57,60} Statins (Scheme 16) illustrate this well. These compounds are cholesterol-lowering drugs which inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase (or HMG-CoA reductase), a key enzyme in cholesterol biosynthesis. Every statin contains a 3-hydroxy-3-methylglutaryl-like moiety. Type 2 statins also contain a 4-fluorophenyl group, which is absent in Type 1 statins.⁶¹


The partially negatively charged fluorine of this 4-fluorophenyl group forms an energetically favorable electrostatic interaction with the positively charged guanidinium nitrogen of the Arg590 residue within HMG-CoA reductase, thereby improving binding. Scheme 17 shows this for atorvastatin.⁶¹ It is worth noting that both atorvastatin (the first best selling drug of 2008 in the USA) and rosuvastatin (the 17th best selling drug of 2008 in the USA) were blockbusters.¹⁶

In Section 3.1.1, it was already mentioned that in fluticasone propionate (**55**, Scheme 15) the fluorine at the 9 position increases the acidity of the hydroxyl group at the 11 position. This also improves its binding to the glucocorticoid receptor.⁵⁶


Another possibility for enhancing potency via fluorination is when the slightly bigger fluorinated group fits better to a hydrophobic cavity. A good example is sitagliptin (**62**, Scheme 18). This compound inhibits dipeptidyl peptidase IV (DPP-IV), which would rapidly degrade glucagon-like peptide 1 (GLP-1). GLP-1 is released upon food intake, promotes insulin biosynthesis and secretion, and inhibits glucagon release. Increasing its concentration via blocking DPP-IV enables treatment of diabetes with little or no risk of hypoglycemia. As a result, sitagliptin became a blockbuster drug: in 2019, worldwide revenues from Januvia (sitagliptin only) and Janumet (combi-

Scheme 14. Reducing Clearance by Blocking Aliphatic Hydroxylation During the Development of Alpelisib



Scheme 16. Structure of 3-Hydroxy-3-methylglutaryl-coenzyme A (56) and Different Statins^{a,b}

^aThe conserved 3-hydroxy-3-methylglutaryl-like moieties are highlighted with dashed round rectangles. ^bThe 4-fluorophenyl groups (the trademarks of type 2 statins) are highlighted with bold dashed round rectangles.

Scheme 17. Electrostatic $F^{\delta-} \cdots N^{\delta+}$ Interaction between Atorvastatin and the Arg590 Residue of HMG-CoA Reductase^a

^aThe average fluorine–nitrogen distance is 2.9 Å, lower than the sum of the van der Waals radius of these two atoms.

nation of sitagliptin and metformin) were more than 5.5 billion USD.⁶²

Evaluation of sitagliptin and its analogues containing different fluorinated phenyl groups showed that the 2,4,5-trifluorophenyl group provides the best IC_{50} value (Scheme 18). This was explained by the X-ray crystal structure of sitagliptin bound to DPP-IV, which showed that the 2,4,5-trifluorophenyl moiety fully occupies the S1 hydrophobic pocket of the enzyme. Notably, the pocket that accommodates the CF_3 moiety is also quite tight.^{58,63}

Another example where fluorination induces better fitting to a hydrophobic cavity is alpelisib (54, Scheme 14), which was already discussed in Section 3.1.1. Compared to its analogue 53 (Scheme 14), fluorination not only reduced clearance but also improved inhibitory activity (IC_{50} values against p110 α : 0.014 μ M for compound 53 and 0.005 μ M for compound 54). This was explained with a docking model which showed that the *t*Bu moiety in compound 53 does not fully occupy a small cavity



because there is still some space around one of its methyl groups.⁵⁹

3.1.3. Fluorination and Bioavailability. Highlighted: Sitagliptin. Fluorination influences bioavailability via modulation of pK_a values and lipophilicity, a key parameter in pharmaceutical chemistry. The first effect is based on the strong inductive electron withdrawal of fluorine, which makes nearby acidic groups (for example, alcoholic or phenolic OH groups) more acidic and decreases the basicity of nearby basic groups (mostly amino groups). This pK_a lowering effect shifts the ratio of charged and neutral drug species, affecting binding affinity, bioavailability (for neutral molecules, passive transport through membranes is easier), and lipophilicity (see below).^{12,56,57,60}

Lipophilicity is quantified by measuring the partition coefficient ($\log P$) of the molecule between octanol (apolar layer) and water (polar layer). When charge states need to be considered, $\log D$ (the logarithmic coefficient of the distribution of a molecule between octanol and water at a given pH, typically 7.4) is also used.¹² Usually, proteins are less polar than the surrounding aqueous solution, so some lipophilicity of the ligand is often required for efficient binding. However, too lipophilic molecules tend to have insolubility issues, and during passive transport, they can get trapped in the lipid cores of membranes instead of passing through them.^{12,56,57,60}

A thorough study on the effect of fluorination on lipophilicity used 283 pairs of molecules from the Roche in-house database which differed by just one fluorine atom (Scheme 19). On average, a H \rightarrow F exchange increased $\log D$ with approximately 0.25, but specific groups of molecules behaved differently.⁵⁷ A high $\log D$ increase was found when fluorine was introduced near to basic nitrogens because the decrease in basicity increased the ratio of the more lipophilic unprotonated amine.^{12,56,57} It is worth noting that introduction of a CF_3 group also considerably

Scheme 18. Structure and DPP-IV Inhibitory Activity of Sitagliptin (62) and Its Analogues 63–67

Scheme 19. Effect of a Single H \rightarrow F Exchange on Lipophilicity^a


^aThe log $D_{R-F} - \log D_{R-H}$ difference is shown.

increased log D .^{12,56} The most common outcome was an increase of log D only with 0 to 0.5. This can be explained by the polar but hydrophobic nature of the C–F bond. However, in a

number of cases, a H \rightarrow F exchange reduced log D . In these molecules, fluorine was introduced near to ether, hydroxyl, or carbonyl groups. Possibly, the combined presence of the C–F dipole and the C–O dipole increases the overall polarity of the molecule.⁵⁷ Incorporation of fluorine (polarity) into previously apolar regions (e.g., alkyl chains) also decreases lipophilicity.^{12,56,60}

Sitagliptin (**62**, Scheme 20) is a good example of improving bioavailability via fluorination. The effect of the fluorination pattern on its phenyl group on potency was already discussed (Scheme 18, Section 3.1.2), but the role of the CF_3 substituent was not addressed. It was found that replacing it with a hydrogen atom (compound **68**) resulted in almost complete loss of oral bioavailability and some decrease of potency. Replacing the CF_3 group with an ethyl group (compound **69**) produced a similar outcome. Replacement of the CF_3 group with the CF_2CF_3 group (compound **70**) did not change the oral bioavailability

Scheme 20. Effect of Triazole Ring Substitution on Oral Bioavailability (F) and DPP-IV Inhibitory Activity of Sitagliptin (62) and Its Analogues




significantly, but it also led to some loss of potency. To sum up (Scheme 20), the most important function of the CF₃ group was providing good oral bioavailability, although its effect on DPP-IV inhibitory activity was also useful.^{58,63} The latter can be explained by the fact that the CF₃ group fits tightly into a hydrophobic cavity,⁶³ while smaller groups (hydrogen, ethyl)⁵⁶ or larger groups (pentafluoroethyl) do not.

3.1.4. Isosteric Replacement by Fluorine or Fluorinated Moieties. Highlighted: Odanacatib. Because the van der Waals radius of the fluorine atom (1.47 Å) is between the values of hydrogen (1.20 Å) and oxygen (1.57 Å),¹² fluorine can often be used for isosteric replacement of hydrogens, hydroxyl groups, or methoxy groups. These isosteric replacements usually do not change the shape of the molecule considerably (for exceptions, see Section 3.1.5).⁶⁰


It is also possible to replace other functional groups with fluorinated moieties in an isosteric manner. One important example is the case of phosphates. Since phosphorylation is common in biochemistry, nonhydrolyzable phosphate analogues of nucleotides, enzyme substrates, and enzyme inhibitors received great interest. Isosteric replacement of the oxygen linkage with a CH₂ group yields phosphonates, which cannot be hydrolyzed; however, their second pK_a value is increased, and the CH₂ group is ineffective at mimicking the oxygen electronically. α -Monofluorinated and α,α -difluorinated phosphonates, however, are both isosteric and isoelectronic to organophosphates, making them better phosphate mimics. In the case of α -monofluorinated phosphonates, even the pK_{a2} value is close to the one found in phosphates (Scheme 21).^{56,64,65}

Scheme 21. Phosphate Isosteres



Another important example is the amide group. This highly polar moiety can both accept and donate hydrogen bonds. Its usual problem is its susceptibility to enzymatic hydrolysis. Within nonhydrolyzable amide isosteres which have the appropriate geometry (Scheme 22), *trans*-alkenes have almost

Scheme 22. Amide Isosteres



no dipole moment, and they are incapable of forming hydrogen bonds. Fluoroalkene moieties are better; however, their dipole moment is only $\approx 40\%$ of the dipole moment present in amides, and they also lack the ability to form hydrogen bonds. Trifluoromethylated alkene moieties are quite good: they have $\approx 60\%$ of the dipole moment of amides, and the CF₃ group electronically mimics the carbonyl oxygen well despite its considerably larger size. However, this isostere still cannot form hydrogen bonds. α -Trifluoromethyl amines are quite promising

amide isosteres: the CF₃ group mimics the carbonyl oxygen, and its strong inductive electron withdrawal decreases the basicity of the nitrogen atom. As a result, the NH group is relatively nonbasic and has excellent hydrogen bond forming ability.^{56,58,60}

Good examples for the use of the α -trifluoromethyl amine isostere are cathepsin K inhibitors 72a–b and 74 (odanacatib). Cathepsin K, a lysosomal cysteine protease, seems to be the most important enzyme involved in osteoclastic bone resorption, and its inhibitors were promising for the treatment of osteoporosis. As shown on Scheme 23, compounds 72–74 originate from molecule 71. Incorporation of the α -trifluoromethyl amine isostere and the 4-(piperazin-1-yl)phenyl group resulted in compound 72a, an extremely potent cathepsin K inhibitor. It was more active than its peptide analogue 73. Interestingly, the remaining amide bond in 72a was resistant to hydrolysis. Unfortunately, thanks to the basic piperazine ring, compound 72a accumulated in lysosomes, which decreased its cathepsin K selectivity in cell-based assays compared to the values measured in enzyme assays. Replacement of the piperazine ring with a methylsulfonyl group led to compound 72b, which was highly selective even in cell-based assays but had a short half-life in monkeys.^{56,58,66} Incubations in human hepatocytes showed that the major cause was hydroxylation on the methine of the leucine side chain, while the minor cause was hydrolysis of the amide bond. Blocking the major pathway by H \rightarrow F exchange and the minor pathway by incorporation of a cyclopropane ring yielded odanacatib (74), which was subjected to clinical development.⁶⁶ Unfortunately, Phase 3 studies showed that although odanacatib is effective against osteoporosis it also increases the risk of stroke, and development was discontinued.⁶⁷


It is also worth noting that fluorinated arenes can be used as nucleobase isosteres. Notably, several high-fidelity DNA polymerases were able to incorporate nucleotide mimics containing fluoroarene moieties into DNA.⁵⁶

3.1.5. Conformational Changes Triggered by Fluorine Incorporation. Although isosteric replacement of H, OH, or OMe with F generally does not affect the conformations of the molecule too much, stereoelectronic effects originating from the very high electronegativity of fluorine can overwrite this.


Usually, vicinally disubstituted alkanes adopt antiperiplanar conformation to maximize the distance between the substituents (minimizing steric repulsion). However, in vicinal difluorides, 2-fluoroamines, 2-fluoroalcohols, and 2-fluoroalkyl ethers, *gauche* geometry of the two heteroatoms is favored. In this way, the C–F bond is antiperiplanar with a C–H bond, and the filled σ_{C-H} orbital can donate some electrons to the lower-lying vacant σ^*_{C-F} orbital (Scheme 24). The energy gain from this hyperconjugation effect compensates for the steric repulsion between the small fluorine and the other heteroatom, as long as the other atom is not too big (1-fluoro-2-chloroethane prefers the *anti* conformation).^{56,68–71}

Study of fluorinated amino acids demonstrated that in α -fluoro amides antiperiplanar arrangement of the carbonyl oxygen and the vicinal fluorine is preferred (Scheme 24). Its main causes seem to be dipole effects. Since fluorinated amino acids also contain amino nitrogens, this effect can occur together with the *gauche* effect, yielding conformationally restricted amino acids which are quite useful in peptide and foldamer chemistry to achieve specific secondary structures.^{68–71} They can also be applied to study conformational effects in peptides. For example, in natural collagens, many proline residues are

Scheme 23. Use of α -Trifluoromethyl Amines (Highlighted with Dashed Round Rectangles) as Amide Isosteres Among Cathepsin K Inhibitors



Scheme 24. Stereoelectronic Factors Associated with Fluorination



oxidized to (4*R*)-hydroxyproline residues which stabilize the triple helix structure. Originally, it was suspected that the hydrogen bond donor/acceptor properties of the introduced OH groups are responsible for the stabilization. However, replacing (4*R*)-hydroxyproline residues with (4*R*)-fluoroproline residues (which cannot participate in such hydrogen bonding) resulted in more stable triple helices, and it was discovered that the effect of proline hydroxylation is based on changing the conformation of the proline ring via stereoelectronic effects.^{72,73}

Trifluoromethoxybenzenes provide a well-known example for fluorination-induced conformational changes. Compared to methoxybenzenes, which have a coplanar structure (unless they are *ortho*-disubstituted), trifluoromethoxybenzenes clearly prefer a nonplanar structure (Scheme 24).^{12,57,60}


Among recently approved drugs, sonidegib⁷⁴ and pretomanid⁷⁵ contain 4-trifluoromethoxyphenyl moieties. The X-ray crystal structure of the latter clearly shows the nonplanar structure of this moiety.⁷⁶ Unfortunately, the advantage of the CF_3O group over the CH_3O group cannot be determined unequivocally from the published data.

3.1.6. Fluorination- and Mechanism-Based Inhibitors. Highlighted: 5-Fluorouracil and Trifluridine. A mechanism-based enzyme inhibitor is a compound which is inactive in itself, but the target enzyme's normal working converts it to an active species. This reactive intermediate then either binds strongly to the target enzyme or forms a covalent bond with it.⁷⁷ Fluorination can be used to create mechanism-based inhibitors

for two reasons. On one hand, fluorine and hydrogen are isosteric, so after the $H \rightarrow F$ exchange the new compound usually remains a substrate of the target enzyme. On the other hand, chemical properties of hydrogen and fluorine are very different: hydrogens in the α -position relative to conjugatively electron-withdrawing groups can be removed as protons, while fluorines can be removed as fluoride ions (usually via E1cB elimination).


Taking the above facts into account, one way of using fluorination to create a mechanism-based inhibitor is to find a hydrogen which has to be removed as a proton during the enzyme mechanism and replace it with fluorine. As a result, the enzymatic transformation will be stopped midway. A good example of this strategy is 5-fluorouracil (75, Scheme 25), one of

Scheme 25. Structure of 5-Fluorouracil (75) and Trifluridine (76), Mechanism-Based Inhibitors of Thymidylate Synthase



the most ancient fluorinated drug molecules (it was discovered and developed in the 1950s as an anticancer drug). This compound inhibits thymidylate synthase, which is necessary for DNA biosynthesis, causing apoptosis of rapidly dividing cells (e.g., cancer cells). Normally, thymidylate synthase forms a ternary complex with 2'-deoxyuridine-5'-phosphate and methylenetetrahydrofolate ($CH_2=FAH_4^+$). After Michael addition of the active site cysteine thiolate to the uracil ring, the resulting enolate alkylates methylenetetrahydrofolate. This is followed by 5-deprotonation of the uracil ring, elimination of tetrahydrofolate, hydride ion transfer from tetrahydrofolate to the exomethylene group of the intermediate, and release of 2'-deoxythymidine-5'-phosphate (Scheme 26). During analogous transformation of 2'-deoxy-5-fluorouridine-5'-phosphate (formed in vivo from 5-fluorouracil), 5-deprotonation of the

Scheme 26. Mechanism of Thymidylate Synthase and Its Inhibition by 2'-Deoxy-5-fluorouridine-5'-phosphate^a



^aThe active metabolite of fluorouracil 75. CH₂=FAH₄⁺ = methylenetetrahydrofolate, FAH₄ = tetrahydrofolate, FAH₂ = dihydrofolate, dUMP = deoxyuridine monophosphate, dTMP = deoxythymidine monophosphate.

uracil ring is impossible (there are not any hydrogens at that position), and the reaction cannot proceed further (Scheme 26).^{12,78}

The other way of using fluorination to create a mechanism-based inhibitor is incorporation of fluorine in such a way that during enzymatic transformation of the fluorinated molecule a reactive intermediate is formed via E1cB elimination of fluoride. Then, this reactive intermediate undergoes conjugate addition with nearby nucleophilic groups of the enzyme, binding to it covalently (irreversibly). A good example of this strategy is trifluridine (76, Scheme 25), another thymidylate synthase inhibitor which is used to treat viral infections of the eye. During its transformation by thymidylate synthase, the first formed enolate loses a fluoride ion instead of alkylating methylenetetrahydrofolate. The resulting β,β-difluorinated α,β-unsaturated amide is a good Michael acceptor and reacts with a nearby nucleophilic amino side chain of the enzyme. Loss of the second fluoride ion and subsequent hydrolysis result in irreversible binding to thymidylate synthase via a peptide bond (Scheme 27).¹²

3.2. Agrochemicals

Within new active ingredients which were provisionally approved by ISO between 1998 and 2008 and used as agrochemicals, 78.5% contained halogens.¹⁹ Furthermore, in the time frame 1940–2003, ≈28% of all commercially available

halogenated products contained fluorine.¹⁸ This conclusion is supported by the findings of more recent surveys.^{20,79}

The main effects of fluorination on agrochemicals and drugs should be the same. However, since agrochemicals are applied externally, chemical degradation should also be taken into account in addition to biological degradation. It is also worth noting that the literature about the development and structure–activity relationships of fluorine-containing agrochemicals^{18–20,80,81} is scarce compared to the analogous literature of fluorinated drugs. Even in the case of well-defined structure–activity relationships, the molecular background behind the beneficial effect of fluorine is often missing.^{18–20,80,81}

3.2.1. Fluorination and Degradation. Within commercial insect growth regulators, *N*-benzoyl-*N'*-phenyl ureas are an important compound family. These compounds are acting as chitin formation inhibitors. Notably, many of them contain a 2,6-difluorobenzoyl moiety (Scheme 28). Originally, the reason behind fluorine introduction was reduction of environmental stability to avoid persistence: the half-life of chlorinated 86 in soil is 6–12 months, while the half-life of its fluorinated analogue, diflubenzuron (77), is only 2–3 days under the same conditions (Scheme 29). It was showed that as a result of the size difference of F and Cl (F is isosteric with H, while Cl is quite big) the 2,6-difluorobenzoyl moiety is in plane with the rest of the urea structure, while the 2,6-dichlorobenzoyl moiety is perpendicular to it (Scheme 29). This causes the difference between the environmental stability and degradation pathway of 86 and diflubenzuron (77).¹⁸ Later studies also found that the 2- and 6-substituents of the *N*-benzoyl moiety in these ureas should be small, hydrophobic, and electron-withdrawing groups for optimal bioactivity. So fluorination was beneficial for activity too.⁸¹


3.2.2. Fluorination and Activity. Since studying structure–activity relationships is an easy and effective way to determine the effect of fluorination on activity, many examples are known where fluorination improved bioactivity. However, the molecular background of this effect is often missing.^{18–20,80,81}

Type A pyrethroids, which are analogues of the natural compounds pyrethrin I (87a) and pyrethrin II (87b), are good examples.¹⁹ Both natural and synthetic pyrethroids are potent insecticides. It was found that placement of a 2-chloro-3,3,3-trifluoroprop-1-en-1-yl group on the cyclopropyl ring gave the highest activity. Incorporation of 2,3,3,3-tetrafluoroprop-1-en-1-yl, 2,2-dichlorovinyl, and 2,2-difluorovinyl gave comparable results, while the 3,3,3-trifluoro-2-(trifluoromethyl)prop-1-en-1-yl was the least effective within the groups above. These data together with the structure of some commercially available pyrethroids as an illustration are summarized in Scheme 30.^{18,19}

Eflusilanate (92, Scheme 31) is a type C pyrethroid introduced to the market in 1991.¹⁹ Removal of its fluorine atom results in 10-fold loss of insecticide activity.⁸⁰

Diphenyl ether herbicides (protoporphyrinogen-IX-oxidase (PPO) inhibitors) also illustrate well the impact of fluorination.^{20,80} The first members of this compound family, nitrofen (93a) and bifenox (93b), were introduced in the 1960s, but they did not have a significant role in the control of weeds in commercial crops. The most important step toward changing this situation was replacing one of the chlorines with a trifluoromethyl group. After further minor optimization, oxyfluorfen (94a) and acifluorfen sodium (94b) were introduced in the 1970s (Scheme 32). Compounds 94a,b were much more

Scheme 27. Inhibition of Thymidylate Synthase by Trifluridine



potent than their predecessors, and they were able to control a wider spectrum of weeds.⁸⁰


Scheme 33 shows some other examples where fluorine incorporation improved activity. In the case of herbicide flufenacet (**95**, R = CF₃), a cell growth, and division inhibitor, the relationship between the R group and the activity was Cl < CHF₂ < CF₃.¹⁸ For flurtamone (**96**, R = CF₃), a herbicide which works by inhibiting phytoene desaturase (disrupting the synthesis of carotenoids),¹⁹ the same relationship was H ≪ OCH₃ < Cl < CF₃.⁸⁰ The same *meta*-(trifluoromethyl)phenyl group can be found in many other herbicides with the same mechanism of action.¹⁸ In the case of indoxacarb (**97**, R = OCF₃), an insecticide which acts by blocking the sodium channel, the relationship between the R group and the activity was F < Cl < OCHF₂ ≈ Br < CF₃ < OCF₃.⁸⁰ Among analogues of the protoporphyrinogen-IX-oxidase (PPO) inhibitor herbicides sulfentrazone (**98**, R = CHF₂) and carfentrazone-ethyl [(±)-**99**, R = CHF₂], activity as a function of the R group was Me < CH₂F < Et ≈ *i*Pr ≪ CHF₂.⁸⁰ Finally, replacement of the CF₃ group of the protoporphyrinogen-IX-oxidase (PPO) inhibitor herbicide benzfendizone [(±)-**100**] with a methyl group completely eliminates bioactivity.⁸⁰

3.2.3. Fluorination and Lipophilicity. Flubendiamide (**101**, Scheme 34), an insecticide with a novel mechanism of action (it activates ryanodine-sensitive intracellular Ca²⁺ release


channels in insects but not in mammals), contains a unique heptafluoroisopropyl group.⁸⁰ The main reason for its introduction was its lipophilicity.⁸¹

3.3. Observable Trends Related to Fluorinated Bioactive Compounds

3.3.1. Pharmaceuticals. To investigate the advance of fluorination in the pharmaceutical industry, the method described below was followed. For every year, the ratio of fluorine-containing drug molecules within drugs launched in that year was calculated. Then, these ratios were displayed as a function of time. For the time frame 1957–2006, William K. Hagmann already performed these steps with the help of an MDL Drug Data Report on drugs launched worldwide (biologics, inorganics, reformulations, and agricultural agents were omitted).⁵⁸ His data are shown in Scheme 35. Although there is a considerable and seemingly random oscillation in these percentages, there is still evidence to the increasing prevalence of fluorinated drugs. Since 1981, fluorine-containing drugs were launched in every investigated year (previously, this was not the case). Also, from the six cases when the yearly percentages of fluorine-containing drugs reached 20% or higher, four happened in the last 10 years of the 49 year long time period. One of these cases, the year 2003, has the highest yearly percentage between 1957 and 2006 (well above 35%).⁵⁸

Scheme 28. Commercial Insect Growth Regulators Belonging to the *N*-2,6-Difluorobenzoyl-*N'*-phenyl Urea Compound Family^a


^aThe year of their commercial introduction is also given.

Scheme 29. Comparison of Diflubenzuron (77) and Its Chlorine-Containing Analogue 86: Decomposition in Soil and Conformations^a

^aDashed rectangles highlight coplanar moieties.


To uncover more recent developments, drugs approved by the FDA in 2007–2019 were investigated. In this case, biologics and inorganics were not excluded, and after performing the calculations as above, the percentages shown on Scheme 36 were obtained. Drugs with at least one fluorine-containing active pharmaceutical ingredient (API) were categorized as “Every fluorinated drug”. Within these, “New fluorinated drugs” contained at least one, previously not approved fluorinated API. Most fluorine-containing drugs fell into this category. The

exceptions were Breo Ellipta (2013, fluorinated API: fluticasone furoate), Genvoya (2015, fluorinated APIs: elvitegravir and emtricitabine), Lonsurf (2015, fluorinated API: trifluridine), and Eplusa (2016, fluorinated API: sofosbuvir). Similarly to the time period 2002–2006 (Scheme 35), most percentages are in the 15–30% region. The trend line indicates that the prevalence of fluorine-containing drugs is still increasing. Taking into account the recent advance of biologics within approved drugs,


Scheme 30. Structure–Activity Relationship of Type A Pyrethroids and Some Examples⁴

⁴Year of commercial introductions are also given.

Scheme 31. Type C Pyrethroid Eflusilanate: Structure and Year of Commercial Introduction



Scheme 32. Evolution of Diphenyl Ether Herbicides




this is remarkable.⁸⁷ Interestingly, 2010 was the first year since 1980 when no fluorinated drugs were approved.

For new fluorinated APIs within drugs approved by the FDA in 2007–2019, the prevalence of different fluorine-containing moieties is shown in Scheme 37. (Note: since there were exactly 100 new fluorinated APIs, this percentage is equal to the number of APIs containing the group in question.) The most common motifs are (hetero)aryl fluoride (59%) and the trifluoromethyl group bound to the (hetero)aryl group (20%). Aliphatic moieties like fluorides (7%), CF₂ groups (5%), and CF₃ groups (5%) are much less common. 2,2,2-Trifluoroethylamino motifs (3%), aryl trifluoromethyl ethers (2%), difluoromethylene ethers (2%), and difluoromethylated arenes (1%) are rare. The aryl difluoromethyl ether moiety of roflumilast and the SF₆ component in the ultrasound-enhancing agent Lumason were classified as “Other” (2%). Note that the sum of the above


percentages is higher than 100% since molecules can contain more than one kind of fluorinated group.

Because fluorination reactions are still challenging,^{82,83} most fluorine-containing drugs are synthesized using commercially available fluorinated building blocks.^{17,84–87} As a result, the occurrence of different fluorine-containing moieties is connected with both the pharmaceutical usefulness of different fluorinated groups and the availability of appropriate fluorinated compounds (which depends on the limits and possibilities of current fluorine incorporation methods). To gain some insight into the latter, the TCI brochure “Fluorination Reagents, Fluorinated Building Blocks” was analyzed.⁸⁸ Under “Fluorinated Building Blocks”, this brochure listed 1815 compounds. After exclusion of highly fluorinated ethers like isoflurane (catalogue code: C2485) which have low synthetic usefulness, the remaining 1803 molecules were grouped according to their fluorine-containing moieties. As shown in Scheme 26, the two most common motifs are the same as in the APIs, and even their frequencies are roughly the same [(Het)Ar–F: 67% of building blocks and 59% of APIs, (Het)Ar–CF₃: 17% of building blocks and 20% of APIs]. This clearly demonstrates that the most common fluorinated motifs in APIs are the most accessible ones. However, less frequent fluorinated moieties show that other factors are present too. Although the occurrence of aliphatic CF₃ moieties is similar within the two compound groups (4% of building blocks and 5% of APIs), alkyl fluoride and aliphatic CF₂ moieties are significantly more represented in APIs than in the TCI brochure (aliphatic F: 1% of building blocks and 7% of APIs, aliphatic CF₂: 1% in building blocks and 5% in APIs). On the other hand, aryl trifluoromethyl ethers are more represented among building blocks (4%) than in APIs (2%). (Het)Ar–CF₂ moieties are quite rare (only 1 API and 2 building blocks contained it), so the difference between their frequencies (0% of building blocks and 1% of APIs) is not meaningful. The case of

Scheme 33. Examples of Agrochemicals Where Fluorination Enhanced Potency



Scheme 34. Structure of Insecticide Flubendiamide




difluoromethylene ethers is special: this moiety is present only in two drugs, lumacaftor and tezacaftor, which have high structural similarity, have the same indication, and were developed by the same company, and their approvals were only 3 years apart. So, the higher prevalence of the O–CF₂–O moiety among APIs (2 compounds, 2%) compared to building blocks (2 compounds, 0%) is not relevant. 2,2,2-Trifluoroethylamino motifs are another special case: since this group is a unique, very weakly basic amine (see Section 3.1.3) and an amide isostere (see Section 3.1.4), we can explain its higher occurrence within APIs (3 compounds, 3%) compared to building blocks (0

compounds, 0%). Finally, the higher percentage of other motifs in building blocks (5%) compared to APIs (2%) is mostly caused by perfluorinated building blocks (perfluorinated groups with at least two carbons are completely absent in the investigated APIs).


There is more evidence that incorporation of (Het)Ar–F moieties is relatively easy: on average, there are 1.49 (Het)Ar–F moieties within APIs containing them. To be more precise, within the 59 (Het)Ar–F-containing APIs, 64.4% contain only one such moiety; 25.4% contain two; and 10.2% contain three or more (five is the record in pibrentasvir).

To see trends in the usage of different fluorine-containing moieties within new fluorinated APIs, it is worth taking a look at the yearly percentages of these motifs. For (hetero)aryl fluorides, ratios are shown in Scheme 38. Although this structural unit is still the most common, it seems that its prevalence is slowly decreasing.

Yearly percentages of (Het)Ar–CF₃ motifs can be seen in Scheme 39. The trend line indicates the increasing popularity of


Scheme 35. Yearly Percentages of Fluorine-Containing Drug Molecules within Drugs Launched Worldwide in that Year^{a,b}

^aExcluding biologics, inorganics, reformulations, and agricultural agents. ^bAdapted from ref 58 with some modifications. Copyright 2008. American Chemical Society.

Scheme 36. Yearly Percentages of Fluorine-Containing Drug Molecules within Drugs Approved by the FDA in That Year^{a,b}

^aBiologics and inorganics were included. ^bThe dashed line is the trend line of new fluorinated drugs.


Scheme 37. Prevalence of Different Fluorine-Containing Moieties within New Fluorinated APIs of Drugs Approved by the FDA between 2007 and 2019 (Grey Columns) and within Commercially Available Fluorinated Building Blocks of TCI (Black Columns)




this structural element. This is corroborated by the fact that from the 20 APIs containing this moiety 19 were approved after 2011.

Only five fluorinated APIs were approved by the FDA between 2007 and 2019 which contained aliphatic CF₃ moieties, making statistical analysis difficult. However, 4 out of the 5 APIs in question were approved in 2015 or more recently, suggesting increased usage of this structural element. Similarly, there were only 2 APIs with the Ar-OCF₃ moiety: sonidegib (approved in 2015) and pretomanid (approved in 2019). It is possible that these are the first signs of the emergence of trifluoromethoxylated drugs, but there are not enough members in this compound family to say this for sure.

In 2014, Zhu et al. predicted that the revolution in the area of trifluoromethylation, which happened in the 2000s, would increase the number of drugs with (Het)Ar-CF₃, aliphatic CF₃, or Ar-OCF₃ moieties.⁸⁹ (Drug development is a slow process, and a considerable amount of time is required for any synthetic advances to manifest in approved drugs.) To check if this prediction was correct, ratios of the 3 groups were displayed together as a function of time (Scheme 40). The trend line clearly indicates that these CF₃-containing drugs are more and more common. The yearly numbers of these APIs (1–1 such compound was approved in 2007 and 2008 and 25 more since 2012) also support that Zhu et al. were right.

Scheme 38. Ratio of (Het)Ar–F Containing APIs as a Function of Time^{a,b}


^aThe thick black line shows the average value for the 2007–2019 period. ^bThe dashed line is the trend line.

Scheme 39. Ratio of (Het)Ar–CF₃ Containing APIs as a Function of Time^{a,b}


^aThe thick black line shows the average value for the 2007–2019 period. ^bThe dashed line is the trend line.

Yearly percentages of alkyl fluoride motifs can be seen in Scheme 41. Seven APIs contained this structural element, and up to one was approved in every year. The trend line indicates slowly decreasing popularity, but the low number of drugs in this compound family decreases its reliability. Notably, however, this is the most common fluorinated motif in ¹⁸F-containing radiopharmaceuticals (PET tracers used in diagnostics): from

the 5 such compounds approved between 2007 and 2019, 3 contain an alkyl-[¹⁸F] moiety, while the remaining 2 contain Ar-[¹⁸F] moieties. This most likely originates in the unique synthetic challenges of this compound family. First, since the half-life of ¹⁸F is only 110 min, it has to be introduced at a late stage of the synthesis. This necessitates the use of a quick, effective, and functional group tolerant fluorination reaction.

Scheme 40. Ratios of CF₃-Containing APIs as a Function of Time^{a,b,c}

^aBlack columns: (Het)Ar-CF₃, gray columns: aliphatic CF₃, squared columns: Ar-OCF₃. ^bThe thick black line shows the average value for the 2007–2019 period. ^cThe dashed line is the trend line.


Scheme 41. Ratio of APIs Containing Alkyl Fluoride Motifs as a Function of Time^{a,b}

^aThe thick black line shows the average value for the 2007–2019 period. ^bThe dashed line is the trend line.

Second, the most practical and most widely available source of this isotope is ¹⁸F⁻ (produced by cyclotrons as an aqueous solution, water can be removed by azeotropic evaporation), so nucleophilic fluorination methods are highly preferred. S_N2 reactions of alkyl sulfonates with ¹⁸F⁻ to produce alkyl-[¹⁸F] moieties fulfill the above criteria effectively.^{21,22,82} For more

comprehensive reviews of ¹⁸F-containing radiopharmaceuticals, see refs 21 and 22.

Aliphatic CF₂ moieties are even less prevalent than alkyl fluoride motifs. Between 2007 and 2019, only 5 of the investigated APIs contained them. One such drug was approved by the FDA in 2007, 2012, and 2018 and two in 2017. The low number of data points decreases the reliability of any statistical

Scheme 42. Drugs with *N*-(2,2,2-Trifluoroethyl) Groups, Approved by the FDA in the 2007–2019 Period

analyses. For similar reasons, analysis of (Het)Ar–CF₂-containing APIs (1 compound, ledipasvir, approved by FDA in 2014) and the 2 fluorinated compounds classified as “Other” (roflumilast, approved in 2011, with the Ar–OCHF₂ moiety and the SF₆ component in ultrasound-enhancing agent Lumason, approved in 2014) was omitted.

As mentioned previously during the discussion about Scheme 26, the case of difluoromethylene ethers is special. The two drugs where such a moiety is present are closely related (same developer company, same indication, and high structural similarity), and their approvals were only 3 years apart (lumacaftor: 2015, tezacaftor: 2018). Therefore, it is unlikely that this moiety will become significantly more frequent in the future.

The situation seems to be different for APIs with 2,2,2-trifluoroethylamino motifs. As mentioned previously during the discussion about Scheme 26, this structural unit can serve as a unique weakly basic amino group or as an amide isostere. Although there were only 3 fluorinated APIs approved by the FDA in the 2007–2019 period with this moiety, these are quite different (Scheme 42). Lomitapide (**102**, Aegerion Pharmaceuticals, approved by the FDA in 2012) inhibits the microsomal triglyceride transfer protein which plays a key role in the early stages of very low-density lipoprotein (VLDL) assembly and is used to treat adult patients with homozygous familial hypercholesterolemia.⁹⁰ Upadacitinib (**103**, AbbVie, approved by the FDA in 2019) is a selective JAK1 inhibitor which is used for the treatment of adults with rheumatoid arthritis.¹⁷ Finally, ubrogepant (**104**, Allergan, approved by the FDA in 2019), a CGRP receptor antagonist, is used for the acute treatment of migraines.¹⁷ Odanacatib (**74**, Scheme 23), a cathepsin K inhibitor which was promising for the treatment of osteoporosis but whose development was discontinued because of safety reasons, also contained a 2,2,2-trifluoroethylamino motif.⁶⁶ Taking these into account, the fact that every drug belonging to this compound family (molecules **102**–**104**) was approved since 2012 (in fact, two-thirds of them were approved last year) strongly suggests that we are witnessing the first steps in the emergence of drugs with 2,2,2-trifluoroethylamino motifs. The current low number of such APIs causes some uncertainty, but the upcoming years will definitely show whether the above prediction was correct or not.

3.3.2. Agrochemicals. Fluorination is more and more widespread among agrochemicals. Herbicides demonstrate this very well. Up to 2010, almost 25% of licensed herbicides were fluorine-containing.⁷⁹ However, among herbicides commercialized between 2010 and 2016, the same ratio increased drastically to 75% (see details below).²⁰

Together with herbicides, other classes of pesticides commercialized between 2010 and 2016 were also investigated. Within all pesticides (8 herbicides, 8 fungicides, 4 insecticides/acaricides, and 4 nematocides; 24 compounds in total), the ratio

of fluorine-containing ones was 75% (6 herbicides, 7 fungicides, 3 insecticides/acaricides, and 2 nematocides). From the above data (ratio of fluorinated agrochemicals was almost 88% among fungicides, 75% among insecticides/acaricides, and 50% among nematocides), it is clear that fluorination became quite popular in every class of pesticides.²⁰

4. FLUORINE IN THE ENVIRONMENT

Fluorine is the most reactive chemical element, and since recently it was believed to not occur in nature. Minerals antozonite³⁹ and villiamite⁹¹ were reported as the only two exceptions in which occlusions of fluorine as gas were reported. In combination, fluorine comprises 0.059% of the earth's crust, being the 13th element in abundance and the most abundant halogen.²³ Fluorine plays an important role in geochemical and biogeochemical systems despite its relatively low overall abundance on the Earth and in the Cosmos.⁹² There is some confusion on the use of the terms fluorine and fluoride in the literature. In this text, the term fluorine (F) will be used to denote the element or the element in any of its forms, and the term fluoride may be taken either for a compound/material or the fluoride anion (F⁻).

Inorganic fluorides and organofluorine compounds are present in the environment due to natural and anthropogenic activities. The natural sources include the weathering and dissolution of minerals, emissions from volcanoes, forest fires, and marine aerosols.^{93,94} The anthropogenic sources include different industrial processes, like coal-fired power generation, brick making and ceramic manufacture, and aluminum production and phosphate fertilizer production, and agricultural practices, including use of phosphate fertilizer and sewage sludge application and use of fluorine-containing herbicides and pesticides, etc.⁹⁵ Controlled fluoridation of drinking water supplies also contributes to the fluoride dispersion. All these processes result in accumulation of fluorine-containing compounds in the soil, air, and water and through the food chains also in humans.

4.1. Fluorine in the Lithosphere, Air, and Water

4.1.1. Lithosphere. Fluorine in the lithosphere is distributed in various minerals, like fluorspar (CaF₂), cryolite (Na₃AlF₆), and apatite (Ca₅(PO₄)₃(OH,F,Cl)), and in groups of minerals, such as mica, hornblende, and pegmatites such as topaz and tourmaline. Fluoroapatite is considered to be the most common fluoride mineral found in soil. Other fluorides (e.g., CaF₂, AlF₃) and aluminosilicates [e.g., Al₂(SiF₆)₃] are also reported to occur in soils. The fluorine content in soil ranges from under 100 to several mg kg⁻¹ dry weight (DW).⁹⁶ In many regions, the average F content is between 100 and 600 mg kg⁻¹ DW from which between 0.05 and 0.5% is available in the form of the F⁻ ion.^{97,98}

Table 1. Average Contents and Ranges of Fluoride in Food Groups

	USDA Database			UK Database		
	<i>n</i>	w_{F^-} (mg kg ⁻¹) average (SD)	range	<i>n</i>	w_{F^-} (mg kg ⁻¹) average (SD)	range
tea (<i>Camellia sinensis</i> L)	23	2.83 (1.18)	0.72–5.84	2	0.38 (0.32)	0.16–0.61
finfish and shellfish products	7	1.11 (0.87)	0.18–2.10	13	1.49 (2.98)	0.08–10.54
beverages and water	134	0.47 (0.34)	0.02–2.04	23	0.13 (0.11)	0.00–0.45
breakfast cereals	12	0.44 (0.19)	0.17–0.72	12	0.26 (0.30)	0.04–0.75
soups, sauces, and gravies	22	0.39 (0.34)	0.01–1.32	11	0.15 (0.21)	0.01–0.49
dishes	28	0.37 (0.20)	0.05–0.84	30	0.15 (0.12)	0.01–0.51
sweets & snacks	46	0.33 (0.26)	0.01–1.06	81	0.16 (0.19)	0.01–0.90
cereal products	9	0.27 (0.18)	0.06–0.51	16	0.31 (0.21)	0.04–0.57
meat and meat products	17	0.24 (0.14)	0.04–0.48	25	0.07 (0.07)	0.02–0.24
vegetables, spices, herbs	37 ^a	0.17 (0.15)	0.01–0.49	23	0.08 (0.06)	0.01–0.19
milk and egg products	13 ^b	0.12 (0.13)	0.01–0.35	28	0.07 (0.13)	0.01–0.59
infant food	50	0.12 (0.14)	0.00–0.67	251	0.15 (0.16)	0.00–1.20
fats and oils	6	0.09 (0.10)	0.01–0.25	8	0.04 (0.08)	0.00–0.17
fruits, nuts	19 ^c	0.05 (0.03)	0.01–0.12	19	0.04 (0.04)	0.01–0.19
all food groups	14	0.50 (1.62)	0.00–5.84	14	0.25 (3.04)	0.00–10.54

^aThe highest content was not considered (1.15 mg kg⁻¹ of F in commercial french fries). ^bThe highest content was not considered (1.12 mg kg⁻¹ of F in cream substitute, powdered). ^cThe highest content was not considered (2.34 mg kg⁻¹ of F in raisins).

4.1.2. Air. Airborne fluorine exists in gaseous and particulate forms. Its distribution and deposition are dependent upon emission strength, meteorological conditions, topography, particle size, and chemical reactivity.^{99,100} The gaseous forms include hydrogen fluoride (HF), tetrafluoromethane (CF₄), hexafluoroethane (C₂F₆), and silicon tetrafluoride (SiF₄), while particulate forms include cryolite (Na₃AlF₆), chiolite (Na₅Al₃F₁₄), calcium fluoride (CaF₂), aluminum fluoride (AlF₃), and sodium fluoride (NaF).¹⁰¹ Gaseous HF and SiF₄ are between 1 and 3 orders of magnitude more toxic than other common pollutants (O₃, SO₂, peroxyacyl nitrates, and Cl₂).¹⁰² Modern fluoride-emitting industries have generally little or no environmental impact; however, periods of higher than normal emissions can still occur due to routine maintenance or failure of scrubbing equipment.^{98,103,104} The maximum observed concentrations of fluoride in ambient air were 0.16 from nonurban and 1.89 μg m⁻³ from urban locations.¹⁰⁵

4.1.3. Water. The concentration of fluoride in natural waters depends mainly on factors such as geology, chemistry, physical characteristic, and climate, while the pH and complexing ions, e.g., aluminum, calcium, and magnesium, may affect the speciation.^{103,106,107}

Seawater dominates the global hydrological cycle, and its F⁻ concentration is typically between 1.2 and 1.5 mg L⁻¹.^{94,108} Surface water in areas with low natural presence of fluoride usually contains 0.01–0.3 mg L⁻¹ of F⁻.¹⁰¹ Levels above 1 mg L⁻¹ of F⁻ are often observed in areas with high naturally occurring fluoride reaching up to 50 mg L⁻¹ in hot springs and geysers.¹⁰¹ The highest fluoride levels ever have been recorded in the Kenyan lakes Elementaita (1640 mg L⁻¹) and Nakuru (2800 mg L⁻¹).¹⁰⁹

Well water (groundwater) fluoride levels vary mainly in dependence on the residence time and on the fluoride content of the minerals in the rock and ores that the water passes through. The potential fluoride-rich environments with fluoride content in groundwater above 1.5 mg L⁻¹ are mainly linked with the Precambrian basement areas and areas affected by recent volcanism.¹¹⁰

4.2. Fluorine in Drinking Water, Food, and Beverages and Dietary Fluoride Supplements and Dental Products

In humans, the predominant route of absorption of fluoride is via the gastrointestinal tract through systemic (drinking water, food and beverages, and dietary fluoride supplements) and topical sources (dental products) of fluoride delivery,^{111,112} thus knowing fluorine content (see section 4.3) of these sources is of crucial importance to avoid potential problems associated with too high intakes.

4.2.1. Drinking Water. The concentration of fluoride in natural waters ranges from trace to toxic concentrations. The World Health Organization (WHO) guideline value for F⁻ concentration in drinking water was set at 1.5 mg L⁻¹ in 2010, based on the guideline value set in 1984 and reaffirmed in 1993.¹¹³ It is interesting to note that in 1994 the WHO Expert Committee on Oral Health Status and Fluoride Use suggested that 1.0 mg L⁻¹ of F⁻ should be seen as an upper limit for fluoride in drinking water even in cold climates.¹¹⁴

In some countries, fluoride is deliberately added into water supplies.¹¹⁵ The WHO-recommended value for artificially added fluoride is usually between 0.5 and 1.0 mg L⁻¹.¹¹³ Recently, in the United States (US), the earlier recommended optimal fluoride concentration in water was reduced from 0.7–1.2 mg L⁻¹ to 0.7 mg L⁻¹.¹¹⁶ It has to be pointed out that only a few subjects in medicine have proved more controversial than public water fluoridation. While the US Centers for Disease Control and Prevention (CDC) claimed that water fluoridation is one of the ten greatest public health achievements in the US during the 20th century¹¹⁵—69% of the population receives fluoridated drinking water¹¹⁵—water fluoridation was rejected, stopped, or banned in many developed European¹¹⁷ and Asian countries.¹¹⁸

4.2.2. Food and Beverages. The US Department of Agriculture (USDA) National Fluoride Database (compiled between 1977 and 2003) and the United Kingdom (UK) Fluoride Database (compiled between 2003 and 2015) report fluoride content in different ready-to-eat food items prepared using water with an average F⁻ concentration of 0.71 mg L⁻¹ in the US and three different F⁻ concentrations in the UK Database

(for simplicity, only results obtained using water with 0.05–0.13 mg L⁻¹ of F⁻ are presented).^{119,120} Classification of foods into food groups in these databases is different. Thus, all analyzed items were categorized into 14 food groups. Average content and range of fluoride in these food groups are listed in Table 1.¹²¹

The fluoride contents between and within food groups are highly variable (Table 1). Factors that can influence the level of fluoride in food include the locality in which the food is grown, the amount of fertilizer and pesticides applied, and the content of fluoride in water used for the production, processing, and preparation. Accordingly, the average content of fluoride of all food groups is about 2-fold higher in the USDA Database than in the UK Database. The food groups with the highest fluoride content are the tea group (*Camellia sinensis* L) and finfish and shellfish products. The former group might contain even much higher fluoride contents due to the uptake of fluoride by the teaplant from the soil,^{122–126} while high fluoride contents of the latter might be ascribed to the possible remains of the skeleton due to mechanical deboning. The average content of fluoride in other food groups ranges from trace amounts to about 0.5 mg kg⁻¹ with relatively high maximum content in the beverage group. Milk and egg products, food and drinks for infants, fats and oils, and fruits and nuts are groups with the lowest fluoride content. The reported fluorine contents (Table 1) should be probably regarded as informative values only. While the concentration of fluoride in liquids was determined directly with a fluoride ion selective electrode (F-ISE), the other (solid) foods were prepared for the analysis by different methods, which may not ensure release of the entire fluorine.¹²⁷ Additionally, results are not reported according to the “Guide to the Expression of Uncertainty in Measurement” (GUM). Issues related to (1) determination of fluorine in solids and expression of results of measurements according to GUM¹²⁸ and (2) lack of fluorine-containing certified reference materials (CRMs) suitable for the analysis of food and environmental samples¹²⁹ were recently raised.

4.2.3. Salt, Milk, and Dietary Supplements. Systemic methods to deliver fluoride other than water, beverages, or food can be regarded as a choice for the consumer and include salt and milk fluoridation and fluoride-containing supplements (Table 2).

Table 2. Usual Content of Fluoride in Fluoride-Containing Salt, Milk, and Dietary Supplements

vehicle	fluoride compound	w _F
salt	potassium fluoride, sodium fluoride	250–350 mg kg ⁻¹ ¹¹³⁰
milk	sodium fluoride, disodium monofluorophosphate	2.5–5 mg L ⁻¹ ¹¹³¹
dietary supplements (tablets, drops, lozenges, or chewing gums)	sodium fluoride, acidulated phosphate fluoride, potassium fluoride, calcium fluoride	0.25–1.0 mg unit ⁻¹ ¹¹³²

Salt fluoridation is sometimes suggested for communities with low F⁻ natural water concentration or communities having no possibility of implementing community water fluoridation.¹³³ About 40–280 million people worldwide use fluoridated salt mainly in European, South American, and Central American countries.^{130,134} Milk was suggested as a relatively cost-effective method and effective vehicle for fluoride delivery in the prevention of dental caries.¹³¹ The balance between the caries'

preventive benefits and the risk of dental fluorosis has to be evaluated for the appropriate implementation of dietary fluoride supplements.¹³⁰

4.2.4. Dental Products. Systemic methods of fluoride delivery for the prevention of dental caries are questioned, and the use of dental products aimed for topical applications is recommended.^{135,136} Oral hygiene products aimed for topical applications and their fluoride content are listed in Table 3.

Table 3. Fluoride Content in Products Aimed for Topical Applications

source	w _F (mg kg ⁻¹)	comments
toothpaste	250–2800 ¹³⁷	<ul style="list-style-type: none"> • typical strength of family toothpaste between 1000 and 1500 μg kg⁻¹ of F⁻¹³⁸ • lower F⁻ content for the use in children has not been shown to be as effective in preventing caries as the 1000 μg g⁻¹ formulation¹³⁷ • preventive effects in children observed at 1000 μg g⁻¹ of F⁻ and higher—the decision on F⁻ levels for the use in children < 6 years should be balanced with the risk of fluorosis¹³⁸
mouth rinses	230–900 ¹³⁹	<ul style="list-style-type: none"> • not recommended for children < 6 years because of poor control of swallowing reflex • lower concentration for daily and higher for weekly use
gel	1000–12300 ¹⁴⁰	• for professional use
varnish	7000–22600 ¹⁴¹	• for professional use

In addition to these products, bioactive ceramics and glasses containing fluoride ions releasing the active ingredients for long periods of time are used in conservative dentistry.¹⁴²

4.3. Adequate Intake of Fluoride/Fluorine

Next to the European Food Safety Authority (EFSA)¹⁴³ and Institute of Medicine (IOM),¹⁴⁴ there are many health authorities worldwide that have considered the beneficial effects of fluoride on the prevention of dental caries as an appropriate indicator to set the adequate intake (AI) of fluoride from all sources (including nondietary sources) to between 0.05 and 0.07 mg day⁻¹ kg⁻¹ of body weight (BW) for children and adults.

The AI is based on empirical observation. Based on extensive research, Dean (1942) concluded that water fluoride concentration close to 1.0 mg L⁻¹ was associated with a high degree of protection against caries and a low prevalence of the milder forms of enamel fluorosis.¹⁴⁵ The first conversion from the exposure to fluoride in water to fluorine from intake from water and food was made in 1943 by McClure who estimated that **total fluoride intake** (and not “**only fluoride intake**”) in children at the age between 1 and 12 years ranges between 0.02 and 0.10 mg kg⁻¹ of BW (average 0.05 mg kg⁻¹ of BW).¹⁴⁶ The genesis on how this intake became interpreted as a recommendation can be regarded as dubious.¹⁴⁷ Note that the F⁻ ion has beneficial effects on the protection against dental caries and possible adverse effects on developing teeth and many other organs and tissues (see section 5). However, the total F intake is considered in the definition of AI. In accord with the genesis of AI, the term **fluoride** should be replaced by **fluorine**. Interchangeable use of these two terms is confusing and aggravates assessment of risks associated with fluoride/fluorine intake.

4.4. Daily Intake of Fluorine

Water, tea, beverages, fluoride supplements, and dental products are regarded as the main contributors to the oral intake of fluorine in humans.¹²¹ The contribution of inhaled airborne fluoride is, except for occupational exposure or exposure to

fluoride by coal or fuel burning, negligible.^{148,149} Dermal absorption is insignificant except in cases of hydrofluoric acid burns.¹⁵⁰

4.4.1. Fluorine Intake in Children. Fluoride intakes in breastfed children are usually low even at high intakes of fluoride by mothers.¹⁵¹ Daily intakes of fluoride from drinks (water + beverages), foods, and toothpaste for 2- to 12-year-olds children residing in areas with the low, optimal, and high concentrations of F⁻ in drinking water were estimated based on research reported over the past decade (Table 4).^{152–161}

Table 4. Daily Intake of Fluoride for 2- to 12-Year-Old Children Residing in Areas with Low, Optimal, and High Concentrations of F⁻ in Drinking Water

	intake (mg day ⁻¹ kg ⁻¹ BW)			total
	drinks	food	toothpaste	
low fluoride water, C _F ⁻ < 0.15 mg L ⁻¹				
average	0.007	0.022	0.025	0.054
SD	0.004	0.008	0.016	0.019
min	0.003	0.009	0.012	0.023
max	0.013	0.028	0.055	0.062
rel. cont. %	14	40	46	100
optimal fluoride water, C _F ⁻ = 0.47–1.2 mg L ⁻¹				
average	0.020	0.014	0.025	0.059
SD	0.005	0.008	0.012	0.015
min	0.015	0.005	0.010	0.015
max	0.030	0.025	0.046	0.064
rel. cont. %	34	24	42	100
high fluoride water, C _F ⁻ > 2.0 mg L ⁻¹				
average	0.122	0.166	0.017	0.305
SD	0.086	0.095	0.006	0.128
min	0.021	0.030	0.010	0.061
max	0.274	0.268	0.022	0.385
rel. cont. %	40	54	6	100


In general, the daily intake of fluorine increases with increasing concentration of fluoride in drinking water (Table 4). Wide variations in the intakes in areas with comparable concentration of fluoride in drinking water are mainly due to different methodological approaches to collecting the data. The average intake of fluoride in children residing in areas with low and optimal concentrations of F⁻ in water exceeds the AI for 8% and 18%, respectively. In these areas, the intake of F⁻ with toothpaste accounts for almost half of the total daily intake. In high fluoride areas, drinks and food represent the major sources of fluoride intake. The intake might be in average up to 6-fold higher than the AI. The estimated intakes in children are high enough to pose a risk for development of dental fluorosis and other adverse effects caused by excessive fluoride intake.

4.4.2. Fluorine Intake in Adults. There is a critical lack of recent studies on the intake of fluorine with diet in adults. The presented estimates are based on the average total intakes of fluorine with total diet (food, water, and beverages) reported before 2007.


The average daily fluorine intake in nonfluorinated areas ranges between 0.86 and 1.5 mg (average of 0.95 mg) (equivalent to 0.012–0.021 (average 0.014) mg kg⁻¹ of BW for a 70 kg man).^{162–166} The average daily intake of fluorine in fluorinated areas is almost 2-fold higher, being 0.99–2.8 (average 1.8) mg, equivalent to 0.014–0.040 (average 0.026) mg kg⁻¹ of BW for a 70 kg man.^{162,164,167,168}

The daily intakes of fluoride can also be significantly higher. Daily consumption of 1 L of tea can contribute between 0.3 and 8.8 mg of F⁻ (equivalent to 0.004–0.126 mg kg⁻¹ of BW for a 70 kg man).¹²¹ Some exotic leafy superfoods were suggested to contribute up to 1.25 mg of F⁻ (equivalent to 0.018 mg kg⁻¹ of BW for a 70 kg man) to the total daily intake.¹²⁹ Based on the estimate for the consumption of salt in EU, the intake of fluoride from salt can range between 2–4.2 mg day⁻¹ (equivalent to 0.029–0.060 mg kg⁻¹ of BW for a 70 kg man).¹⁶⁹ The intake can be further increased by consumption of fluoride-containing

Scheme 43. Synthesis of Fluorinated Analogues of Drugs by a Sequential Process of CYP450-Mediated Oxidation and DAST-Mediated Fluorination



Scheme 44. Fluorinated Derivatives of Phenylpyrroloquinolinones Shown to Have Antitubulin Activity and the Effect of the Fluorine Substituent on Metabolic Stability Against HLM



supplements other than fluoridated salt and the use of dental products containing fluoride.

5. METABOLISM OF FLUORINE-CONTAINING DRUGS

The incorporation of fluorine into biologically active organic molecules is often stated to increase their metabolic stability,^{12,57} usually based on the premise that the C–F bond is much more resistant than the C–H bond to oxidation by cytochrome P450 enzymes, which generally carry out the first metabolic transformations. To date, this has been exploited in the development of many pharmaceuticals such as ezetimibe,¹⁷⁰ an oral cholesterol absorption inhibitor, and celecoxib, a COX-2 inhibitor,¹⁷¹ both of which are covered in section 3.1.1.

5.1. Metabolic Differences between Fluorinated and Nonfluorinated Compounds

Despite these examples, the generalized statement that the introduction of fluorine in a biologically active organic molecule improves the metabolic stability can be somewhat misleading. In fact, there are many reported examples in which the introduction of fluorine in the molecule does *not* improve its metabolic stability. On the contrary, there are many reports in which the presence of fluorine increases the susceptibility of a molecule toward metabolism in the body. For example, there is evidence that a fluorine substituent *ortho* to a phenol group increases its reactivity toward methylation and glucuronidation reactions *in vivo*.^{172–174} Clearly, as demonstrated in the examples of ezetimibe and celecoxib, the introduction of fluorine into strategic positions of an organic molecule can favorably modify the metabolic profile, but the simple fact of incorporating a fluorine atom does not necessarily mean that the pharmacological and pharmacokinetic characteristics of the molecule will be improved.

In 2016, Obach et al. reported interesting findings exploring the effects of replacing a metabolically labile alkyl C–H bond with a C–F bond in several commercial pharmaceuticals.¹⁷⁵

First, the authors incubated midazolam, ramelteon, celecoxib, and risperidone with P450 enzymes in order to obtain the hydroxyl metabolite, and these were then subjected to deoxyfluorination reactions with DAST which produced the corresponding fluorinated derivatives (Scheme 43). In this way, the authors successfully introduced a fluorine atom at the position most susceptible to metabolism by P450 enzymes, thereby hoping to block oxidation in that position and produce a fluorinated version of the drug with a longer biological half-life *in vivo*. When the fluorinated analogues were reincubated with the same P450 enzymes used to introduce the hydroxyl group during the original preparation, only F-celecoxib **110** and F-risperidone **111** were found to be more stable compared to their nonfluorinated counterparts. The introduction of fluorine had no effect on the half-lives of F-midazolam **108** and F-ramelteon **109** in this assay. On the other hand, when incubated with human liver microsomes, the results were rather different: F-midazolam was slightly more resistant to metabolism than imidazole; however, the higher stability exhibited by F-risperidone toward CYP2D6 was considerably reduced, and both F-celecoxib and F-ramelteon were metabolized *faster* than their nonfluorinated analogues by human liver microsomes.

From this study, the authors deduced that this strategy works best on substrates that are only metabolized by P450 enzymes in one position rather than those that are hydroxylated at several sites. Furthermore, the impact of fluorine substitution at P450 hydroxylation sites on metabolic stability is somewhat unpredictable and could also depend on other factors, such as lipophilicity. Incidentally, the fact that “fluorine increases the lipophilicity of organic compounds” is another generalized yet misleading statement. In fact, the mono- or trifluorination of saturated alkyl chains often results in a *less* lipophilic molecule due to the strong electron-withdrawing capability of fluorine.^{12,176} This is also a function of fluorination pattern—vicinal difluorides on an alkyl chain are more polar than geminal

difluorides due to the gauche effect favoring a conformation in which the C–F dipoles are aligned.^{177,178}


In a later study by Ferlin et al. dealing with the synthesis and biological evaluation of phenylpyrroloquinolinones, a class of compounds shown to have potent antiproliferative activity, four fluorinated derivatives were synthesized and compared to the parent nonfluorinated compounds (Scheme 44).¹⁷⁹ The authors found that, although active, the fluorinated derivatives were in fact not more metabolically stable than the parent molecules. On the contrary, compounds 113–115 were found to have shorter half-lives than 112 when incubated with human liver microsomes and NADPH. Therefore, the authors suggested that the phenyl ring in the 7-position of 117 was not a metabolic hotspot for oxidation by CYP and that the introduction of fluorine on this ring instead caused “metabolic switching”, making the resulting compound more metabolically labile. Similarly, fluorinating the benzoyl group in 116, which is fairly stable against NADPH-dependent oxidative metabolism but is susceptible to hydrolysis by human liver microsomes, had no effect on the stability of the compound against hydrolysis of the amide group.

5.2. Loss of Fluoride and the Formation of Toxic Metabolites

5.2.1. Via Conjugation and Enzymatic Transformations.

As well as studying the beneficial effects brought about by the introduction of fluorine, one should also consider the potential adverse effects that could arise, an aspect that is often overlooked. In many cases, the metabolism of fluorine-containing drugs, so-called *organic fluorine*, results in the loss of fluoride or hydrogen fluoride, or *inorganic fluorine*, from the molecule. Dinitrofluorobenzene 119 readily reacts with lysine residues in proteins and enzymes to form the dinitrophenyl hapten, producing an immune response.¹⁸⁰ This accounts for around 10% of the dose in vivo, and the remaining material is conjugated to glutathione and excreted without complications (Scheme 45).¹⁸¹

Scheme 45. Metabolism of Dinitrofluorobenzene: Its Conjugation with Glutathione and Concomitant Loss of Fluoride



Not only does this give rise to potential toxicity from the free fluoride anion, as discussed in section 4 of this review, but also other metabolites formed as a direct result of fluoride's potential as a leaving group can also produce secondary effects. This has been exploited effectively in the development of certain *suicide inhibitors* such as eflornithine (trade name Ornidyl), which is used to treat African trypanosomiasis (sleeping sickness).¹⁸²

Eflornithine, a difluoromethylated analogue of the natural substrate ornithine, is a potent inhibitor of ornithine decarboxylase (ODC), the enzyme responsible for the synthesis of putrescine from ornithine and representing the first step in the


synthesis of polyamines. In this way, eflornithine is accepted as a substrate into the active site of the enzyme but behaves quite differently from the natural substrate (Scheme 46).¹⁸³ While ornithine loses a molecule of carbon dioxide to reform the starting imine, which is able to undergo a second transamination event with the nearby lysine residue to release the final product putrescine, eflornithine instead loses a fluoride ion. The resulting vinyl fluoride is then subject to nucleophilic attack by a cysteine residue located near the active site, prompting the loss of a second fluoride ion and covalently and irreversibly binding eflornithine to the enzyme active site. From there, transamination can take place to reform the starting imine to be ready for the next reaction; however, the active site remains blocked by the final 5-membered ring that remains bound to the cysteine residue within the active site (Scheme 46).¹⁸⁴

Fluoride can also be lost as the result of enzymatic transformations, the most typical being through the action of cytochrome P450 enzymes. Although fluorinated benzene rings are often more resistant to CYP450 oxidation, hence why fluorinated phenyl rings are a common feature of pharmaceuticals and agrochemicals, the defluorination of fluorobenzene derivatives by CYP450 enzymes does still occur and is well documented.^{172,185,186} In compounds in which the fluorine substituent lies in the *para* position relative to a heteroatom such as oxygen or nitrogen, the process generally occurs via a quinone-like intermediate following oxygenation and elimination of the geminal fluoride (Scheme 47 a, red). The antimalarial drug 5-fluoro-amodiaquine, for example, is oxidized to the quinoneimine intermediate and subsequently attacked by glutathione, resulting in the 5-glutathionyl adduct and the release of free fluoride (Scheme 47b).^{172,187} Furthermore, there is also a well-established phenomenon known as the *fluorine NIH shift* by which the fluorine atom migrates to balance the positive charge, resulting in the corresponding α -fluorocarbonyl compound 127 rather than defluorinated derivative 125 (Scheme 47 a, green).^{188–190}


In 2005, Shang et al. demonstrated how compound 131, originally developed as a dipeptidyl peptidase IV inhibitor, undergoes several transformations involving the terminal pentafluorophenyl ring.¹⁹¹ As discussed earlier, the introduction of fluorine substituents on a phenyl ring is a common strategy to improve metabolic stability against CYP450 oxidation. However, in this case, with five fluorine substituents withdrawing electron density, the phenyl ring is rendered sufficiently electrophilic enough to undergo direct attack by glutathione with loss of a fluoride ion (Scheme 48). In addition, as seen in the previous example, oxidation of fluorinated phenyl rings by CYP450 can still occur and is well documented, often taking place via the formation of reactive intermediates such as quinones, quinoneimines, and/or arene oxides.¹⁹² The authors also detected several species resulting from the conjugation of glutathione with these oxygenated intermediates, once again losing one or more fluoride ions in the process (Scheme 48).

Chlorotrifluoroethylene (132), a commonly used refrigerant and monomer used to produce polychlorotrifluoroethylene (PCTFE), has been shown to undergo similar bioactivation.¹⁹³ First, the chlorofluorocarbon is conjugated with glutathione through the action of hepatic cytosolic and microsomal glutathione S-transferases to form the nephrotoxic glutathione conjugate. From there, the glutathione can be hydrolyzed to give the corresponding, and also nephrotoxic, cysteine derivative 134 (Scheme 49).¹⁹⁴ The authors suggest the toxicity could be due to the next steps in the metabolic fate of the cysteine conjugate,


Scheme 46. Mechanism of Action of Eflornithine




Scheme 47. Loss of Fluoride through the Action of CYP450 Enzymes




Scheme 48. Metabolism of 131 by CYP450 to Produce Defluorinated Glutathione Conjugates



Scheme 49. Bioactivation of Chlorotrifluoroethylene Metabolites Leading to Cell Toxicity



Scheme 50. Metabolism of Aliphatic Polychlorotrifluoroethylene




which give rise to several reactive intermediates. In addition, the authors mention that the nephrotoxicity of the released inorganic fluoride ion may play a role. The highly reactive thioacyl fluoride derivative 136, and to a lesser extent chlorotrifluoroacetic acid 138, may also give rise to cytotoxicity through the indiscriminate acylation of cellular nucleophiles.

The metabolism of trimers and tetramers of polychlorotrifluoroethylene has also been studied by Brashear et al. with similar conclusions.¹⁹⁵ In aliphatic chains, the loss of fluorine as hydrogen fluoride generally takes place after hydroxylation of the center adjacent to the carbon–fluorine bond.¹⁷² In this case, the authors suggest that only those oligomers with two chlorine


atoms at the terminal position could be metabolized by CYP450 enzymes, starting with a reductive dehalogenation event cleaving a C–Cl bond, consistent with the relative C–F and C–Cl bond strengths (Scheme 50). Following this, the free radical abstracts a hydrogen atom, and the resulting compound 141 can then be oxidized by CYP450 enzymes to the corresponding unstable halohydrin. From there, hydrogen chloride is lost, leaving the reactive acyl fluoride derivative 142, another potentially harmful acylating agent, which is then hydrolyzed to the final carboxylic acid.

The widely used anticancer drug 5-fluorouracil has also been shown to give rise to toxic metabolites and can cause, in certain

Scheme 51. Bioactivation and Consequent Inhibition of the Citric Acid Cycle by Anticancer Drug 5-Fluorouracil



Scheme 52. Bioactivation and Toxicity of 1,3-Difluoropropan-2-ol, the Major Ingredient in Gliftor



cases, serious side effects such as diarrhea, nausea, or even death in severe cases.^{30,196} This is believed to be due to its conversion into α -fluoro- β -alanine and, subsequently, into fluoroacetate and fluorocitrate which have all been shown to severely limit energy production as well as exert neurotoxic effects (Scheme 51).^{197–200} The second of these is the final catabolite of fluorouracil and can enter the citric acid cycle in the same way as the native substrate acetate. In this way, fluoroacetate is transformed into fluoroacetyl CoA by the action of acetate thiokinase in the presence of ATP and Mg²⁺, which then reacts with oxaloacetate to form fluorocitrate (Scheme 51).²⁰¹ Fluorocitrate then disrupts the citric acid cycle and causes toxicity through an accumulation of citric acid in tissues (the mechanism of this is discussed more extensively in section 2.2).

Fluoroacetate was used in the USA and Australia as a pesticide but was later withdrawn given the low specificity; fluoroacetate is toxic to the vast majority of mammalian species.²⁰² Similarly, 1,3-difluoropropan-2-ol (146) was used extensively in Russia and China and was the major ingredient in the rodenticide Gliftor, which is now mostly withdrawn from use. This had a bioactivation lag of around 2 h due to the necessity for the prior formation of fluoroacetate (Scheme 52).²⁰³ First, 1,3-difluoropropan-2-ol undergoes NAD⁺-dependent oxidation to difluoroacetone, which is then converted to fluoroacetyl CoA 7a and enters the citric acid cycle as seen in the previous example.

5.2.2. Organophosphorus Compounds. Although the ability of fluorine to act as a leaving group has been exploited in

pharmaceuticals that are beneficial for human health, it has also been applied to the development of other substances that have quite the opposite effect: nerve agents. The first nerve agent, tabun, was discovered in 1936 when the German chemist Gerhard Schrader was carrying out his research into the development of new organophosphate insecticides. Although tabun did not contain fluorine, the next compound in the series, sarin, did indeed contain a fluoride leaving group and is arguably one of the most deadly nerve agents that has been used to date (Figure 1).²⁰⁴





Figure 1. Fluorine-containing nerve agents discussed in this review.

These agents work by irreversibly inhibiting acetylcholinesterase, thereby causing a buildup of acetylcholine and generally causing death by asphyxia due to loss of control of the muscles involved in breathing. The mechanism of action is simple and effective; the Ser-200 residue on acetylcholinesterase attacks the phosphorus center of the nerve agent and expels the fluoride leaving group. The resulting phosphonate is stable and paralyzes all enzyme activity (Scheme 53).²⁰⁵

Scheme 53. Mechanism of Action of Phosphorus-Based Nerve Agents



It is worth noting that these molecules are chiral since the phosphorus is bound to four different groups, and the S_P enantiomers are generally more active than their R_P counterparts.^{206,207} However, given its comparative ease of preparation and similar effectiveness in chemical warfare, the racemate is generally used. Racemic sarin is prepared via a simple mixture of relatively nontoxic starting materials: methylphosphonyl difluoride, isopropyl alcohol, and isopropylamine.²⁰⁸

Although these compounds were developed over 50 years ago, sarin especially has seen use in modern times due to its effectiveness in war. Nerve agents were not used in World War II, but sarin is thought to have been used in the Iran–Iraq conflict in the 1980s.²⁰⁹ In fact, the largest attack using nerve agents was in this period, following an Iraqi attack on the Kurdish civilian population of Halabja, killing around 5000 people.¹⁸⁵

A Japanese terrorist group known as Aum Shinrikyo used sarin in two well-documented attacks in the 1990s. One night of June 1994, they released 12 liters of sarin from the back of a truck, by means of a heater and a fan, into Matsumoto city, killing 7 and injuring approximately 500 more. Some of the victims still showed symptoms a year after the incident.²¹⁰ A year later, the same group carried out a second attack on the Tokyo subway system, releasing sarin into trains on three separate lines.²¹¹ This attack was far less successful than it could have been due to the inefficient dispersion method; the sarin was contained as a liquid in plastic bags, which were pierced as the terrorists fled the scene.²¹² Even so, the attack produced 13 fatalities and affected over 5000 more, including over 50 people with severe injuries (some of whom died thereafter) and around 1000 with temporary vision problems.

Sarin has also been used in the Syria conflict throughout the 2010s in some of the most deadly attacks since the aforementioned attacks in the 1980s Iraq–Iran conflict. In August 2013, sarin was dispersed in the eastern outskirts of Damascus, causing around 1400 civilian deaths and thousands more nonfatal casualties.^{213,214} Later, in 2017, sarin was once again used in the Syrian town of Khan Shaykhun, killing over 80 people and injuring hundreds more.²¹⁵ This attack caused U.S. President Donald Trump to retaliate and implement a strike against the base from which the attacks were believed to have been launched.

More recently, a former Russian spy, Sergei Skripal, and his daughter Yulia were found gravely ill on a park bench in Salisbury, U.K. in early 2018. It was later found that they had been poisoned with A-232, a so-called *Novichok agent* (Figure 1).²¹⁶ The pair remained in intensive care for around a month before they were discharged.

Nevertheless, one must not forget why compounds with such activity were developed in the first place, for use as insecticides. In fact, the same Gerard Schrader responsible for the discovery of tabun and sarin also developed dimefox, an effective insecticide that is now prohibited in the vast majority of developed countries including the E.U. and the U.S. (Figure 2).





Figure 2. Structures of withdrawn organophosphate insecticides.

Another organophosphorus insecticide bearing the same fluoride leaving group, the structurally similar mipafox, was also withdrawn from use following toxicity concerns (Figure 2).²¹⁷ However, organophosphorus acetylcholinesterase inhibitors as a compound class are still used to this day as insecticides despite their relatively high toxicity in mammals—they are thought to cause up to 200 000 accidental deaths each year,²¹⁸ and curiously, they are a relatively common suicide method in Turkey.^{219,220}


5.2.3. Fluorinated Anesthetics. Since the 1950s, fluorinated compounds have been extensively used as anesthetics, starting with fluoroxene which replaced diethyl ether due to a kinetic enhancement.²²¹ However, fluoroxene was quickly put into misuse since it was flammable, toxic, and pungent and had several unwanted postoperative side effects on patients. In fact, it has been shown that fluoroxene, as well as vinyl fluoride, inhibit the action of CYP450 enzymes through a suicide-based mechanism (Scheme 54).²²² The authors provided evidence of a free-radical-based mechanism, by which the oxidation takes place on the double bond at the same carbon as the substitution (F in the case of vinyl fluoride and OCH_2CF_3 in the case of fluoroxene), leaving a free radical at the terminal position. This then alkylates one of the nitrogen atoms of the porphyrin ring, and the leaving group is subsequently expelled, leaving the porphyrin ring alkylated and the CYP450 inhibited.

Halothane quickly took over from fluoroxene after it was found to be highly potent as an inhaled anesthetic and has relatively low toxicity compared to fluoroxene. However, it was later shown to cause to a certain degree of nephrotoxicity, due to hepatic CYP450 oxidation giving rise to the reactive trifluoroacetyl chloride which can acylate cellular proteins, as seen previously (Scheme 55).²²³ Another anesthetic, methoxyflurane, was also shown to cause a certain degree of nephrotoxicity, albeit through a different mechanism. In this case, CYP450 has been shown to metabolize methoxyflurane into two different products, neither of which are toxic individually. However, when dichloroacetic acid is formed, two molecules of fluoride are also released, and the mixture of these two compounds together is indeed nephrotoxic (Scheme 55).^{224,225} Due to this, the use of methoxyflurane was discontinued in the USA and Canada in 1999, although other places such as New Zealand, Australia, the UK, and Europe continue to use methoxyflurane in specific situations.²²⁰

Scheme 54. CYP450 Inhibition by Fluoroxene, An Early Anaesthetic, and Vinyl Fluoride



Scheme 55. Formation of Toxic Metabolites from Fluorinated Anaesthetics



Enflurane replaced these anesthetics in part since it seemed to be safer, although further studies showed that it produced nephrotoxicity similar to methoxyflurane (Scheme 55).²²⁶ This is also thought to be due to the release of fluoride ions; this is similar in other modern fluorinated anesthetics. However, the modern anesthetics are much more resistant to metabolism and as such are generally deemed much safer.²²⁰

5.3. Environmental Factors and Bioaccumulation of Fluorine-Containing Compounds


Fluorinated compounds have also caused a certain degree of environmental damage over the years since upon discovery of new compounds with positive characteristics for a certain application there has been a general hastiness to put them to use. Any toxicity studies in terms of humans and the environment have come much later once the damage had already been done. A very typical example of this is DDT, which was found to be an excellent insecticide and was extensively put to use between the 1950s and 1980s. It was later banned once its toxic effects were discovered and is now largely blamed for the decline of several species of marine life and birds of prey. Although DDT does not contain any fluorine atoms, it does contain chlorine atoms and shares similar physical chemical properties with many fluorinated compounds: highly lipophilic and a very long half-life in the environment.

In fact, many studies on the presence and geographical distribution of pharmaceuticals and agrochemicals have been published previously. Of the 61 most frequently encountered pharmaceuticals in the environment, 14% contain fluorine, and more specifically 8% correspond to fluorinated antibiotics.³⁴ Perhaps unsurprisingly, the drug encountered at the highest concentrations globally is ciprofloxacin, a fluoroquinolone that is one of the most widely used antibiotics worldwide. The figures can be worrying since many of these compounds are found in water systems and in organisms at biologically relevant concentrations; in fact, many studies exist reporting how such concentrations affect various organisms.²²⁷ Schoenfuss et al. found that the predator avoidance behavior of larval fathead minnows is hampered upon treatment with environmental concentrations of antidepressants such as fluoxetine.²²⁸ The same drug also resulted in reduced growth rate for tadpoles, resulting in smaller frogs at a disadvantage for predator evasion, seeking new territories, and mating successfully.²²⁹ Recently, Yokoyama described how pollutant levels of the insecticide diflubenzuron are enough to affect the embryonic development of the caddisfly, causing thorax and leg abnormalities and reducing their survival rates.³⁶ These few examples are just an indicator of the effects humans are having on the environment in terms of pollutants from the pharmaceutical and agrochemical

industries, but many more studies have been published with similarly concerning results.³⁴

5.3.1. Chlorofluorocarbons (CFCs) and Hydrofluorocarbons (HFCs). A well-known example of the potential problems of fluorinated compounds in the environment is the use of chlorofluorocarbons (CFCs). These were first developed in the 1930s and widely used in many applications including propellants, foam-blowing agents, refrigerants, and solvents due to their ideal properties (low toxicity, high stability, low flammability, etc.).²³⁰ Unfortunately, the fact that their use would lead to the destruction of the ozone layer was not predicted until the year 1974, and from then on it quickly became apparent that this was becoming a reality.²³¹ However, the ozone-depleting properties of these compounds is not strictly due to their fluorine content. The actual mechanism by which CFCs destroy ozone is through chain reactions involving chlorine that can be released from the starting compounds through photolysis of the C–Cl bond. In fact, CFCs have been largely replaced with hydrochlorofluorocarbons (HCFCs) and hydrofluorocarbons (HFCs) which do not have such a disastrous effect on the ozone layer; given their shorter half-life, they mainly remain within the lower atmosphere and generally do not reach the stratosphere (Scheme 56). Incidentally, CFCs have also been found in groundwater samples, even in 2019, and have been shown to degrade to the toxic compound difluoroacetic acid.²³²

Scheme 56. Effects of CFCs and Derivatives in the Atmosphere^a



^aCFCs destroy the ozone and allow harmful UV radiation through to the Earth's surface. HCFCs and HFCs do not reach the stratosphere and therefore do not destroy the ozone layer but absorb and re-emit IR radiation from the Earth's surface, producing a greenhouse effect.

Nevertheless, the newer HFCs are also beginning to be more restricted in their use in recent years. Although they do not contribute as much to the depletion of the ozone layer, they are in fact greenhouse gases and contribute significantly to global warming through the absorption of IR radiation.²³³ Due to this, an amendment to the Montreal Protocol was passed in 2016 to begin phasing out the use of HFCs in 85% of countries by 2024.

Volatile anesthetics can be similar in structure to CFCs and therefore possess similar properties with regard to their atmospheric presence; they also contribute to the greenhouse effect and have long atmospheric lifetimes (desflurane remains in the atmosphere for approximately 14 years after being released).²³⁴ Significant amounts are generated as waste and released into the atmosphere from hospitals. Therefore, there

have been many efforts in recent years to develop ways to capture the waste gases and recycle them due to the low metabolic rates inside the body; only <0.1% of desflurane and 3–5% of sevoflurane are metabolized, and the vast majority passes through the patient unaffected. In early studies, soda lime was explored for this purpose,²³⁵ but more recently zeolites, activated carbon, molecular sieves, and silica gel have all been tested for this purpose with varying levels of success.²³⁶

5.3.2. Perfluoroalkyl Substances (PFASs). Fluoropolymer-based materials have become some of the most important out there due to their outstanding properties that are perfect for a myriad of high-tech applications; they have valuable implications in everything from energy-related materials such as fuel-cell membranes and electrolytes in lithium-ion batteries to protective coatings and fire retardants in the aeronautical industry.^{4,237} Some of their most important properties include their thermal stability, chemical inertness, and excellent weatherability and durability. However, it is precisely these properties that have caused, and continue to cause, environmental damage with regard to certain classes of these compounds.

Perfluoroalkyl acids (PFAAs) are defined as aliphatic acids in which all of the hydrogen atoms attached to the carbon backbone have been replaced with fluorine, except those present in the terminal acid functional groups, and first came into use in the 1940s when their unique physicochemical properties were discovered (Figure 3).²³⁸ They are both lipophilic and hydrophobic





Figure 3. Perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), the two most prevalent perfluoroalkyl substances (PFASs).

and have found applications as surfactants, in fire-fighting foams, and as additives in the manufacture of many materials, as well as being used in the production of PTFE, polyvinylidene fluoride, and fluoroelastomers. The most popular were the C-8 derivatives, perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), although these were phased out in 2001 and replaced with other shorter-chain derivatives since they were thought to be less noxious for environmental and human health. However, the C-8 derivatives were so widely used and so environmentally stable that they remain even to this day. They are, some scientists claim, “the most persistent chemicals we are facing today”.³³

After half a century of production and commercialization of over 3000 poly- and perfluoroalkyl substances, certain compounds now appear on the Stockholm Convention list as Persistent Organic Pollutants; due to their high chemical and thermal stability, they are deemed *practically nonbiodegradable*.^{33,239} The aqueous phase is considered a major sink for these compounds, and as such they have been detected in many water samples—including groundwater, surface water, ocean samples, and even drinking water—all across the globe, even in remote locations such as the Arctic or Antarctic Oceans.^{240,241} Despite current measures to restrict the production and use of several longer-chain PFASs, there is little to no research data available for similar compounds, such as those with a shorter perfluoroalkyl chain or other derivatives.²⁴² For example,

Scheme 57. General Approaches for the Synthesis of Fluoroquinolones



Cousins et al. point out that in the period between 2002 and November 2016 an average of just 16 peer-reviewed articles were published containing studies on each phosphorus and ether containing PFASs.²⁴¹ Having said this, it is important to note that it is thought that branched isomers and those with perfluoroalkyl chains shorter than seven carbons are generally eliminated faster from organisms and as such are not considered to be especially bioaccumulative.²⁴³

Another variable is the type of predator–prey interaction being considered. For example, PFASs are thought to bioaccumulate in mammalian and aquatic predators that prey on fish more than in their avian counterparts. This could be explained through the geographical locations of these interactions; mammalian and aquatic predators tend to live in the same area and always hunt in the same area, whereas avian predators tend to venture further afield.²⁴² For example, significant concentrations of PFASs have been found in polar bears,²⁴⁴ as well as in different trophic levels of fish.²⁴⁵

Clearly, we also belong in the food chain and as such are also susceptible to such bioaccumulation. Human blood samples from around the globe have also been tested for this class of organic pollutant with similar results. Furthermore, based on blood collected from retired fluorochemical workers, Olsen et al. estimated their half-lives to be relatively long: 3.5 and 4.8 years for PFOA and PFOS, respectively.²⁴⁶ Due to these long half-lives, accumulation in tissues is possible over time, a worrying prospect given the potential health concerns associated with these compounds.

Over the past decade, following the first concerns for environmental health and bioaccumulation, there have been many studies on the toxicity of PFASs. The striking lack of knowledge we had about the toxicity of these compounds can be highlighted simply by the fact that, in 2018, the European Food Safety Authority revised its decades-old safety limits of exposure to the most common C8 compounds: from 1050 nanograms per kilogram of body weight per week down to 13 ng kg⁻¹ in the case of PFOS and from an astounding 10 500 ng kg⁻¹ down to just 6 ng kg⁻¹ per week for PFOA. Nonetheless, recent studies suggest that PFASs (more specifically the traditional PFOA and PFAS) could exert negative effects on mammary development,²⁴⁷ the immune system,²⁴⁶ thyroid,^{248,249} and liver function,²⁵⁰ as well as cause neurological problems.²⁵¹ Studies involving the toxic effects of PFOS have been summarized in a recent review, and it seems that the main mechanism by which this compound causes biological damage is through interference with fat metabolism and oxidative stress.²⁵² It has even been suggested that high levels of PFOA can induce a cohort of cancers, although the results are rarely decisive.^{253–256}

Thankfully, recent data suggest that the levels of PFAS found in adult Americans' blood have been slowly decreasing over time, likely due to the ever-increasing control imposed on the

production and use of this class of polyfluorinated compounds.²⁵⁷ Moreover, shorter-chain PFASs that are emerging as viable alternatives to the older C8 derivatives have been shown to be significantly less toxic, such as perfluorohexanoic acid which has only been demonstrated to exert mild and/or reversible effects on the kidneys.^{258,259} With new measures in place and more knowledge about the dangers and problems associated with these pollutants, in the future we may be able to avoid more unnecessary damage to wildlife, ourselves, and the environment.

6. FLUORINE-CONTAINING PHARMACEUTICALS WITHDRAWN FROM THE MARKET

Although the drug development process is long and cost-intensive, problems with efficacy, manufacturing, regulation, and severe toxicity-related side effects can result in the voluntary withdrawal of a drug from the market or a prohibition by drug regulatory agencies. Many of these adverse effects are related to efficacy and safety, two decisive factors for viability of a chemical entity.²⁶⁰

Nowadays, a large number of therapeutic agents contain strategically placed fluorine atoms, the benefits of which have been widely reported.^{84–87} In this sense and very recently, Shibata and co-workers analyzed and reported the latest contributions of organofluorine compounds to the fields of agrochemicals⁸⁶ and pharmaceuticals⁸⁷ and categorized them into several groups based on the chemotype of their fluoro-functional substituents. In these reviews, the authors have shown the rapid progress of synthetic organofluorine chemistry over the last two decades.

However, the involvement of fluorine in the adverse effects of certain drugs, often caused by defluorination, remains much more scarcely studied.¹⁷²

In this regard, one of the main gaps in our knowledge for future drug development is how fluorine substitution affects the metabolism and the mechanisms leading to toxicity.²⁶¹ Some examples of fluorine-containing pharmaceuticals withdrawn from the market are summarized here, classified according to the fluorine group present in aromatic and aliphatic systems.

6.1. Aromatic Substitution

6.1.1. Aromatic Fluoro-Substituted Compounds.

6.1.1.1. Fluoroquinolone Derivatives. The quinolone family of drugs is one of the most important in medicinal chemistry. Used in both human and veterinary medicine, the quinolone nucleus is the backbone of a large group of broad-spectrum antibiotics, as well as certain derivatives proving active in chemotherapy in recent years.²⁶² Quinolone derivatives are characterized by their easy synthesis through various methods, affording numerous and interesting chemical structures.^{263,264} Their structure–activity relationship has been studied exten-

sively, and the structural requirements of the active pharmacophore in the quinolone nucleus are fairly well understood.^{265,266} In this sense, the presence of a fluorine atom in the C-6 position of the bicyclic scaffold has given rise to a very important subclass of quinolones, the fluoroquinolones, which present a wide spectrum of antibacterial activity.²⁶⁷

For the synthesis of these fluoroquinolone derivatives, two approaches are generally used. The first of these uses fluorinated anilines, or 2-aminopyridines, **151** as the starting material (Scheme 57, Method A). From there, a simple condensation reaction and treatment with polyphosphoric acid (PPA) lead to fluoroquinolone derivative **152**. On the other hand, the use of fluorine-containing benzoyl derivatives **153**, followed by cyclization of intermediates **154**, comprises another method for the synthesis of fluoroquinolone derivatives (Scheme 57, Method B).²⁶⁸

It has been widely reported that the presence of a fluorine atom in the C-6 position enhances antibacterial activity, potentially because of improved cell penetration of the fluorinated derivatives due to their increased lipophilicity.¹⁸⁸ This substitution has therefore allowed the development of new inhibitors of DNA gyrase, an essential enzyme which controls bacterial DNA replication.

Regarding the fluorine substitution, although the benefits of fluorinated drugs have been widely reported and despite the great number of them currently in use,^{84,85} the possible dangers of these drugs have not been sufficiently studied. This is possibly due to the scarce information in the literature about the involvement of the fluorine atom in biodegradation processes. Very few studies about the biotransformation of model organofluorine compounds discerning the mechanisms of their biochemical degradation or showing that the position of the fluorine substitution in the molecule has an important role in the C–F bond cleavage have been reported,^{269,270} which is often necessary for the biodegradation of fluorinated drugs.²⁷¹

In some cases, defluorination can take place spontaneously or during drug biotransformation, depending on the electrophilicity of the molecule toward direct reaction with nucleophilic groups present in amino acids or proteins. Despite the strength of the C–F bond, defluorination can occur during drug metabolism, favoring the formation of smaller fluorinated metabolites and/or the stable fluoride ion, which is a good leaving group.^{172,196} This toxic ion and other metabolites, such as fluoroacetate, could act as enzymatic poisons, inhibiting enzyme activities and interrupting metabolic processes.

The accumulation of these toxic substances obtained by the biotransformation of certain fluorinated drugs could be the cause of the adverse effects observed after their use in treating patients. For instance, adverse effects on the gastrointestinal tract and central nervous system, as well as hepatotoxicity, neurotoxicity, and phototoxicity, have all been observed in patients treated with certain fluoroquinolone derivatives,²⁷² leading to their withdrawal from the market. Some such cases of fluoroquinolone derivatives are reviewed here (Figure 4).

6.1.1.1.1. Temafloxacin. Temafloxacin **155** (Figure 4), a trifluorinated quinolone marketed by Abbott Laboratories as *Omniflox*, belongs to the third generation of fluoroquinolones. Temafloxacin was approved by the FDA in January of 1992 as an antibiotic agent to treat respiratory tract, urinary, genital, and skin infections related with Gram-negative pathogens, by interference with the activity of the enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. However, due to serious adverse




Figure 4. Fluoroquinolone derivatives withdrawn from the market.

reactions reported including anaphylaxis, hemolytic anemia, renal failure, hypoglycemia, and hemolysis, *Omniflox* was withdrawn a few months later.²⁷³


6.1.1.1.2. Grepafloxacin. Grepafloxacin **156** (Figure 4) is also a third-generation fluoroquinolone antibiotic indicated for a variety of infections including bronchitis, pneumonia, and sexually transmitted bacterial infections, marketed by Glaxo Wellcome in 1997 under the trade name *Raxar* or *Vaxar*.²⁷⁴ After severe cardiovascular events were reported,²⁷⁵ such as QT lengthening, Glaxo Wellcome announced its withdrawal from the worldwide market in 1999.

6.1.1.1.3. Sparfloxacin. Sparfloxacin **157** (Figure 4) is another third-generation aminodifluoroquinolone derivative and is a synthetic broad-spectrum antimicrobial agent indicated for the treatment of various types of bacterial infections including salmonella and staphylococcus infection.²⁷⁶ Sparfloxacin (AT-4140) was patented in 1985 and approved for medical use in 1993 under the trade name *Zagam*.


Its structure presents a second fluorine atom in the C-8 position, which has been associated with phototoxicity, one of the main unwanted side effects of this drug. This group is highly photosensitive and can be eliminated under UVR exposure, losing its antibacterial activity.²⁷⁷ Other adverse reactions associated with sparfloxacin are prolongation of the QTc interval in patients with an underlying cardiac condition, insomnia, and other sleep disorders,²⁷⁶ leading to its withdrawal from the market.

6.1.1.1.4. Gatifloxacin. Approved for sale and commercialized with the brand name *Tequin* by Bristol-Myers Squibb in 1999, gatifloxacin **158** (Figure 4) is a member of the fourth and latest generation of the fluoroquinolone family of antibiotics. Gatifloxacin was shown to be highly active against both penicillin-susceptible and penicillin-resistant strains of *S. pneumoniae*, the main pathogen behind the bacterial pneumonia infection.²⁷⁸ This 8-methylfluoroquinolone derivative has been used to treat lung, sinus, skin, and urinary-tract infections but has also been shown to produce dangerous changes in blood-sugar levels. Although the complete mechanism leading to hypoglycemia is not yet fully understood, experiments have shown that it can stimulate insulin release and block the ATP-sensitive potassium channels of pancreatic cells, which can both lead to hypoglycemia.^{279,280} Due to these severe side effects, Bristol-Myers Squibb announced in 2006 that gatifloxacin was to be withdrawn from the market.

Scheme 58. Trovafloxacin and Its Prodrug Alatrofloxacin



Scheme 59. Proposed Terminal Metabolite of Flosequinan



6.1.1.1.5. *Trovafloxacin/Alatrofloxacin*. Trovafloxacin **160** (CP-99,219), also a fourth-generation fluoroquinolone antibiotic, is a trifluorinated derivative with a single fluorine substitution in the C-6 position of the naphthyridine ring, as well as a cyclopropyl-fused pyrrolidine at the C-7 position, which enhances its activity against Gram-positive and Gram-negative organisms (Scheme 58).²⁸¹ While trovafloxacin is administered orally, alatrofloxacin **159** (CP-116,517) (Scheme 58), a highly hydrolyzable prodrug of the active form **160** containing an L-alanyl-L-alanyl moiety, is used intravenously due to its better solubility.²⁸²

Trovafloxacin and alatrofloxacin were approved for sale in 1998 and sold as *Trovan* and *Trovan IV*, respectively, by Pfizer, for the treatment of pulmonary, surgical, intraabdominal, gynecologic, pelvic, skin, and important urinary tract infections. Although the active form, trovafloxacin, was first associated only with moderate gastrointestinal effects, headaches, and very slight phototoxicity, several cases of liver toxicity were later reported in patients treated with this drug, to the point that some even required liver transplants.²⁸³ Extended treatments with trovafloxacin (2 weeks) substantially increased the risk of liver toxicity, but short treatments did not necessarily avoid liver failure. In view of these data, trovafloxacin was withdrawn from the market just three years later in 2001.

6.1.1.1.6. *Flosequinan*. Flosequinan is a quinolone derivative used as a potent direct-acting vasodilator, developed for the treatment of chronic heart failure (Scheme 59). Flosequinan acts on both peripheral arterial and venous vessels, improving the atrioventricular condition in patients with atrial fibrillation, although the mechanism implied is not fully understood.²⁸⁴ The metabolic pathways proposed by Kashiyama and co-workers consist of the oxidation of the sulfinyl moiety in both flosequinan stereoisomers (Scheme 59, (S)-161 and (R)-161), catalyzed by the cytochrome enzyme P450, providing the flosequinan sulfone form FSO₂ **162** as the terminal metabolite.²⁸⁵

The drug was researched and developed by Boots Co. Plc. and was launched onto the market in 1992 under the name *Manoplax* in 50 and 100 mg doses. However, since no reduction in mortality was observed in heart failure patients treated with the drug, Boots decided to explore the product's safety and efficacy on survival and mortality in congestive heart-failure patients. This study, denominated PROFILE (PROspective randomized Flosequinan Longevity Evaluation), indicated that flosequinan has adverse effects and actually showed a significant

increase in mortality in patients treated with the 100 mg dose. This suggested that no benefits were being provided with the treatment, and the drug was withdrawn in 1994 by the company.

6.1.1.2. *Cerivastatin*. Cerivastatin **163** is a synthetic and enantiomerically pure pyridine derivative used as a sodium salt (Figure 5). It is a lipid-lowering drug and is a more potent




Figure 5. Cerivastatin structure.


inhibitor of HMG-CoA reductase than other statin derivatives on the market, thereby blocking the synthesis of mevalonate, which is a key step in cholesterol synthesis. It was marketed by Bayer in 1997 under the brand name *Baycol* or *Lipobay* and has been used to lower cholesterol levels at microgram doses and to prevent cardiovascular diseases.²⁸⁶

Postmarketing reports about the potential breakdown of muscle tissue, and as a consequence its possible relationship with severe rhabdomyolysis cases, set off alarms about the continuity of cerivastatin in the market.



Rhabdomyolysis, a condition in which damaged skeletal muscle breaks down rapidly causing weakness, fever, dark urine, and nausea, has been associated with statins in general; however, reports of this serious syndrome were higher for cerivastatin, especially when it was administered in high doses or in combination with fibrates, another class of substances for the treatment of blood lipid disorders.²⁸⁷ Due to the risk of these serious side effects, in August 2001 Bayer decided on the voluntary withdrawal of this drug.²⁸⁸

6.1.1.3. *Lumiracoxib*. Lumiracoxib **164** (Scheme 60) belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and has excellent cyclooxygenase 2 (COX-2) selectivity.²⁸⁹ It was patented in 1997, approved for medical use in 2003, and was marketed by Novartis under the trade name *Prexige* for the treatment of inflammatory effects of osteoarthritis and rheumatoid arthritis.²⁹⁰

Scheme 60. Synthesis of Lumiracoxib



Scheme 61. Toxic Metabolite Formation from Lumiracoxib

Scheme 62. Asymmetric Synthesis of (+)-(3*S*,4*R*)-Cisapride

As an alternative for the original synthesis, in 2010 Yu and co-workers developed an efficient approach toward this kind of drug through a highly versatile Pd-catalyzed *ortho*-C–H iodination reaction of the phenylacetic acid group present in its structure (Scheme 60).²⁹¹


Despite its strong anti-inflammatory activity, lumiracoxib was withdrawn from the market due to its hepatotoxicity.²⁹² Its potential for causing liver failure even led patients to require liver transplants. In this sense, subsequent studies have shown that *p*-benzoquinone imine **165** is formed *in vivo* after electrophilic hydroxylation by cytochrome P450 enzymes (Scheme 61). This reactive intermediate is an unselective electrophile and is then conjugated with liver proteins with concomitant fluoride ion elimination, leading to the formation of protein adducts and ultimately liver necrosis.²⁹³

6.1.1.4. Cisapride. Discovered by Janssen Pharmaceutica in 1980, cisapride **166** (Scheme 62) acts as an agonist for 5-HT₄ receptors and as an antagonist for 5-HT₃ and 5-HT₂ receptors (5-hydroxytryptamine or serotonin receptors). Cisapride was marketed under the trade name *Propulsid* by Janssen-Ortho and *Propulsid* (United States) as a motility stimulant indicated for the treatment of hypomotility disorders of the upper gastrointestinal tract.²⁹⁴

Although the commercial preparation of this drug is the racemic mixture of two enantiomers [(±)-cisapride], it is well-known that the (+)-enantiomer is more active.²⁹⁵ For this reason, despite all reported methods for its total synthesis,^{296,297} the search for an asymmetric synthesis has been an interesting objective. In this sense, Davies and co-workers developed an asymmetric synthesis of (+)-(3*S*,4*R*)-cisapride using commercially available starting materials (Scheme 63).²⁹⁸

A few years after its launch to the market, many cases of severe arrhythmia were detected, and most studies indicated that cisapride may increase the incidence of long QT syndrome,

Scheme 63. Synthesis of Astemizole





leading to serious cardiac side effects. Cisapride was therefore withdrawn in 2000 from the market worldwide.²⁹⁴

6.1.1.5. Astemizole. Astemizole **167** (Scheme 63) is a second-generation histamine H₁ receptor blocker and was discovered by Janssen Pharmaceutica in 1977. It was marketed in the UK in 1983 and approved for use in the USA in 1988 under the brand name *Hismanal*. As a long-acting and nonsedating antihistamine, astemizole was used for symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria.


Ruijter and co-workers studied a novel aerobic oxidative coupling of diamines as bisnucleophiles and isocyanides using palladium catalysis to access to a wide range of guanidine-containing heterocycles.²⁹⁹ Aiming to improve on the previously reported multistage synthesis of astemizol,³⁰⁰ the authors developed a new synthetic route using this novel palladium-catalyzed oxidation reaction (Scheme 63).

However, Johnson & Johnson voluntarily withdrew astemizole from the global market in 1999 due to several cases of *torsades de pointes* (ventricular arrhythmia) which arose in patients treated with this drug. This side effect is related with the

Scheme 64. Astemizole and Its Metabolites

Scheme 65. Flunitrazepam and Its *in Vivo* Metabolites

Scheme 66. Synthesis of Mibefradil




blocking of cardiac potassium channels, resulting in a prolongation of the QT interval.³⁰¹

The blocking of potassium channels could be due to the accumulation of the drug given its long duration of action as well as its active metabolite desmethylastemizole **168** (Scheme 64) which has a half-life of about 12 days. Both astemizole and desmethylastemizole could block the cardiac potassium channels, causing impaired repolarization of the heart and, therefore, ventricular arrhythmias. On the other hand, norastemizole **169** (Scheme 64), another active metabolite of astemizole, has a shorter half-life and does not seem to be involved in this blockade.

6.1.1.6. Flunitrazepam. Flunitrazepam **170** (Scheme 65) is a benzodiazepine central nervous depressant, a class of drugs used as sedative–hypnotics compounds to treat anxiety, insomnia, and sleep disorders. It has a nitro group and a fluorine atom in the molecule, both of which increase the hypnotic effects of benzodiazepines. The sedative, antianxiety, and muscle-relaxing properties of flunitrazepam are similar to other benzodiazepine derivatives, but its sedative and sleep-inducing properties are more pronounced and longer lasting.

Flunitrazepam was discovered and patented by the Swiss pharmaceutical company Hoffman-La Roche in 1962. It was marketed in 1974 with the brand name *Rohypnol* for the treatment of severe insomnia and was used as preanesthetic

Scheme 67. Synthesis and Metabolites of Sertindole



drug.³⁰² Its metabolism involves hydroxylation and demethylation processes, leading to the formation of two active metabolites, fonazepam 171 (desmethylflunitrazepam) (Scheme 65) and nifoxipam 172 (3-hydroxy-desmethylflunitrazepam) (Scheme 65).³⁰³

The most frequently reported side effects associated with this drug include physical and psychological dependence, reduced sleep quality resulting in somnolence, respiratory depression, and loss of motor control or decreased reaction time, all adverse effects related with benzodiazepine derivatives in general. Cases of intoxication with flunitrazepam were not initially reported, possibly due to its difficult detection in serum. Severe cases of toxicity began to appear in combination with alcohol abuse, leading to flunitrazepam's classification as a dangerous drug. Because of its potent sedative hypnotic activity, this drug was also used in rape cases. Consequently, the drug was withdrawn from the market.³⁰⁴

6.1.1.7. Mibefradil. Mibefradil 174 (Ro 40-5967) (Scheme 66) was marketed under the trade name *Posicor* and is a tetralol derivative marketed by Hoffmann-La Roche in 1997 used for the treatment of hypertension and chronic angina pectoris. This drug is a calcium channel blocker, relaxing blood vessels and increasing the supply of blood and oxygen to the heart. Mibefradil blocks both L-type and T-type calcium channels but has a higher affinity for the latter.³⁰⁵

Its benzimidazolyl-substituted tetraline structure contains two chiral centers and was used as a single enantiomer. Two possible synthetic routes were reported by Schmid and co-workers in 1997: the first employing a base-catalyzed resolution of (*R*)-173 into the desired (*S*)-173 enantiomer (Scheme 66, Method A) and the second through asymmetric hydrogenation (Scheme 66, Method B). The latter resulted in higher total yields.³⁰⁶

Mibefradil was withdrawn from the market by Roche in 1998 due to continued reports of sometimes deadly adverse effects from multiple interactions with other drugs, such as common antibiotics, antihistamines, and anticancer drugs. Mibefradil inhibits CYP 3A4 and CYP 2D6, liver enzymes involved in normal drug metabolism. Due to this, the metabolism of other drugs was blocked, resulting in the plasma concentrations of coadministered drugs increasing to dangerous levels.³⁰⁷ However, mibefradil has been investigated for its anticancer potential, minimizing unwanted drug–drug interactions by short-term dose exposure. This research could show the

importance of T-type calcium channel blockers in cancer treatment.^{308,309}

6.1.1.8. Sertindole. The atypical second-generation antipsychotic agent sertindole 175 (Scheme 67) was discovered and patented by the Danish pharmaceutical company H. Lundbeck A/S in collaboration with Abbot Laboratories for the treatment of schizophrenia. This drug has an affinity for dopamine D2 and serotonin 5-HT2A and 5-HT2C receptors, lending itself to the treatment of anxiety, hypertension, and cognitive disorders. In contrast to other antipsychotics, this drug is not associated with sedative effects.³¹⁰

The synthesis of this phenylindole derivative has been recently reported by Kumar and co-workers with the aim of identifying the impurities formed during its preparation.³¹¹ This synthesis implies the previous copper-catalyzed N-arylation of 5-chloroindole with 4-fluorobromobenzene (Scheme 67).

Sertindole is metabolized by CYP2D6 to dehydrosertindole 176 and by CYP3A into norsertindole 177, both with insignificant pharmacological activity.

This drug was authorized and introduced into the market in 1996 but was voluntarily withdrawn in 1998 after numerous cardiac adverse effects were reported.³¹² Various studies revealed that increased drug concentration could lead to increased risk of QTc prolongation.^{313,314} However, after a reevaluation of its risks and benefits, sertindole was reintroduced into the European market in 2005, and the drug is currently available in several countries.³¹⁵

6.1.2. Aromatic Trifluoromethyl-Substituted Compounds. Although the trifluoromethyl group (CF₃) is a component of several commonly used drugs, studies into the metabolism of trifluoromethyl-substituted aromatic compounds are far less common. The trifluoromethyl group, like fluorine itself, is a strong electron-withdrawing group in aromatic systems, in contrast to a methyl group. Although the CF₃ group itself is not known to suffer metabolic degradation, metabolic attack can occur at *ortho* and *para* positions in aromatic substituted systems by cytochrome P450 enzymes.¹⁷²

In order to better define the safety and efficacy of drugs, it is important to understand how metabolites act in the body since they can present very different activity from that of the parent compound.

A collection of aromatic trifluoromethyl-substituted compounds that have been withdrawn from the market due to the

formation of metabolic species with undesirable side effects are reviewed in this section.

6.1.2.1. *Fenfluramine/Fen-phen/Dexfenfluramine*. Racemic fenfluramine **178** (trade name *Pondimin*) (Figure 6) was





Figure 6. Fenfluramine and derivatives.

approved for sale in 1973 and acts as an appetite suppressant for the short-term treatment of obesity marketed by American Home Products. The eutomer dexfenfluramine **179** (*Redux*) (Figure 6) was later developed as a single enantiomer drug by Wyeth–Ayerst Laboratories and approved for sale in 1996.

Fenfluramine was available alone and in combination with phentermine (*Ionamin*), another appetite suppressant that has been on the market since 1959. The combination was called fen-phen (**180**, Figure 6) and had a better business outcome. Although the activity of both drugs is similar, these compounds were combined for the equilibrium between their adverse effects, drowsiness and sedation in the case of fenfluramine and irritability or insomnia in the case of phentermine.³¹⁶

Duhamel and co-workers developed a synthetic route toward the active enantiomer (*S*)-dexfenfluramine with good enantiomeric excess, using the Sharpless method for asymmetric epoxidation of primary allylic alcohol **182** (Scheme 68).³¹⁷


Scheme 68. Synthesis of (*S*)-Dexfenfluramine



Fenfluramine acts as a serotonin-releasing agent and selectively inhibits its reuptake. An increase in serotonin levels results in a feeling of fullness and, consequently, loss of appetite. However, the use of these appetite suppressants was associated with cases of primary pulmonary arterial hypertension (PAH) and changes at the heart valves.³¹⁸ Through receptorome screening, Roth and Setola showed the role of the metabolite formation in the undesirable side effects observed of these drugs.³¹⁶ The activation of mitogenic 5-HT_{2B} receptors by norfenfluramine **184** (Scheme 69), a fenfluramine metabolite, revealed the possible molecular mechanism responsible for the adverse cardiopulmonary effects of fenfluramine.

Due to the high incidence of cardiac valve problems reported after fen-phen combination treatment, as well as after fenflur-

Scheme 69. Fenfluramine Metabolite



amine or dexfenfluramine alone, these drugs were removed from the market in 1997.

6.1.2.2. *Benfluorex*. Benfluorex **185** (Scheme 70), a structural analogue of fenfluramine, is an anorectic and hypolipidemic agent marketed by the French pharmaceutical company Servier Laboratories in 1976 under the trade name *Mediator*.³¹⁹

The beneficial effects of benfluorex in the treatment of obesity disorders were masked by the adverse effects observed. Like with fenfluramine, an increased risk of valvular heart disease (VHD) and pulmonary artery hypertension was the reason behind the benfluorex withdrawal in 2009. It was assumed that benfluorex induced VHD through formation of norfenfluramine, a common metabolite with fenfluramine with high affinity to 5-HT_{2B} receptors.³²¹

6.1.2.3. *Tolrestat*. The aldose reductase inhibitor tolrestat **187** (Scheme 71) was developed for the control of certain diabetic complications, including diabetic neuropathy, retinopathy, and nephropathy.³²² As a group of metabolic disorders related with lack of insulin, diabetes can lead to chronic hyperglycemia. Several studies have linked this glucose-metabolism disorder with the enzyme aldose reductase, which is involved in the reduction of a variety of aldehydes as well as plays an important role in inflammatory disorders. In this sense, the development of effective aldose reductase inhibitors represents one of the main goals to combat this disease.³²³

Tolrestat was approved for sale in several countries under the trade name *Alredase*. Its naphthalene nucleus and thioamide moiety are the key for inhibition of aldose reductase.³²⁴ This structure was synthesized using carboxylic acid intermediate **186** by treatment of its acid chloride and methyl sarcosinate (Scheme 71).³²⁵

To identify the possible metabolites of tolrestat, several studies were carried out in various species, including humans. In one report, metabolites **188**, corresponding to thioamide oxidation, and **189**, corresponding to O-demethylation, were both identified in rat urine and bile.³²⁶


In 1996, the manufacturer Wyeth withdrew tolrestat from the market worldwide due to reported cases of hepatic necrosis associated with its use.³²⁷

6.2. Aliphatic Substitution


In contrast to the previously discussed aromatic compounds, which are generally more resistant to metabolism, the release of fluoride from aliphatic compounds is readily achieved by hydroxylation in the α position relative to the carbon–fluorine bond and subsequent elimination of hydrofluoric acid, leading to the formation of a ketone or an acyl halide.¹⁷²

6.2.1. *Odanacatib*. Odanacatib **74** (MK-0822) (Scheme 72) is a selective inhibitor of Cathepsin K activity, developed by Merck for the treatment of osteoporosis and bone metastasis.³²⁸


Osteoporosis is characterized by abundant bone loss, causing skeletal fragility, along with an increased risk of fracture. Osteoclasts, a type of bone cell that breaks down bone tissue, are directly involved in the disturbance of bone remodeling when bone resorption exceeds bone formation. These cells express various enzymes for the degradation of the bone matrix,

Scheme 70. Synthesis of Benfluorex³²⁰

Scheme 71. Synthesis and Metabolism of Tolrestat



Scheme 72. Synthesis of Odanacatib




including Cathepsin K, a lysosomal cysteine protease with collagenase properties. Odanacatib was shown to be a potent inhibitor of this enzyme, reducing bone resorption and preserving bone formation.³²⁹

O'Shea and co-workers reported a practical and enantioselective synthesis of odanacatib on a multikilogram scale in 2009.³³⁰ The nucleophilic displacement of the appropriately activated chiral α -trifluoromethylbenzyl alcohol **191**, which had been previously obtained via oxazaborolidine-catalyzed enantioselective reduction (OAB) of ketone **190**, with α -amino ester **192**, provided odanacatib **74**. This chromatography-free synthesis was developed in six steps with a 61% global yield (Scheme 72).

Although the long-term clinical utility of this drug to reduce the risk of osteoporotic fractures was fully determined in Phase III clinical trials, in 2016 the company decided to discontinue its development after reports of major cardiovascular events and a higher risk of strokes.

6.2.2. Begacestat. Begacestat **196** (Scheme 73), developed by Wyeth (now Pfizer) with code name GSI-953, is a selective

Scheme 73. γ -Secretase Inhibitors and Synthesis of Begacestat

thiophene sulfonamide derivative used as a γ -secretase inhibitor (GSI) in the treatment of Alzheimer's disease.




Figure 7. General features of fluoride digestion and absorption, distribution, and elimination.

Alzheimer's disease is a progressive neurodegenerative disorder characterized by amyloid β -peptide ($A\beta$) accumulation, which is produced by the transmembrane protease γ -secretase.^{331–333} Thus, the inhibition of γ -secretase activity is the principal function of GSI-953. Begacestat was passed to phase I clinical trials in 2007; however, it was discontinued in 2010 for unknown reasons.

In 2008, Mayer and co-workers reported the synthesis of begacestat as a fluorinated derivative of previous γ -secretase inhibitors developed by the same authors (Scheme 73, 193A and 193B). After several analyses of efficacy and metabolic stability, the authors found that the introduction of trifluoromethyl groups avoided metabolism at certain oxidation sites in the side chain, granting better metabolic stability. For its preparation, they started from the chiral α -amino ester 194. Reduction and treatment with H_2 using a palladium catalyst provided the amino alcohol 195, a key intermediate in the synthesis of begacestat 196 (Scheme 73).³³⁴

7. FLUORIDE TOXICITY

7.1. Digestion and Absorption, Distribution, and Elimination of Fluoride

The general features of fluoride digestion and absorption, distribution, and elimination are schematically presented in Figure 7.

7.1.1. Fluoride Absorption. Under normal conditions most of the fluorine enters the body by ingestion. In stomach lumen, fluoride formed during digestion is largely converted to weak acid hydrogen fluoride (HF) with a pK_a of 3.19.⁹² The higher acidity of the stomach speeds up the process of absorption by passive diffusion.³³⁵ The coefficient of permeability of lipid bilayer membranes to HF is 1 million times higher than that of F^- .³³⁶ About 20–25% of fluoride is absorbed from the stomach in a pH-dependent process, and about 75–80% of the remaining fluoride is absorbed from the small intestine in a pH-independent process.^{337–339} Ingestion of well-soluble compounds like NaF results in faster absorption, whereas less soluble fluoride compounds like CaF_2 slow absorption.³⁴⁰

The bioavailability of fluoride from different foods in adults varies between 2 and 79% in dependence on the factors such as amount of ingested food, the presence and solubility of minerals in ingested food, emptying the stomach, the presence of bile salts, and concentrations of pepsin.¹²¹

7.1.2. Fluoride in Plasma. The half time for fluoride absorption is approximately 30 min, and peak plasma concentration usually occurs within 30–60 min.^{341–346} Baseline plasma fluoride levels are generally reached within 3–11 h after ingestion, depending on the amount ingested.³⁴⁷ Fluoride in

plasma is available as ionic F^- and nonionic (organic or bound fluoride).³⁴⁸ Ionic F^- is significant in dentistry, medicine, and public health.³⁴⁹ Plasma fluoride concentration is not homeostatically regulated, which means it increases or decreases depending on the amount of fluoride ingestion, deposition or removal from the soft and hard tissues, and excretion.³⁵⁰ The fluoride balance can be negative if chronic intake is reduced sufficiently to allow plasma concentration to fall, which promotes demobilization of F^- from calcified tissues.¹⁴⁴

7.1.3. Distribution and Elimination. After the absorption, fluoride is rapidly distributed in plasma and then to all tissues and organs. About 50% of the daily intake of fluoride is, within 24 h, deposited mainly in calcified tissues—such as bones and teeth, as well as calcium-containing glands such as the pineal gland. These tissues contain approximately 99% of the body's fluoride, and the remainder is distributed between the blood and soft tissues, where rapidly a steady-state distribution between extracellular and intracellular fluids is established.^{350,351} The remaining 50% is predominantly excreted via the kidneys and is influenced by a number of factors, including glomerular filtration rate, urinary flow, and urinary pH.^{347,351} This 50:50 distribution is strongly shifted to greater retention in the very early and probably toward greater excretion in the later years of life.^{352–354} Young children can retain up to 80% of fluoride due to increased uptake by the developing skeleton and teeth.^{355,356} To a lesser extent, fluoride is also excreted in the faeces, sweat, and saliva.³⁵⁷

7.2. Mechanisms of Fluoride Cytotoxicity

The effects of fluoride on cellular metabolism and physiology vary according to the cell type, concentration, and duration of exposure.³⁵⁸ The main toxic effects of fluoride in cells can be ascribed to inhibition and sometimes stimulation of a variety of enzymes by a mechanism dependent on the type of enzyme affected.^{358–360}

Fluoride effects on cellular processes include the influence on gene expression, cell cycle, proliferation and migration, respiration, metabolism, ion transport, secretion, endocytosis, and oxidative stress, ultimately leading to necrosis or apoptosis.^{358,359,361–365} Necrosis has been observed as a primary mechanism of cell death after a short exposure (≈ 1 h) to fluoride at relatively high concentrations (≈ 100 mmol).³⁶⁶ At lower concentrations (a few mmol or even less) fluoride triggers apoptotic cell death from different tissues and organs by the activation of caspases in both intrinsic (mitochondrial) and extrinsic (death receptor) pathways, which converge on caspase-3 activation.^{358,361,364,365,367–369}

Fluoride interferes with enzymes as the F^- ion or as aluminum fluoride (AlF_x^{3-x} , $x = 1-6$, abbreviated as AlF_x) complexes, which are able to activate G-protein-coupled receptors

(GPCRs) at several times lower concentrations than either Al^{3+} or F^- acting alone.²⁹ The average stoichiometry of the complexes formed between fluoride in the presence of even trace amounts of aluminum is mainly dependent on the excess of fluoride and the pH.³⁷⁰ The AlF_x 's activate a G-protein-signaling pathway by binding to the active site of guanosine diphosphate (GDP) as a tetra-coordinate AlF_4^- ^{371,372} or $\text{AlF}_3(\text{OH})^-$ ^{373,374} ion. The spatial and structural similarities of AlF_4^- and PO_4^{3-} ions are schematically presented in Figure 8.




Figure 8. Schematic drawing of (a) AlF_4^- and (b) PO_4^{3-} ions.

Initially, it was assumed that the AlF_4^- occupies the γ -phosphate binding site on the protein and together with bound GDP makes the G protein act as if it has bound guanosine triphosphate (GTP).³⁷¹ Later, the bound AlF_4^- was concluded to mimic the PO_4^{3-} in its pentavalent transition state during hydrolysis.³⁷⁵ In addition, beryllium forms soluble ionic complexes (BeF_x^{x-2} , $x = 1-4$) which were found to be as effective a cofactor as aluminum at μmol concentrations and in the presence of mmol fluoride concentrations.^{376,377} Effects of AlF_x on cell-signaling pathways can result in changes in gene expression, cytoskeletal reorganization, intracellular vesicle trafficking, and nucleocytoplasmic transport.³⁷⁸

The actual concentrations of fluoride in organisms may be lower (a few mmol) than those used in laboratory experiments. However, the fluoride dose–response relationship is not always monotonic. In certain studies, a paradoxical effect of fluoride with inhibitory or stimulatory impact being greater at a lower level of intake than at a higher level (hormesis effect) was observed.^{358,379,380} Therefore, stating a “safe” dose of fluoride is illusive—environmental exposure, dietary patterns, certain medical conditions, and genetic background all play a major role in influencing the risk to fluoride toxicity.^{381–383}

7.3. Toxicity in Relation to the Exposure to Fluoride

The margin between the beneficial and deleterious effects of fluoride appears to be narrow. Therefore, the toxic effects of fluoride on human health should be evaluated considering factors such as (1) fluoridation of public water supplies at safe levels; (2) proven toxic effects in cells; (3) possible occurrence of adverse effects at the intakes lower than the AI; (4) awareness that adverse effects are often not recognized and are ascribed to other causes; (5) conflicting results of the studies; (6) cautious interpretation of the studies' results; and (7) awareness that correlation is not necessarily a causation. Acute toxicity involves harmful effects in an organism through a single or short-term exposure to a toxic substance. On the other hand, chronic toxicity is a result of continuous or repeated exposure of an organism to a toxic substance.

7.3.1. Acute Toxicity. The toxicity of fluoride depends on the solubility of the compound ingested—the more soluble salts of inorganic fluorides, such as sodium or potassium fluoride, are more toxic than weakly soluble or insoluble.³⁴⁰ Acute high oral exposure to fluoride may lead to (with increased seriousness of observed symptoms) nausea, vomiting, abdominal pain, diarrhea, drowsiness, headaches, polyuria and polydipsia, coma, convulsions, cardiac arrest, muscle paralysis, carpedal spasm, spasm of the extremities, and death.^{384–386}

The probable toxic dose (PTD) for children, defined as the dose of ingested fluoride that should trigger immediate therapeutic intervention and hospitalization, because of the likelihood of serious toxic consequences is set at $5.0 \text{ mg kg BW}^{-1}$.³⁸⁶ Lower intakes than that should however not be regarded as eventually harmless. The most frequently cited estimate for a reasonable certainly lethal dose (CLD) of sodium fluoride is set between 32 and 64 mg kg BW^{-1} of fluoride, which corresponds to 5 – 10 g of sodium fluoride for a 70 kg person.^{386,387}

7.3.2. Chronic Toxicity. Excessive intake of fluoride during a prolonged period of time can result in (1) development of dental fluorosis in children; (2) skeletal fluorosis in both children and adults; and (3) damage to virtually all nonskeletal tissues. Environmental exposure, dietary patterns, certain medical conditions, and genetic background could play a major role in influencing the risk to fluoride toxicity.^{381–383}

Symptoms of chronic fluoride intoxication include: (1) irritable bowel syndrome; (2) polyuria and polydipsia; (3) extreme fatigue/exhaustion/loss of muscle power; (4) insomnia; (5) low hemoglobin; (6) depression; (7) high cholesterol and high blood pressure; (8) joint pain; (9) frequent breaking of bones; (10) disabled children with bowleg, knock-knee, short stature, and mental retardation; and (11) pregnant women with anemia, low birth weight babies, preterm deliveries, intrauterine death, neonatal death, and infant mortality.^{388,389} Some of the fluoride effects on different tissues and organs of a human body are shown in Figure 9.




Figure 9. Fluoride effects on different tissues and organs of a human body.

7.3.2.1. Dental Fluorosis. Enamel fluorosis and primary dentin fluorosis are caused by excessive intake of fluoride during critical periods of amelogenesis of both primary and secondary teeth. Altered protein/mineral interactions are in part responsible for retention of amelogenins and the resultant hypomineralization that occurs in fluorosed enamel.^{390,391} Other indirect effects of fluoride on cells at different stages of formation are likely to be expected. Fluorosed enamel has a

higher protein content than nonfluorosed enamel, resulting in increased porosity.^{392–394}

There is a clear linear relationship between fluoride dose and enamel fluorosis regardless of whether fluoride is ingested from drinking water or diet, supplements, or other sources.^{395,396} This suggests that no threshold value exists below which the effect of fluoride on dental enamel will not be manifested.¹³⁶ A threshold of $0.03 \text{ mg day}^{-1} \text{ kg BW}^{-1}$ has been suggested for the appearance of dental fluorosis.^{136,396}

The “gold standard” for quantifying dental fluorosis is Dean’s index³⁹⁷ suggested in its final form in 1942, though other indexes including the widely used Thylstrup and Fejerskov Fluorosis Index,³⁹⁸ which has an expanded range for the more severe forms of dental fluorosis, were also developed. According to Dean’s index, dental fluorosis is classified on a scale from 0 to 4 into six classes from normal or unaffected enamel to very mild fluorosis with “small, opaque, paper white areas scattered irregularly over the tooth but not involving as much as approximately 25% of the tooth surface” to severe fluorosis, when “all enamel surfaces are affected and hypoplasia is so marked that the general form of the tooth may be affected”.

Dental fluorosis is due to fluoride prevention benefits often presented merely as a cosmetic problem and not as an adverse effect.³⁹⁶ Its prevalence is in increase.^{399–401} Endemic fluorosis is present in many countries, in particular in Africa and Asia due to contaminated drinking water, pollution from coal burning, and brick-tea drinking.^{357,365,402}

7.3.2.2. Skeletal Fluorosis. Skeletal fluorosis is a result of high chronic intake of fluoride, which accumulates progressively in the bone. Excessive fluoride intake disrupts a dynamic balance of bone turnover and metabolism by influencing different signaling pathways at a cellular level.^{365,403}

Early symptoms of skeletal fluorosis include stiffness and pain in the joints. Crippling skeletal fluorosis is associated with osteosclerosis, calcification of tendons and ligaments, bone deformities, and neurological defects associated with compression of the spinal cord.³⁵¹

Skeletal fluorosis with adverse changes in bone structure may be observed when drinking water contains $3\text{--}6 \text{ mg L}^{-1}$ of fluoride.^{114,404} Crippling skeletal fluorosis develops at water fluoride concentrations higher than 10 mg L^{-1} .^{27,404} Despite relatively shorter exposure, skeletal fluorosis can develop also in children living in fluoride endemic areas.^{158,405}

7.3.2.3. Gastrointestinal System. Symptoms associated with mild fluoride toxicity are nonspecific and may be attributed to colic or gastroenteritis.⁴⁰⁶ The primary gastrointestinal (GI) effects associated with chronic or acute exposure to fluoride include nausea, pain, and vomiting.⁴⁰⁷ GI symptoms are commonly observed in humans suffering from skeletal fluorosis or osteoporosis patients treated with fluoride.^{27,408} The irritation of gastric mucosa is due to HF formed under acidic conditions of the stomach lumen. The effects on the stomach resemble those of acetylsalicylic acid (pK_a 3.6), which causes structural and functional alterations of the gastric mucosa.^{409–411}

The concentration of fluoride in drinking water of 4 mg L^{-1} was suggested as the concentration at which approximately 1% of the population might experience GI symptoms; as the fluoride concentration in drinking water increases, the percentage of the population with GI symptoms also increases.⁴⁰⁷

To our knowledge, no human studies have systematically studied the GI effects of low fluoride exposure.

7.3.2.4. Kidney and Liver. Kidneys followed by the liver accumulate higher concentrations of fluoride than other organs and tissues.^{347,351} This suggests that the renal system and liver might be at a higher risk of fluoride toxicity than most soft tissues.^{347,407} The position statement regarding fluoridation developed in Australia says that “There is no evidence that consumption of optimally fluoridated drinking water increases the risk of developing chronic kidney disease (CKD), although only limited studies addressing this issue are available.”⁴¹² The statement was accepted with criticism that the “absence of evidence is not evidence of absence”.⁴¹³ Of special concern should be patients with impaired renal failure, who may develop skeletal fluorosis even at 1 mg L^{-1} of F^- in drinking water.^{414,415} Recently, a direct correlation between CKD and the consumption of excess amounts of fluoride showing immediate adverse effects on the tubular area of the kidneys in animals and humans was suggested.^{416,417} In children, renal fluoride clearance rates are lower than in adults.³⁵² Consumption of drinking water with fluoride concentration above 2.0 mg L^{-1} in children was suggested to cause damage to the kidney, which increases with the F^- concentration.⁴¹⁸ The prevalence of urolithiasis in fluoride endemic areas with water containing between 3.5 and 4.9 mg L^{-1} of F^- was reported to be 4.6-fold higher than in the nonendemic area with water F^- below 0.5 mg L^{-1} , probably also because of malnutrition.⁴¹⁹ Recently, geogenic fluoride has been hypothesized as one of the causative factors in developing chronic kidney disease of multifactorial origin.⁴²¹

Fluoride has been shown to induce morphological changes and liver dysfunction.³⁶⁵ The mechanism for understanding the dose and time dependency of the effects of fluoride in the liver has been proposed.⁴²⁰

Adverse renal and hepatic effects of fluoride were found in rats at early stages of fluoride intoxication, where alterations in liver enzyme activities were first observed and then followed by renal damage.⁴²² In children, the dose–effect relationship between the concentration of fluoride in drinking water ($C_{\text{F}^-} > 2 \text{ mg L}^{-1}$) and damage to liver and kidney functions was observed.⁴²³ The results of a recent study conducted in the US suggested that in adolescents exposure to drinking water generally containing less than 1 mg L^{-1} of F^- may contribute to complex changes in kidney and liver-related parameters.⁴²⁴

The liver is the primary organ for oxidative detoxification including the detoxification of organofluorides.⁴⁰⁷ Nephrotoxicity due to fluoride was reported in patients who received methoxyflurane anesthesia for surgery.⁴²⁵ The kidney and liver function of children and adults should be considered in relation to the recommended fluoride concentration of drinking water.

7.3.2.5. Cardiovascular System. Calcification in the aorta of rabbits has been observed after 17–24 months of daily administration of 10 mg of NaF kg BW^{-1} .⁴²⁶ The calcification of medial elastic fibers eventually contributes to increased arterial stiffness, resulting in cardiovascular diseases.⁴²⁷ Excessive exposure to fluoride could eventually increase plasma Endothelin-1 levels,⁴²⁸ which is suggested to play a crucial role in several cardiovascular diseases, like congestive heart failure (CHF), hypertension (HTN), atherosclerosis (AS), and renal disease.^{429,430} Already, early fluoride exposure may favor the atherosclerotic process, which could contribute to the development of cardiovascular diseases.⁴³¹

Dental fluorosis in children living in the fluoride endemic area with water F^- concentration above 1.2 mg L^{-1} was suggested as a risk factor for some cardiovascular system dysfunctions such as

arrhythmias or syncope.⁴³² The severity of skeletal fluorosis in the fluoride endemic area with water F^- concentration between 4.1 and 8.6 $mg L^{-1}$ has been reported to be related to the severity of abnormal cardiac function.⁴³³ In contrast, no effect on the electrocardiogram was reported in a study of patients with dental fluorosis living in a fluoride endemic area consuming water with fluoride concentration above 1.2 $mg L^{-1}$.⁴³⁴ Aortic elasticity and left ventricular diastolic and global functions were impaired in patients with dental fluorosis living in the fluoride endemic region with natural water fluoride concentrations above 1.2 $mg L^{-1}$.^{435,436} Fluoride exposure from drinking water with fluoride concentrations between less than 1.2 to more than 3.0 $mg L^{-1}$ in adults living in fluoride endemic areas was related to the prevalence of carotid artery atherosclerosis.⁴³⁷ An increase of hypertension prevalence with the increase of fluoride levels in drinking water from low to endemic concentrations was observed.^{438,439}

In nonendemic regions, naturally present fluoride in water was suggested to have a slight protective effect with respect to coronary heart disease.⁴⁴⁰ Natural contents of fluoride in water between less than 0.3 $mg L^{-1}$ to 1.5 $mg L^{-1}$ and above appear not to be associated with myocardial infarction.⁴⁴¹

Association of fluoride with toxic or beneficial effects on the cardiovascular system needs more experimental and epidemiological studies, including adequate control of confounding cofactors.⁴⁴²

7.3.2.6. Thyroid. Iodine is involved in the synthesis of the thyroid hormones, thyroxine (T4) and triiodothyronine (T3), which is controlled by thyroid-stimulating hormone (TSH).⁴⁴³ The thyroid hormones have multiple effects on metabolism and are associated with different systems and organs, e.g. cardiovascular, central nervous and digestion system, bone growth, and breathing. The parathyroid hormone has an important role in bone remodeling.⁴⁴⁴

In the 1950s, fluoride was used to treat hyperthyroidism with a daily dose between 2 and 5 mg of fluoride, which is within the range of estimated daily intake of fluoride in adults (see section 4.4.2).^{357,445} Much of the recent research has been devoted to the impact of fluoride on the thyroid.⁴⁴⁶

Based on the examination of the impact of fluoride on thyroid function, it was concluded that fluoride is an endocrine disruptor with the potential to disrupt the function of tissues that require iodine.^{407,447} The impact of iodine deficiency can be exacerbated by fluoride, which is of special concern in children.⁴⁴⁸ Daily exposures to fluoride between 0.05 and 0.13 $mg kg BW^{-1}$ have been associated with adverse thyroid effects among iodine-sufficient people and between 0.01 and 0.03 $mg kg BW^{-1}$ among iodine-deficient people.⁴⁰⁷

In England, the general practitioners that practice in areas with water fluoride concentration of 1 $mg L^{-1}$ were nearly twice as likely to report high hypothyroidism prevalence in comparison to the nonfluoridated area.⁴⁴⁹ Impacts of fluoride on TSH and T3 hormones were suggested even at low water F^- concentrations below 0.5 $mg L^{-1}$.⁴⁵⁰ In Canada, at the population level, fluoride exposure was reported not to be associated with impaired thyroid functioning in a time and place where multiple sources of fluoride exposure, including community water fluoridation, exist.⁴⁵¹ Also in Canada, adults who had moderate-to-severe iodine deficiencies and higher levels of urinary fluoride were shown to be at an increased risk for underactive thyroid gland activity.⁴⁵²

Secretion of the parathyroid hormone (PTH) has been suggested to be directly influenced by fluoride.^{453,454} Higher

PTH levels were observed in patients with endemic fluorosis than in controls.⁴⁵⁵

Further studies are needed to elucidate the mechanisms of fluoride impact on thyroid functions and the possible outcomes among different populations and settings.

7.3.2.7. Central Nervous System (CNS). Fluoride was identified as an industrial chemical known to cause developmental neurotoxicity in humans.⁴⁵⁶ A justified critique of the paper was that the authors should have made clear that listing fluoride as a neurotoxin does not apply to fluoridation at the recommended levels of 0.7–1.2 $mg L^{-1}$.⁴⁵⁷ As a reply to this critique, the authors commented that “the fact that a trace element has beneficial effects at low doses in specific tissues does not negate the possibility that neurotoxicity might also be occurring, especially at increased levels of exposure”.⁴⁵⁸

According to the literature, fluoride is capable of crossing the placenta^{459,460} and brain barrier,⁴⁶¹ and the toxicity of even low concentrations of F^- is enhanced in the presence of Al^{3+} .⁴⁶² Systematic reviews and meta-analysis of the studies published between 1989 and 2015 support the possibility of adverse effects of exposure to high levels of fluoride on children’s neurodevelopment.^{463–465} Research on a possible relationship between fluoride exposure and neurotoxic effects in children continues to receive attention. A lot of data come also from Mexico^{466,467} and Canada.^{468–471} Higher prenatal fluoride exposure (via fluoridated salt containing 250 $mg kg^{-1}$ of F^- and naturally present fluoride in water with concentrations between 0.15 and 1.38 $mg L^{-1}$ of F^-), as measured by maternal urinary fluoride (MUF) during pregnancy, was associated with lower scores on tests of cognitive function in the offspring at the age of 4 years and between 6 and 12 years⁴⁶⁶ and more behavioral symptoms of inattention but not hyperactivity or impulse control between 3 and 12 years of age.⁴⁶⁷ Maternal exposure to fluoride through fluoridated water ($C_F^- = 0.59 mg L^{-1}$), as measured by MUF during pregnancy, was associated with lower IQ scores (assessed at the age 3–4 years) in offspring in comparison to a control group living in nonfluoridated areas ($C_F^- = 0.13 mg L^{-1}$).⁴⁶⁸ An exposure to fluoride in water ($C_F^- = 0.59 mg L^{-1}$) was correlated with diminished nonverbal intellectual abilities in children between 3 and 4 years of age with the effect being more pronounced among formula-fed children as opposed to breast-fed children (see section 8.1).⁴⁶⁹ Increased levels of fluoride in tap water were associated with a higher risk of an attention deficit hyperactivity disorder (ADHD) diagnosis as well as increased symptoms of hyperactivity and inattention in youth between 6 and 17 years of age, especially among adolescents.⁴⁷⁰ No association between urinary fluoride levels and a diagnosis of ADHD or hyperactive/inattentive symptoms in youth between 6 and 17 years of age⁴⁷⁰ and between urinary fluoride corrected for dilution and a diagnosis of a learning disability in children aged 3–12 years was found.⁴⁷¹ The absence of correlation is likely to be related also to fluctuations in elimination kinetics of fluoride (see section 7.1.3). The hypothesis that chronic fluoride intake is involved in autism spectrum disorder (ASD) etiopathology needs additional research.³⁸⁰

In 1980, fluoride was suggested as having a protective effect against Alzheimer disease.⁴⁷² In a recent longitudinal study conducted in Scotland, even relatively low levels of aluminum ($C_{Al} = 0.0374 \pm 0.0100 mg L^{-1}$, range: 0.0105–0.0928 $mg L^{-1}$) and fluoride ($C_F^- = 0.0534 \pm 0.016 mg L^{-1}$, range: 0.0238–0.0181 $mg L^{-1}$) in drinking water—as compared to the guideline values for aluminum and fluoride in drinking water

set by the WHO¹¹³—were associated with effects on dementia risk.⁴⁷³

At this point, it must be noticed that correlation is not necessarily a causation. Further research on possible neurotoxic effects of fluoride on children and adults is a prerequisite before firm conclusions or recommendations can be drawn. We should not avoid discussion and criticism—papers criticized in comments^{453,454} have high scientific impact⁴⁷⁴ and assist in pushing research to new landmarks.

7.3.2.8. Pineal Gland. The pineal gland is a mineralizing tissue with the main and most conserved function being nighttime secretion of melatonin.⁴⁷⁵ Fluoride has been reported to readily accumulate in the human pineal gland and could affect pineal metabolism, in a similar way as it impacts the metabolism of other calcified tissues.⁴⁷⁶

In female gerbils, exposure to fluoride was suggested to have a role in accelerated sexual maturation. A fluoride-free diet was observed to stimulate pineal growth in aged male rats.⁴⁷⁷ In humans, findings on associations between fluoride concentration in water and its effect on the pineal gland in humans are not univocal. Results of an early study in the fluoridated area with water F^- concentration between 1.0 and 1.2 $mg L^{-1}$ suggested an earlier age at menarche in relation to fluoride exposure.⁴⁷⁸ In another study, no association in the onset of menarcheal age in the fluoridated area ($C_F^- = 1.1 mg L^{-1}$) as opposed to the nonfluoridated area was reported.⁴⁷⁹ Recently, possible association between an increase in peripubertal fluoride and later pubertal development in boys, but not girls, exposed to fluoride through fluoridated table salt (200–250 $mg kg^{-1}$ of F^-) was suggested.⁴⁸⁰

7.3.2.9. Reproductive Function. The excessive intake of fluoride might have an effect on reproduction ability. In male animals, excessive exposure to fluoride was found to negatively affect the male sperm function, including its morphology, motility, capacitation, and acrosome reaction, and damage the structure of the testis, epididymis, and prostate and function of the reproductive endocrine system.^{481–486} Sperm mitochondrial DNA copy number has been suggested as a sensitive biomarker to reflect the sperm toxicity of fluoride.⁴⁸⁷

The exposure to fluoride in female animals was reported to negatively affect reproductive hormone activities, maturation capacity of oocytes, and embryonic development and to cause ovarian and uterine structural damage.^{488–493}

In the US, an apparent connection between the consumption of drinking water containing at least 3 $mg L^{-1}$ of fluoride and decreased total fertility rate was reported.⁴⁹⁴ Excessive intake of fluoride in occupationally exposed workers or men living in the fluoride endemic area was suggested to negatively affect the semen quality and hormone levels of the hypothalamus–hypophysis–testis axis.^{495–499} Excessive intake of fluoride in women living in the fluoride endemic area was found to affect the hypothalamus–pituitary–ovary axis.⁵⁰⁰

7.4. Mitigation of Fluoride Toxicity

The first intervention in acute fluoride intoxication is an oral administration of calcium gluconate, calcium chloride, or milk, if the former is not available, to slow and reduce the absorption of fluoride.^{386,501,502} The urinary excretion rate of fluoride should be increased by intravenous administration of calcium gluconate, glucose, sodium lactate, or sodium bicarbonate. Treatment might include oxygen therapy, artificial respiration, electrocardiac conversion, and hemodialysis and should

continue until normalization of vital signs and serum chemistry values.^{386,502}

The early signs of chronic fluoride intoxication (e.g., polyuria and polydipsia) can be treated by limiting fluoride intake.^{503,504} The symptoms return, if treatment is discontinued. Dental fluorosis is irreversible and is treated by esthetic dentistry. Skeletal fluorosis treatment is not standardized. The success of available treatments, which include western and Chinese traditional medicine approaches, is limited.^{403,505}

The emerging issues related with fluoride intake are fluoride “linked disorders”. Fluoride effects on tissues and organs other than teeth and bone should be acknowledged as the milestones in the beginning of a new era, which need to be addressed urgently.⁵⁰⁶

8. BIOMARKERS OF FLUORIDE EXPOSURE AND THEIR STATUS

The term biomarker (or biological marker) is generally used in a broad sense to include almost any measurement that reflects an interaction between a biological system and a potential hazard, whether physical, chemical, or biological.^{507,508} It is useful to classify biomarkers into three types: exposure, effect, and susceptibility. Biomarkers of fluoride exposure are of value primarily for identifying and monitoring deficient or excessive intakes of biologically available fluoride, including both dietary and nondietary sources. The fluoride ion does not produce any metabolites, and thus fluoride concentrations in biological fluids or tissues can be used as indices of an individual's exposure.^{114,407} Present exposure to fluoride might be assessed by “contemporary” biomarkers, while more chronic exposure might be assessed by “recent” or “historic” biomarkers.⁵⁰⁸ Biomarkers of fluoride exposure were recently reviewed; therefore, only a brief summary is presented.^{509–513}

8.1. Contemporary Biomarkers

Fluoride concentrations in plasma, urine and urine excretion rate, saliva, milk, sweat, and bone surface have been considered to access contemporary exposure to fluoride.

Plasma fluoride concentrations are highly variable and increase with fluoride intake and age.^{348,349} The mean resting plasma concentration varied between 0.49 and 1.26 $\mu mol L^{-1}$ in nonfluoridated areas with water fluoride concentrations below 0.3 $mg L^{-1}$ and between 0.91 and 1.16 $\mu mol L^{-1}$ in areas with water fluoride concentration between 0.6 and 1.2 $mg L^{-1}$ and reached 1.84 $\mu mol L^{-1}$ in areas with high natural concentrations of fluoride in water of 9.6 $mg L^{-1}$.⁵¹⁰

Daily urinary fluoride excretion is generally recommended for the estimation of daily exposure to fluoride.⁵¹¹ A linear relationship between daily urinary fluoride excretion and total daily fluorine intake for both children and adults was suggested.³⁵⁴ The excretion of fluoride in urine is reduced in individuals with impaired renal function.¹⁰¹ Urine fluoride excretion was 0.79 $mg day^{-1}$ in humans with normal renal function, 0.53 $mg day^{-1}$ in those with questionable renal function, and 0.27 $mg day^{-1}$ in those with impaired renal function.³⁴⁸

Fluoride concentrations in submandibular/sublingual duct saliva and parotid duct saliva are preferred over whole saliva as biomarkers of fluoride exposure because whole saliva can be contaminated with fluoride from the diet, dietary fluoride supplements, and dental products. Ratios of saliva to plasma fluoride concentrations, under resting conditions, varied from

0.32 to 0.55 for parotid saliva⁵¹⁴ and from 0.61 to 0.88 for submandibular saliva.⁵¹⁵

Breast milk fluoride concentrations are correlated to plasma fluoride levels and range between 0.002 and 0.073 mg L⁻¹ with a trend for lower concentrations in regions with low fluoride concentrations in drinking water.^{407,516} Fluoride contents of breast milk of mothers with dental fluorosis in the high altitude were surprisingly high and ranged between 0.13 and 0.99 mg L⁻¹. This suggests that factors affecting the level of fluoride in breast milk need further investigation.^{517–519}

Sweat fluoride concentrations were reported to be comparable to those in plasma (1–3 μmol L⁻¹).⁵²⁰ The bone surface has been suggested as a terminal biomarker of acute fluoride exposure.^{510,520}

Fluoride concentrations in plasma, saliva, and urine fluids and urinary excretion rate give some indication of the contemporary exposure to fluoride for groups of people but not individuals.⁵¹⁰ There is a lack of data to suggest the use of breast milk and sweat as viable biomarkers of exposure to fluoride. The suitability of bone surface to humans has not been evaluated so far.

8.2. Recent Biomarkers

The endogenous trace element composition of hair and nails is believed to reflect the metabolic milieu of the matrix cells, including circulating blood and lymph and extracellular fluids, during their formation.⁵²¹ The measured content is cumulative and reflects the average intake of fluoride over an extended period taking into account the growth rate.

Nail fluoride contents are influenced by age, gender, geographical area and urban/rural class.⁵²² Toenails were suggested as more appropriate biomarkers of subchronic exposure to fluoride than fingernails.^{522,523} In children from 3- to 7-year-old, who are at risk for dental fluorosis, a positive correlation between fluoride concentration in drinking water (0.09 or 2.3 mg l⁻¹) and nail fluoride contents (1.56 or 7.52 μg g⁻¹) was observed.^{522,524} In adults, the reported mean content of fluoride in nails usually ranges between 0.49–12.5 μg g⁻¹^{522,525,526} and was highly increased under occupational exposure.⁵²⁷

The reported mean F content in hair is highly variable and ranges from a few hundredths to a few tens of μg g⁻¹. Hair F content in children was correlated with dental fluorosis level.^{528,529} In children and adults, hair F content was correlated with fluoride content in drinking water.^{528–532} Hair F content can be used as an indicator of occupational exposure to fluoride.^{527,533,534}

Fluorine concentrations in nail and hair give some indication on the contemporary exposure to fluoride for groups of people but not individuals. Samples can be obtained noninvasively, can be easily transported and stored for long periods without degradation.⁵²⁶ The main issues related to the use of nails and hair as bioindicators present external contamination and the sample preparation method resulting in a large variation of literature results.⁵³⁵

8.3. Historic Biomarkers

Fluorine contents of the nonexchangeable inner compartment of bone and dentin increase with age due to continuous fluoride uptake throughout life and may serve as historic biomarkers of systemic exposure to fluoride.¹¹⁴

Factors like level of fluoride intake, age, gender, genetic background, renal function, and bone type influence bone fluoride content.^{509,536} Thus, it is not possible to establish “normal” ranges in bone for individuals, yet fluoride content can

serve as an indicator of chronic exposure to fluoride. The fluoride content of bones in the nonfluorinated area increased from 200 μg g⁻¹ in the first decade of life to an average of 1250 μg g⁻¹ in the ninth decade.⁵³⁷ Fluorine bone contents up to a few thousand of μg g⁻¹ were reported in communities with water fluoride concentrations of 1 mg L⁻¹ or higher.^{414,537,538} Bone tissue is for obvious reasons collected only rarely, and the use of primary or often extracted third molars emerged as a potential biomarker of exposure to fluoride.

The fluoride content of dentin of exfoliated primary teeth in relation to fluoride in water containing from less than 0.3 to 1 mg L⁻¹ of F⁻ ranged from 106 to 2699 μg g⁻¹.⁵³⁹ In communities with water containing between 0.2 and 1 mg L⁻¹ of F⁻, a positive correlation between dentin (101–860 μg g⁻¹) fluoride contents of third molars (101–860 μg g⁻¹) and dental fluorosis but not enamel F contents (39–550 μg g⁻¹) and dental fluorosis was found.⁵⁴⁰ The same authors reported a correlation between tooth F contents and F bone contents in mice but no correlation between enamel or dentin F contents and F bone contents in humans.⁵⁴¹

Reported fluoride contents in biological materials are highly variable and give some indication of exposure to fluoride, but so far normal ranges were not established. The concerns related to the reported results are the same as those identified more than a decade ago; that is, “the results are difficult to compare because: (1) sample pre-treatment methods were used that do not necessarily ensure complete release of fluoride from the sample matrix; (2) adequate information as to how the studies were conducted is not always provided; and (3) although advances in analytical techniques for trace amounts have led to re-examination of many of the published data, the majority of the data on fluorin(d)e still comes from older studies”.³⁵⁷ Further research should be encouraged starting by developing suitable CRMs for fluoride in biological materials to support the results of measurements according to GUM principles.

9. CONCLUSION

Fluorine and its compounds have unique and useful properties. For example, hydrofluorocarbons (HFCs) are nontoxic and nonreactive, and their boiling point is perfect for their use as refrigerants. A more famous example, Teflon (the polymer of tetrafluoroethylene), has low coefficient of friction and high chemical inertness. In the case of pharmaceuticals and agrochemicals, introduction of fluorine atoms often enhances chemical and metabolic stability, potency, and bioavailability. Fluorination also affects lipophilicity. As a consequence, the fluorochemical industry underwent an explosive growth during the last century, and fluorinated drugs and agrochemicals became more and more common (25–30% of newly introduced drugs and 75% of herbicides commercialized between 2010 and 2016 are fluoride-containing molecules).

Unfortunately, a side effect of the above developments was increased pollution of the environment with inorganic and organic fluoride compounds. The problem is aggravated by two factors. First, fluoride is a xenobiotic element because fluoride (its sole natural source) is scarcely available, and fluoride incorporation into organic molecules under biological conditions is a very difficult task (only a handful of organofluorine compounds can be found in nature). Second, fluoride compounds were often used before their toxicities and environmental effects were fully understood.

Studying the effects of fluoride-containing substances on the biosphere and the environment uncovered some unpleasant

surprises. The only well-defined beneficial effect of fluoride is reduction of dental caries, which led to fluoridation of community water in various countries. Notably, even this positive effect is negated by too high fluoride intake. All other bioactivities of fluoride are harmful: excess fluoride intake can result in dental or skeletal fluorosis, impaired thyroid and endocrine system function, or developmental neurotoxicity. In combination with Al^{3+} ions, fluoride readily forms aluminum(III) fluorocomplexes which can activate G-protein-coupled receptors at much lower concentrations than either Al^{3+} or F^- alone. It is also important that fluoride accumulates in the body: a large portion of the fluoride intake is quickly deposited in bones and teeth, from which it is released quite slowly. That is why fluoride content of the bones and teeth can be used as historic biomarkers of fluoride intake. Finally, even strongly bound fluoride sources can pose a danger (for example, strongly bound fluoride in soils can harm grazing livestock).

Within inorganic fluorides, sulfur hexafluoride is notable. This compound is a chemically robust nontoxic gaseous dielectric, but it has a strong greenhouse effect.

Organofluorine compounds also have various risks. A common problem is metabolism. These compounds (especially heavily fluorinated ones) are often highly resistant to degradation and can accumulate in the environment. Such compounds are persistent organic pollutants. The presence of polyfluoroalkyl substances, fluorinated drugs, and fluorine-containing agrochemicals in surface waters and biological samples corroborates this statement. In the case of fluorinated organic compounds, which undergo metabolism, a different danger arises: metabolic processes may produce toxic fluorine-containing metabolites, e.g., fluoride or fluoroacetate. It should not be forgotten that fluorinated drugs are in the most prescribed family, and an average patient may take several such drugs at the same time, increasing the risk. Many fluorinated drugs are known, where toxic fluoro-metabolites considerably contribute to side effects (for example, α -fluoro- β -alanine and fluoroacetate metabolites of the anticancer drug 5-fluorouracil), and some of them had to be withdrawn or restricted (for example, anesthetic agent methoxyflurane). Naturally, not all problems are metabolic in origin. Chlorofluorocarbons (CFCs), which were mainly used as refrigerants, were banned because they seriously damaged the ozone layer, producing chlorine radicals via their degradation in the stratosphere. Hydrofluorocarbons (HFCs), their replacements, have strong greenhouse effects.

Concerning the above problems, various actions should be taken. First of all, in light of more recent studies about the adverse effects of F^- , fluoride intake should be decreased. To achieve this goal, it would be worth limiting the fluoride content of drinking water (which has a high influence on fluoride intake) more strictly. This would be the easiest way to reduce fluoride intake in countries where community water fluoridation is practiced. Fluoride pollution should be reduced too. Important sources of fluoride pollution are the aluminum industry [electrolysis of Al_2O_3 is performed in cryolite (Na_3AlF_6)] and fluoride impurity of phosphate fertilizers (superphosphate can contain 1–3% fluoride). Currently, only the first source is regulated. Further thorough studies on the physiological effects of fluoride and aluminum(III) fluorocomplexes are also welcomed. Finally, reliable and standardized methods are required to assess fluoride intake more accurately from fluoride biomarkers.

Within organofluorine compounds, CFCs possessing ozone-depleting effects are already banned, and some perfluoroalkylated surfactants (perfluorooctanesulfonic acid and perfluorooctanoic acid) were phased out because of their harmful effects (for example, carcinogenicity). Various fluorinated drugs were also withdrawn because of their side effects. However, further studies are needed on the metabolism of various fluorine-containing groups and substances to identify derivatives, which are dangerous to human health or to the environment. Such studies would be especially important in the case of fluorine-containing drugs and agrochemicals. In addition, to reduce environmental pollution, organofluorine compounds should only be used when it is truly necessary. For example, many effective fire-fighting foams are now free from polyfluoroalkyl substances.

From a green chemistry viewpoint, recycling and recovery of fluorine compounds would be beneficial too. Currently, such processes are not widespread, but they do have potential. For example, the fluoride content of phosphate fertilizers and the phosphogypsum byproduct can be easily recovered as hexafluorosilicic acid (H_2SiF_6). This would not only reduce fluoride pollution but also provide a valuable intermediate, which can be used to produce various fluorine compounds (e.g., cryolite). In theory, taking into account the volume of phosphate fertilizer production, a sufficient quantity of H_2SiF_6 can be produced to considerably reduce the need for fluorspar (CaF_2) mining.

AUTHOR INFORMATION

Corresponding Authors

Loránd Kiss – University of Szeged, Institute of Pharmaceutical Chemistry and Interdisciplinary Excellence Centre, 6720 Szeged, Hungary; Email: kiss.lorand@pharm.u-szeged.hu

Santos Fustero – Departamento de Química Orgánica, Universidad de Valencia, 46100 Burjassot, Valencia, Spain; orcid.org/0000-0002-7575-9439; Email: santos.fustero@uv.es

Maja Ponikvar-Svet – Department of Inorganic Chemistry and Technology, Jožef Stefan Institute, 1000 Ljubljana, Slovenia; Email: maja.ponikvar-svet@ijs.si

Vadim A. Soloshonok – Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, 20018 San Sebastian, Spain; IKERBASQUE, Basque Foundation for Science, 48011 Bilbao, Spain; orcid.org/0000-0003-0681-4526; Email: vadym.soloshonok@ehu.es

Authors

Jianlin Han – Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, China; orcid.org/0000-0002-3817-0764

Haibo Mei – Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, China; orcid.org/0000-0002-2857-1935

Attila Márió Remete – University of Szeged, Institute of Pharmaceutical Chemistry and Interdisciplinary Excellence Centre, 6720 Szeged, Hungary

Daniel Mark Sedgwick – Departamento de Química Orgánica, Universidad de Valencia, 46100 Burjassot, Valencia, Spain

Raquel Roman – Departamento de Química Orgánica, Universidad de Valencia, 46100 Burjassot, Valencia, Spain

Hiroki Moriwaki — Hamari Chemicals Ltd., Suminoe-ku,
Osaka 559-0034, Japan

Complete contact information is available at:
<https://pubs.acs.org/10.1021/acs.chemrev.0c01263>

Notes

The authors declare no competing financial interest.

Biographies

Jianlin Han received his Ph.D. in Organic Chemistry in 2007 from Nanjing University. He then carried out postdoctoral studies for one year at Texas Tech University. In 2008, he moved to the University of Oklahoma to continue postdoctoral research for nearly one year. In 2009 he took the position of Associate Professor at the Nanjing University. In 2019, he moved to Nanjing Forestry University and became a professor there. His research topics include organic fluorine chemistry, amino acids, radical reaction, and asymmetric synthesis.

Loránd Kiss completed his Ph.D. in 2002 in the Department of Organic Chemistry at the Faculty of Sciences, Debrecen University (Debrecen, Hungary), under the supervision of Prof. Sándor Antus. In 2003, he joined the research team of Professor Ferenc Fülöp at the Institute of Pharmaceutical Chemistry, University of Szeged (Szeged, Hungary), where he started to work in the area of cyclic β -amino acid chemistry. He followed postdoctoral research in the laboratories of Prof. Norbert De Kimpe at Ghent University (Ghent, Belgium) and Prof. Santos Fustero, University of Valencia. He is currently a professor at the Institute of Pharmaceutical Chemistry, University of Szeged. His scientific interest is directed toward the selective functionalization of β -amino acid derivatives and the synthesis of highly functionalized fluorinated building blocks.

Haibo Mei obtained his B.Sc. in 2009 and Ph.D. in 2014 in organic chemistry from Nanjing University. Then he joined Nanjing University as a research fellow in the area of asymmetric synthesis. In 2018, he moved to Nanjing Forestry University and became an associate professor there. His research interests focus on organic fluorine chemistry, electrochemical synthesis, and asymmetric synthesis.

Attila Márió Remete graduated as a chemist in 2014 from University of Szeged, Faculty of Science and Informatics. He received his Ph.D. at the Institute of Pharmaceutical Chemistry, University of Szeged, under the supervision of Prof. Dr. Loránd Kiss in 2019. Since 2018, he has been an assistant lecturer at the University of Szeged. His research interests include β -amino acids, fluorine incorporation, and selective functionalizations.

Maja Ponikvar-Svet received her Ph.D. in analytical chemistry in 2002 at the University of Ljubljana (Slovenia) under the supervision of Profs. Žemva and Pihlar. She carried out her postdoctoral research in 2006 in the group of Prof. Willner at the University of Wuppertal (Germany). In 2006 she became an assistant professor at International Postgraduate School. Currently she is a Senior Scientific Associate at Jožef Stefan Institute and an Associate Professor at Jožef Stefan International Postgraduate School. Her research interests include analytical chemistry of fluorin(d)e, fluoride impacts on human health and environment, and thermochemistry. She is currently serving as a member of the editorial board of Structural Chemistry.

Daniel M. Sedgwick was born in Leeds (U.K.) in 1991. He obtained his B.Sc. in Medicinal and Pharmaceutical Chemistry from Loughborough University in 2014. He later completed his Master's degree and Ph.D. at the University of Valencia (Spain) under the supervision of Prof. Santos Fustero, during which he also spent three months at the University of Louisville in the group of Prof. G. B. Hammond. His current research

interests include the synthesis of novel fluorinated building blocks and small-molecule peptidomimetics.

Raquel Roman was born in Sevilla (Spain) in 1975. She studied chemistry (2001) and received her Ph.D. in 2009 from the University of Valencia under the supervision of Professor Santos Fustero, working on the regioselective synthesis of new fluorinated pyrazoles. Since then, she has been working as a research technician and assistant professor at the Department of Organic Chemistry of the Faculty of Pharmacy (University of Valencia) and a postdoctoral researcher at the Centro de Investigación Príncipe Felipe (CIPF). Her scientific interests are focused on the asymmetric synthesis of benzo-fused heterocycles and the design and development of new bioactive fluorinated compounds.

Santos Fustero studied chemistry at the University of Zaragoza, where he obtained his bachelor's degree in 1972. He received his Ph.D. in organic chemistry in 1975 from the same university under the supervision of Profs. Barluenga and Gotor. He carried out postdoctoral studies for two years at Prof. Lehmkuhl's group at the Max-Planck-Institut für Kohlenforschung in Mülheim/Ruhr, Germany. In 1983, he became an associate professor at the University of Oviedo, and in 1990, he was promoted to a full professor at the University of Valencia. His research interests include organofluorine and medicinal chemistry, organocatalysis, heterocyclic chemistry, and new reaction methodologies.

Hiroki Moriwaki, Ph.D., graduated from Kyoto Pharmaceutical University in 1985. Then he joined the Technical section at the Manufacturing Department of Hamari Chemicals, Ltd. In 2006 he started working as a Director of Research & Development at Department at Hamari Chemicals, Ltd. From 2010 to 2011 he joined the Institute for Chemical Biology and Drug Discovery (ICB & DD) at Stony Brook University and has been working to develop a new methodology for the synthesis of tailor-made amino acid derivatives. His specialty is development of a practical synthetic method of the special amino acid and peptide. Since 2015, he has been a board member of Hamari Chemicals, Ltd. In addition, He is currently serving as a councilor of the Japan Peptide Society.

Vadim A. Soloshonok graduated from Kiev State University of Ukraine in 1983 and received his Ph.D. in 1987 from the Ukrainian Academy of Sciences. He continued his education in the area of asymmetric synthesis in collaboration with Prof. Y. Belokon (Moscow, USSR, 1987–1990), Prof. P. Bravo (Milan, Italy, 1993), Prof. T. Hayashi (Sapporo, Japan, 1994–1995), and Prof. V. Hruby (Tucson, AZ, USA, 1998–2000). In 1987 he joined the Institute of Bioorganic Chemistry, Kiev, Ukraine, where he worked until 1995. From 1995 through 1999, he was a Senior Researcher at the National Industrial Research Institute, Nagoya, Japan, and from 2001 to 2010 a Professor of Chemistry at the University of Oklahoma, USA. Currently, he is the Ikerbasque Research Professor at the University of the Basque Country, Donostia–San Sebastian, Spain. He is currently serving as a member of the international advisory editorial board of the *Journal of Fluorine Chemistry* (2003–present) and as a Synthesis Field Editor of *Amino Acids* (2009–present). He serves as Past Chair of the ACS Fluorine Division (2010), author of over 350 research papers with over 19 000 citations and an h-index of 83. His major current research interests are fluorine chemistry, asymmetric synthesis, and self-disproportionation of enantiomers.

ACKNOWLEDGMENTS

J.L.H. thanks the National Natural Science Foundation of China (21761132021) and Qing Lan Project of Jiangsu Province. K.L. thanks the Hungarian Research Foundation (NKFIH No K 119282), the GINOP-2.3.2-15-2016-00014 project, the EU-

funded Hungarian grant EFOP-3.6.1-16-2016-00008, and Ministry of Human Capacities, Hungary (grant 20391-3/2018/FEKUSTRAT). M.P.S. thanks the Slovenian Research Agency (ARRS Grant P1-0045, Inorganic Chemistry and Technology) for financial support. S.F., R.R., and D.M.S. thank the Spanish Ministerio de Ciencia, Innovación y Universidades (MICINN), and Agencia Estatal de Investigación (AEI) for financial support (CTQ2017-84249-P). V.A.S. thanks IKERBASQUE, the Basque Foundation for Science.

ABBREVIATIONS

5'-FDA phosphorylase, 5'-fluoro-5'-deoxyadenosine phosphorylase; 5-FDRP isomerase, 5-fluoro-5-deoxy-D-ribose-1-phosphate isomerase; 5-FDRuIP aldolase, (3R,4S)-5-fluoro-5-deoxy-D-ribulose-1-phosphate aldolase; ACP, acyl carrier protein; ADHD, attention-deficit/hyperactivity disorder; AI, adequate intake; AS, atherosclerosis; ASD, autism spectrum disorder; ATP, adenosine triphosphate; BW, body weight; CDC, Centers for Disease Control and prevention; CKD, chronic kidney disease; CLD, certainly lethal dose; CHF, congestive heart failure; CNS, central nervous system; CoA, coenzyme-A; CRM, certified reference material; DW, dry weight; EFSA, European Food Safety Authority; EU, European Union; F-ISE, fluoride-ion selective electrode; F, fluorine as element or fluorine in any of its forms; F⁻, fluoride anion; fluorinase, 5'-fluoro-5'-deoxyadenosine synthase; GDP, guanosine diphosphate; GI, gastrointestinal; GPCR, G protein-coupled receptor; GUM, guide to the expression of uncertainty in measurement; HTN, hypertension; IOM, Institute of Medicine; MUF, maternal urinary fluoride; NAD⁺, nicotinamide adenine dinucleotide; NADH, reduced form of nicotinamide adenine dinucleotide; NADP⁺, nicotinamide adenine dinucleotide phosphate; NADPH, reduced form of nicotinamide adenine dinucleotide phosphate; PLP, pyridoxal phosphate; PTD, probable toxic dose; PTH, parathyroid hormone; UDP-glucose, uridine diphosphate glucose; UK, United Kingdom; US, United States; USDA, United States Department of Agriculture; TSH, thyroid-stimulating hormone; WHO, World Health Organization

REFERENCES

- (1) Villalba, G.; Ayres, R. U.; Schroder, H. Accounting for Fluorine: Production, Use, and Loss. *J. Ind. Ecol.* **2007**, *11*, 85–101.
- (2) Stevenson, A. J.; Serier-Brault, H.; Gredin, P.; Mortier, M. Fluoride Materials for Optical Applications: Single Crystals, Ceramics, Glasses, and Glass-Ceramics. *J. Fluorine Chem.* **2011**, *132*, 1165–1173.
- (3) Su, H.; Shi, S.; Zhu, M.; Crump, D.; Letcher, R. J.; Giesy, J. P.; Su, G. Persistent, Bioaccumulative, and Toxic Properties of Liquid Crystal Monomers and Their Detection in Indoor Residential Dust. *Proc. Natl. Acad. Sci. U. S. A.* **2019**, *116*, 26450–26458.
- (4) Améduri, B. The Promising Future of Fluoropolymers. *Macromol. Chem. Phys.* **2020**, *221*, 1900573.
- (5) Photonic and Electronic Properties of Fluoride Materials. Tressaud, A., Poepelmeier, K. R., Eds.; *Progress in Fluorine Sciences series*; Elsevier, 2016; Vol. 1.
- (6) Oliver, A. J.; Özberk, E. Conversion of Natural Uranium. In *Uranium for Nuclear Power*; Ian, H.-L., Ed.; Woodhead Publishing, 2016.
- (7) Harding, P. Uranium Enrichment. In *Uranium for Nuclear Power*; Ian, H.-L., Ed.; Woodhead Publishing, 2016.
- (8) Cheng, M.; Guo, C.; Gross, M. L. The Application of Fluorine-Containing Reagents in Structural Proteomics. *Angew. Chem., Int. Ed.* **2020**, *59*, 5880–5889.
- (9) Salwiczek, M.; Nyakatura, E. K.; Gerling, U. I. M.; Ye, S.; Koksich, B. Fluorinated Amino Acids: Compatibility with Native Protein

Structures and Effects on Protein-Protein Interactions. *Chem. Soc. Rev.* **2012**, *41*, 2135–2171.

- (10) Meng, H.; Clark, G. A.; Kumar, K. Fluorinated Amino Acids and Biomolecules in Protein Design and Chemical Biology. In *Fluorine in Medicinal Chemistry and Chemical Biology*; Iwao, O., Ed.; Wiley, 2009.
- (11) Berger, R.; Resnati, G.; Metrangolo, P.; Weber, E.; Hulliger, J. Organic Fluorine Compounds: a Great Opportunity for Enhanced Materials Properties. *Chem. Soc. Rev.* **2011**, *40*, 3496–3508.
- (12) Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V. A.; Izawa, K.; Liu, H. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. *Chem. Rev.* **2016**, *116*, 422–518.
- (13) O'Hagan, D. Understanding Organofluorine Chemistry. An Introduction to the C-F Bond. *Chem. Soc. Rev.* **2008**, *37*, 308–319.
- (14) Zhu, Y.; Han, J. L.; Wang, J.; Shibata, N.; Sodeoka, M.; Soloshonok, V. A.; Coelho, J. A. S.; Toste, F. D. Modern Approaches for Asymmetric Construction of Carbon-Fluorine Quaternary Stereogenic Centers: Synthetic Challenges and Pharmaceutical Needs. *Chem. Rev.* **2018**, *118*, 3887–3964.
- (15) Han, J.; Remete, A. M.; Dobson, L. S.; Kiss, L.; Izawa, K.; Moriwaki, H.; Soloshonok, V. A.; O'Hagan, D. Next Generation Organofluorine Containing Blockbuster Drugs. *J. Fluorine Chem.* **2020**, *239*, 109639.
- (16) O'Hagan, D. Fluorine in Health Care: Organofluorine Containing Blockbuster drugs. *J. Fluorine Chem.* **2010**, *131*, 1071–1081.
- (17) Mei, H.; Remete, A. M.; Zou, Y.; Moriwaki, H.; Fustero, S.; Kiss, L.; Soloshonok, V. A.; Han, J. Fluorine-Containing Drugs Approved by the FDA in 2019. *Chin. Chem. Lett.* **2020**, *31*, 2401–2413.
- (18) Jeschke, P. The Unique Role of Fluorine in the Design of Active Ingredients for Modern Crop Protection. *ChemBioChem* **2004**, *5*, 570–589.
- (19) Jeschke, P. The Unique Role of Halogen Substituents in the Design of Modern Agrochemicals. *Pest Manage. Sci.* **2010**, *66*, 10–27.
- (20) Jeschke, P. Latest Generation of Halogen-Containing Pesticides. *Pest Manage. Sci.* **2017**, *73*, 1053–1066.
- (21) Kilbourn, M. R.; Shao, X. Fluorine-18 Radiopharmaceuticals. In *Fluorine in Medicinal Chemistry and Chemical Biology*; Iwao, O.; Wiley-Blackwell: Chichester, 2009.
- (22) Deng, X.; Rong, J.; Wang, L.; Vasdev, N.; Zhang, L.; Josephson, L.; Liang, S. H. Chemistry for Positron Emission Tomography: Recent Advances in ¹¹C-, ¹⁸F-, ¹³N-, and ¹⁵O-Labeling Reactions. *Angew. Chem., Int. Ed.* **2019**, *58*, 2580–2605.
- (23) Abundance of Elements in the Earth's Crust and in the Sea. *CRC Handbook of Chemistry and Physics*, 97th ed.; 2016-2017; p 14.
- (24) Carvalho, M. F.; Oliveira, R. S. Natural Production of Fluorinated Compounds and Biotechnological Prospects of the Fluorinase Enzyme. *Crit. Rev. Biotechnol.* **2017**, *37*, 880–897.
- (25) *Fluorine-Containing Amino Acids. Synthesis and Properties*; Kukhar, V. P., Soloshonok, V. A., Eds.; John Wiley & Sons Ltd., 1994.
- (26) Harper, D. B.; O'Hagan, D. The Fluorinated Natural Products. *Nat. Prod. Rep.* **1994**, *11*, 123–133.
- (27) World Health Organization. *Fluorine and Fluorosis, Environmental Health Criteria 36*; World Health Organization: Geneva, 1984.
- (28) Strunecka, A.; Strunecky, O. Mechanisms of Fluoride Toxicity: From Enzymes to Underlying Integrative Networks. *Appl. Sci.* **2020**, *10*, 7100.
- (29) Strunecka, A.; Blaylock, R. L.; Patocka, J.; Strunecky, O. Immunoexcitotoxicity as the Central Mechanism of Etiopathology and Treatment of Autism Spectrum Disorders: A Possible Role of Fluoride and Aluminum. *Surg. Neurol. Int.* **2018**, *9*, 74.
- (30) Chaney, R. L. Food Safety Issues for Mineral and Organic Fertilizers. In *Advances in Agronomy*; Sparks, D. L., Ed.; Academic Press, Elsevier, 2012; Vol. 117.
- (31) Miura, K.; Kinouchi, M.; Ishida, K.; Fujibuchi, W.; Naitoh, T.; Ogawa, H.; Ando, T.; Yazaki, N.; Watanabe, K.; Haneda, S.; et al. 5-FU Metabolism in Cancer and Orally-Administerable 5-FU Drugs. *Cancers* **2010**, *2*, 1717–1730.

- (32) Ikeda, S. The Reincarnation of Methoxyflurane. *J. Anesth. Hist.* **2020**, *6*, 79–83.
- (33) Lim, X. Tainted Water: the Scientists Tracing Thousands of Fluorinated Chemicals in Our Environment. *Nature* **2019**, *566*, 27–29.
- (34) Hughes, S. R.; Kay, P.; Brown, L. E. Global Synthesis and Critical Evaluation of Pharmaceutical Data Sets Collected from River Systems. *Environ. Sci. Technol.* **2013**, *47*, 661–677.
- (35) Murphy, M. B.; Loi, E. I. H.; Kwok, K. Y.; Lam, P. K. S. Ecotoxicology of Organofluorous Compounds. In *Topics in Current Chemistry*; Horvath, I. T., Ed.; Springer, 2012; Vol. 308.
- (36) Yokoyama, A. Assessing Impacts of Insecticides on Different Embryonic Stages of the Nontarget Aquatic Insect *Cheumatopsyche brevilineata* (Trichoptera: Hydropsychidae). *Environ. Toxicol. Chem.* **2019**, *38*, 1434–1445.
- (37) Jepson, P. D.; Law, R. J. Persistent Pollutants, Persistent Threats. *Science* **2016**, *352*, 1388–1389.
- (38) Gribble, G. W. *Naturally Occurring Organohalogen Compounds - A Comprehensive Update*; Springer-Verlag: Wien, 2010.
- (39) Schmedt auf der Günne, J.; Mangstl, M.; Kraus, F. Occurrence of Difluorine F₂ in Nature-In Situ Proof and Quantification by NMR Spectroscopy. *Angew. Chem., Int. Ed.* **2012**, *51*, 7847–7849.
- (40) O'Hagan, D.; Harper, D. B. Fluorine-Containing Natural Products. *J. Fluorine Chem.* **1999**, *100*, 127–133.
- (41) Dong, C.; Huang, F.; Deng, H.; Schaffrath, C.; Spencer, J. B.; O'Hagan, D.; Naismith, J. H. Crystal Structure and Mechanism of a Bacterial Fluorinating Enzyme. *Nature* **2004**, *427*, 561–565.
- (42) Cadicamo, C. D.; Courtieu, J.; Deng, H.; Meddour, A.; O'Hagan, D. Enzymatic Fluorination in *Streptomyces cattleya* Takes Place with an Inversion of Configuration Consistent with an S_N2 Reaction Mechanism. *ChemBioChem* **2004**, *5*, 685–690.
- (43) Sooklal, S. A.; De Koning, C.; Brady, D.; Rumbold, K. Identification and Characterisation of a Fluorinase from *Actinopolyspora Mzabensis*. *Protein Expression Purif.* **2020**, *166*, 105508.
- (44) Proudfoot, A. T.; Bradberry, S. M.; Vale, J. A. Sodium Fluoroacetate Poisoning. *Toxicol. Rev.* **2006**, *25*, 213–219.
- (45) Christie, W. W.; Hamilton, J. T. G.; Harper, D. B. Mass Spectrometry of Fluorinated Fatty Acids in the Seed Oil of *Dichapetalum Toxicarium*. *Chem. Phys. Lipids* **1998**, *97*, 41–47.
- (46) Hamilton, J. T. G.; Harper, D. B. Fluorinated Fatty Acids in the Seed Oil of *Dichapetalum Toxicarium*. *Phytochemistry* **1997**, *44*, 1129–1132.
- (47) Harper, D. B.; Hamilton, J. T. G.; O'Hagan, D. Identification of Threo-18-fluoro-9,10 Dihydroxystearic Acid: A Novel ω -Fluorinated Fatty Acid from *Dichapetalum Toxicarium* Seeds. *Tetrahedron Lett.* **1990**, *31*, 7661–7662.
- (48) Ma, L.; Bartholome, A.; Tong, M. H.; Qin, Z.; Yu, Y.; Shepherd, T.; Kyeremeh, K.; Deng, H.; O'Hagan, D. Identification of a Fluorometabolite from *Streptomyces* sp. MA37: (2R3S4S)-5-Fluoro-2,3,4-trihydroxypentanoic Acid. *Chem. Sci.* **2015**, *6*, 1414–1419.
- (49) Zhu, X. M.; Hackl, S.; Thaker, M. N.; Kalan, L.; Weber, C.; Urgast, D. S.; Krupp, E. M.; Brewer, A.; Vanner, S.; Szawiola, A.; et al. Biosynthesis of the Fluorinated Natural Product Nucleocidin in *Streptomyces Calvus* Is Dependent on the *bldA*-Specified Leu-trRNA^{UUA} Molecule. *ChemBioChem* **2015**, *16*, 2498–2506.
- (50) Zhang, S.; Klementz, D.; Zhu, J.; Makitrynsky, R.; Pasternak, A. R. O.; Günther, S.; Zechel, D. L.; Bechthold, A. Genome Mining Reveals the Origin of a Bald Phenotype and a Cryptic Nucleocidin Gene Cluster in *Streptomyces Asterosporus* DSM 41452. *J. Biotechnol.* **2019**, *292*, 23–31.
- (51) Feng, X.; Bello, D.; Lowe, P. T.; Clark, J.; O'Hagan, D. Two 3'-O- β -glucosylated Nucleoside Fluorometabolites Related to Nucleocidin in *Streptomyces Calvus*. *Chem. Sci.* **2019**, *10*, 9501–9505.
- (52) Feng, X.; Maharik, N. A.; Bartholomé, A.; Janso, J. E.; Reilly, U.; O'Hagan, D. Incorporation of [²H₁]- (1R,2R)- and [²H₁]- (1S,2R)-Glycerols into the Antibiotic Nucleocidin in *Streptomyces Calvus*. *Org. Biomol. Chem.* **2017**, *15*, 8006–8008.
- (53) Bartholomé, A.; Janso, J. E.; Reilly, U.; O'Hagan, D. Fluorometabolite Biosynthesis: Isotopically Labelled Glycerol Incorporations into the Antibiotic Nucleocidin in *Streptomyces Calvus*. *Org. Biomol. Chem.* **2017**, *15*, 61–64.
- (54) Peters, R. A.; Shorthouse, M. Observations on the Metabolism of Fluoride in *Acacia Georginae* and Some Other Plants. *Nature* **1967**, *216*, 80–81.
- (55) Peters, R. A.; Shorthouse, M. Identification of a Volatile Constituent formed by Homogenates of *Acacia Georginae* Exposed to Fluoride. *Nature* **1971**, *231*, 123–124.
- (56) Yamazaki, T.; Taguchi, T.; Ojima, I. Unique Properties of Fluorine and Their Relevance to Medicinal Chemistry and Chemical Biology. In *Fluorine in Medicinal Chemistry and Chemical Biology*; Iwao, Ojima, Ed.; Wiley-Blackwell: Chichester, 2009.
- (57) Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in Medicinal Chemistry. *ChemBioChem* **2004**, *5*, 637–643.
- (58) Hagmann, W. K. The Many Roles for Fluorine in Medicinal Chemistry. *J. Med. Chem.* **2008**, *51*, 4359–4369.
- (59) Furet, P.; Guagnano, V.; Fairhurst, R. A.; Imbach-Weese, P.; Bruce, I.; Knapp, M.; Fritsch, C.; Blasco, F.; Blanz, J.; Aichholz, R.; et al. Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase α Inhibitor Selected for Clinical Evaluation. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 3741–3748.
- (60) Müller, K.; Faeh, C.; Diederich, F. Fluorine in Pharmaceuticals: Looking beyond Intuition. *Science* **2007**, *317*, 1881–1886.
- (61) Istvan, E. S.; Deisenhofer, J. Structural Mechanism for Statin Inhibition of HMG-CoA Reductase. *Science* **2001**, *292*, 1160–1164.
- (62) Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results. <https://www.mrknewsroom.com/printpdf/1560>.
- (63) Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; et al. (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. *J. Med. Chem.* **2005**, *48*, 141–151.
- (64) Romanenko, V. D.; Kukhar, V. P. Fluorinated Phosphonates: Synthesis and Biomedical Application. *Chem. Rev.* **2006**, *106*, 3868–3935.
- (65) Turcheniuk, K. V.; Kukhar, V. P.; Roeschenthaler, G.-V.; Luis Acena, J.; Soloshonok, V. A.; Sorochinsky, A. E. Recent Advances in the Synthesis of Fluorinated Aminophosphonates and Aminophosphonic Acids. *RSC Adv.* **2013**, *3*, 6693–6716.
- (66) Gauthier, J. Y.; Chauret, N.; Cromlish, W.; Desmarais, S.; Duong, L. T.; Falguyret, J.-P.; Kimmel, D. B.; Lamontagne, S.; Léger, S.; LeRiche, T.; et al. The Discovery of Odanacatib (MK-0822), a Selective Inhibitor of Cathepsin K. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 923–928.
- (67) McClung, M. R.; O'Donoghue, M. L.; Papapoulos, S. E.; Bone, H.; Langdahl, B.; Saag, K. G.; Reid, I. R.; Kiel, D. P.; Cavallari, I.; Bonaca, M. P.; et al. Odanacatib for the Treatment of Postmenopausal Osteoporosis: Results of the LOFT Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial and LOFT Extension Study. *Lancet Diabetes Endocrinol.* **2019**, *7*, 899–911.
- (68) March, T. L.; Johnston, M. R.; Duggan, P. J.; Gardiner, J. Synthesis, Structure, and Biological Applications of α -Fluorinated β -Amino Acids and Derivatives. *Chem. Biodiversity* **2012**, *9*, 2410–2441.
- (69) Mei, H.; Han, J.; White, S.; Graham, D. J.; Izawa, K.; Sato, T.; Fustero, S.; Meanwell, N. A.; Soloshonok, V. A. Tailor-Made Amino Acids and Fluorinated Motifs as Prominent Traits in the Modern Pharmaceuticals. *Chem. - Eur. J.* **2020**, *26*, 11349–11390.
- (70) Mei, H.; Han, J.; Klika, K. D.; Izawa, K.; Sato, T.; Meanwell, N. A.; Soloshonok, V. A. Applications of Fluorine-Containing Amino Acids for Drug Design. *Eur. J. Med. Chem.* **2020**, *186*, 111826.
- (71) Soloshonok, V. A.; Gerus, I. I.; Yagupolskii, Y. L.; Kukhar, V. P. Fluorine-Containing Amino Acids. III.)-Trifluoromethyl-l-Amino Acids. *Zh. Org. Khim.* **1987**, *23*, 2308–2313.
- (72) Doi, M.; Nishi, Y.; Kiritoshi, N.; Iwata, T.; Nago, M.; Nakano, H.; Uchiyama, S.; Nakazawa, T.; Wakamiyad, T.; Kobayashi, Y. Simple and Efficient Syntheses of Boc- and Fmoc-Protected 4 (R)- and 4 (S)-Fluoroproline Solely from 4 (R)-Hydroxyproline. *Tetrahedron* **2002**, *58*, 8453–8459.

- (73) Bretscher, L. E.; Jenkins, C. L.; Taylor, K. M.; DeRider, M. L.; Raines, R. T. Conformational Stability of Collagen Relies on a Stereoelectronic Effect. *J. Am. Chem. Soc.* **2001**, *123*, 777–778.
- (74) Pan, S.; Wu, X.; Jiang, J.; Gao, W.; Wan, Y.; Cheng, D.; Han, D.; Liu, J.; Englund, N. P.; Wang, Y.; et al. Discovery of NVP-LDE225, a Potent and Selective Smoothed Antagonist. *ACS Med. Chem. Lett.* **2010**, *1*, 130–134.
- (75) Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; et al. A Small-Molecule Nitroimidazopyran Drug Candidate for the Treatment of Tuberculosis. *Nature* **2000**, *405*, 962–966.
- (76) Li, X.; Manjunatha, U. H.; Goodwin, M. B.; Knox, J. E.; Lipinski, C. A.; Keller, T. H.; Barry III, C. E.; Dowd, C. S. Synthesis and Antitubercular Activity of 7-(R)- and 7-(S)-Methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]-oxazines, Analogues of PA-824. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2256–2262.
- (77) Moschitto, M. J.; Doubleday, P. F.; Catlin, D. S.; Kelleher, N. L.; Liu, D.; Silverman, R. B. Mechanism of Inactivation of Ornithine Aminotransferase by (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidene)cyclopentane-1-carboxylic Acid. *J. Am. Chem. Soc.* **2019**, *141*, 10711–10721.
- (78) Carreras, C. W.; Santi, D. V. The Catalytic Mechanism and Structure of Thymidylate Synthase. *Annu. Rev. Biochem.* **1995**, *64*, 721–762.
- (79) Fujiwara, T.; O'Hagan, D. Successful Fluorine-Containing Herbicide Agrochemicals. *J. Fluorine Chem.* **2014**, *167*, 16–29.
- (80) Theodoridis, G. Fluorine-Containing Agrochemicals: An Overview of Recent Developments. In *Fluorine and the Environment. Agrochemicals, Archaeology, Green Chemistry & Water*; Tressaud, A., Ed.; Elsevier: Amsterdam, 2006.
- (81) Qacemi, M. E.; Rendine, S.; Maienfisch, P. Chapter 17. Recent Applications of Fluorine in Crop Protection - New Discoveries Originating from the Unique Heptafluoroisopropyl Group. In *Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals*; Haufe, G., Leroux, F. G., Eds.; Academic Press: London, 2019.
- (82) Liang, T.; Neumann, C. N.; Ritter, T. Introduction of Fluorine and Fluorine-Containing Functional Groups. *Angew. Chem., Int. Ed.* **2013**, *52*, 8214–8264.
- (83) Dykstra, K. D.; Ichiishi, N.; Krska, S. W.; Richardson, P. F. Chapter 1. Emerging fluorination methods in organic chemistry relevant for life science application. In *Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals*; Haufe, G., Leroux, F. G., Eds.; Academic Press: London, 2019.
- (84) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011). *Chem. Rev.* **2014**, *114*, 2432–2506.
- (85) Mei, H.; Han, J.; Fustero, S.; Medio-Simon, M.; Sedgwick, D. M.; Santi, C.; Ruzziconi, R.; Soloshonok, V. A. Fluorine-Containing Drugs Approved by the FDA in 2018. *Chem. - Eur. J.* **2019**, *25*, 11797–11819.
- (86) Ogawa, Y.; Tokunaga, E.; Kobayashi, O.; Hirai, K.; Shibata, N. Current Contributions of Organofluorine Compounds to the Agrochemical Industry. *iScience* **2020**, *23*, 101467.
- (87) Inoue, M.; Sumii, Y.; Shibata, N. Contribution of Organofluorine Compounds to Pharmaceuticals. *ACS Omega* **2020**, *5*, 10633–10640.
- (88) TCI brochure “Fluorination Reagents, Fluorinated Building Blocks”. <http://www.tcichemicals.com/pdf/R5051E> (accessed May 21, 2019).
- (89) Zhu, W.; Wang, J.; Wang, S.; Gu, Z.; Aceña, J. L.; Izawa, K.; Liu, H.; Soloshonok, V. A. Recent Advances in the Trifluoromethylation Methodology and New CF₃-Containing Drugs. *J. Fluorine Chem.* **2014**, *167*, 37–54.
- (90) Alonso, R.; Cuevas, A.; Mata, P. Lomitapide: A Review of Its Clinical Use, Efficacy, and Tolerability. *Core Evid.* **2019**, *14*, 19–30.
- (91) Celinski, V. R.; Ditter, M.; Kraus, F.; Fujara, F.; Schmedt auf der Günne, J. Trace Determination and Pressure Estimation of Fluorine F₂ Caused by Irradiation Damage in Minerals and Synthetic Fluorides. *Chem. - Eur. J.* **2016**, *22*, 18388–18393.
- (92) Koga, K. T.; Rose-Koga, E. F. Fluorine in the Earth and the Solar System, Where does It Come from and Can It Be Found? *C. R. Chim.* **2018**, *21*, 749–756.
- (93) Symonds, R. B.; Rose, W. I.; Reed, M. H. Contribution of Cl- and F- Bearing Gases to the Atmosphere by Volcanoes. *Nature* **1988**, *334*, 415–418.
- (94) Agency for Toxic Substances and Disease Registry, U.S. Department of Health and Human Services. *Toxicological Profile for Fluorides, Hydrogen Fluoride, and Fluorine*; Atlanta, 2003.
- (95) Fuge, R. Fluorine in the Environment, A Review of its Sources and Geochemistry. *Appl. Geochem.* **2019**, *100*, 393–406.
- (96) Davison, A. H.; Weinstein, L. H. Some Problems Relating to Fluorides in the Environment: Effects on Plants and Animals. In *Fluorine and the Environment, Atmospheric Chemistry, Emissions, & Lithosphere*; Tressaud, A., Ed.; Elsevier: Amsterdam, The Netherlands, 2006; Vol. 1, pp 252–298.
- (97) Álvarez-Ayuso, E.; Giménez, A.; Ballesteros, J. C. Fluoride Accumulation by Plants Grown in Acid Soils Amended with Flue Gas Desulphurisation Gypsum. *J. Hazard. Mater.* **2011**, *192*, 1659–1666.
- (98) Koblar, A.; Tavčar, G.; Ponikvar-Svet, M. Effects of Airborne Fluoride on Soil and Vegetation. *J. Fluorine Chem.* **2011**, *132*, 755–759.
- (99) Davis, W. L. Ambient Air Fluorides in Salt Lake County. *Rocky Mt. Med. J.* **1972**, *69*, 53–56.
- (100) Low, P. S.; Bloom, H. Atmospheric Deposition of Fluoride in the Lower Tamar Valley, Tasmania. *Atmos. Environ.* **1988**, *22*, 2049–2056.
- (101) World Health Organization. *Environmental Health Criteria 227, Fluorides*; World Health Organization: Geneva, 2002.
- (102) Weinstein, L. H.; Davison, A. W. Native Plant Species Suitable as Bioindicators and Biomonitoring for Airborne Fluoride. *Environ. Pollut.* **2003**, *125*, 3–11.
- (103) Weinstein, L. H.; Davison, A. W. *Fluorides in the Environment*; Cabi Publishing: Cambridge, 2004.
- (104) Štepec, D.; Tavčar, G.; Ponikvar-Svet, M. Fluorine in Vegetation Due to an Uncontrolled Release of Gaseous Fluorides from a Glassworks: A Case Study of Measurement Uncertainty, Dispersion Pattern and Compliance with Regulation. *Environ. Pollut.* **2019**, *248*, 958–964.
- (105) Thompson, R. J.; McMullen, T. B.; Morgan, G. B. Fluoride Concentrations in the Ambient Air. *J. Air Pollut. Control Assoc.* **1971**, *21*, 484–487.
- (106) Ares, J. Fluoride-Aluminium Water Chemistry in Forest Ecosystems of Central Europe. *Chemosphere* **1990**, *21*, 597–612.
- (107) Skjelkvale, B. L. Factors Influencing Fluoride Concentrations in Norwegian Lakes. *Water, Air, Soil Pollut.* **1993**, *77*, 151–167.
- (108) Seyfried, W. E., Jr.; Ding, K. The Hydrothermal Chemistry of Fluoride in Seawater. *Geochim. Cosmochim. Acta* **1995**, *59*, 1063–1071.
- (109) Williamson, M. M. Endemic Dental Fluorosis in Kenya. A Preliminary Report. *East Afr. Med. J.* **1953**, *30*, 217–233.
- (110) Brunt, R.; Vasak, L.; Griffioen, J. *Fluoride in Groundwater: Probability of Occurrence of Excessive Concentration on Global Scale*; International Groundwater Resources Assessment Centre: Utrecht, 2004.
- (111) Ellwood, R. P.; Cury, J. A. How Much Toothpaste Should a Child under the Age of 6 Years use? *Eur. Arch. Paediatr. Dent.* **2009**, *10*, 170–176.
- (112) American Dental Association Council on Scientific Affairs. Fluoride Toothpaste Use for Young Children. *J. Am. Dent. Assoc., JADA* **2014**, *145*, 190–191.
- (113) World Health Organization. *Guidelines for Drinking-water Quality*, 4th ed.; World Health Organization: Geneva, 2010.
- (114) World Health Organization. *318 on Oral Health Status and Fluoride Use, WHO Technical Report Series 846*; World Health Organization: Geneva, 1994.

- (115) Centers for Disease Control and Prevention. Ten Great Public Health Achievements - United States, 1900–1999. *MMWR Weekly* **2008**, *57*, 737–764.
- (116) United States Public Health Service. U.S. Public Health Service Recommendation for Fluoride Concentration in Drinking Water for the Prevention of Dental Caries. *Public Health Rep.* **2015**, *130*, 318–331.
- (117) Scientific Committee on Health and Environmental Risks. *Critical Review of any New Evidence on the Hazard Profile, Health Effects, and Human Exposure to Fluoride and the Fluoridating Agents of Drinking Water*; European Commission: Brussels, 2010.
- (118) Pullishery, F.; Panchmal, G. S.; Siddique, S.; Palliyal, S. Status of Water Fluoridation -An Update from the Asian Countries. *Arch. Dent.* **2015**, *1*, 24–29.
- (119) Nutrient Data Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service. *USDA National Fluoride Database of Selected Beverages and Foods*, Release 2; Baltimore, 2005.
- (120) Zohoori, V.; Maguire, A. *Database of the Fluoride (F) Content of Selected Drinks and Foods in the UK*; Newcastle University and Teesside University, 2015.
- (121) Štepec, D.; Ponikvar-Svet, M. Fluoride in Human Health and Nutrition. *Acta Chim. Slov.* **2019**, *66*, 255–275.
- (122) Fung, K. F.; Zhang, Z. Q.; Wong, J. W. C.; Wong, M. H. Fluoride Contents in Tea and Soil from Tea Plantations and the Release of Fluoride into Tea Liquor During Infusion. *Environ. Pollut.* **1999**, *104*, 197–205.
- (123) Koblar, A.; Tavčar, G.; Ponikvar-Svet, M. Fluoride in Teas of Different Types and Forms and the Exposure of Humans to Fluoride with Tea and Diet. *Food Chem.* **2012**, *130*, 286–290.
- (124) Chan, L.; Mehra, A.; Saikat, S.; Lynch, P. Human Exposure Assessment of Fluoride from Tea (*Camellia sinensis* L.): A UK based issue? *Food Res. Int.* **2013**, *51*, 564–570.
- (125) Peng, C.; Cai, H.; Zhu, X.; Li, D.; Yang, Y.; Hou, R.; Wan, X. Analysis of Naturally Occurring Fluoride in Commercial Teas and Estimation of Its Daily Intake through Tea Consumption. *J. Food Sci.* **2016**, *81*, H235–H239.
- (126) Waugh, D. T.; Potter, W.; Limeback, H.; Godfrey, M. Risk Assessment of Fluoride Intake from Tea in the Republic of Ireland and its Implications for Public Health and Water Fluoridation. *Int. J. Environ. Res. Public Health* **2016**, *13*, 259.
- (127) Venkateswarlu, P. Determination of Fluorine in Biological Materials: A Review. *Adv. Dent. Res.* **1994**, *8*, 80–86.
- (128) Štepec, D.; Tavčar, G.; Ponikvar-Svet, M. Measurement Uncertainty Evaluation and Traceability Assurance for Total Fluorine Determination in Vegetation by Fluoride Ion Selective Electrode. *J. Fluorine Chem.* **2019**, *217*, 22–28.
- (129) Štepec, D.; Tavčar, G.; Ponikvar-Svet, M. Surprisingly High Fluorine Content in Some Exotic Superfoods. *J. Fluorine Chem.* **2020**, *234*, 109521.
- (130) Sampaio, F. C.; Levy, S. M. Systemic Fluoride. *Monogr. Oral Sci.* **2011**, *22*, 133–145.
- (131) Villa, A. E. Evaluating Fluoride Exposure in Milk Fluoridation Programmes. In *Milk Fluoridation for the Prevention of Dental Caries*; Bánóczy, J., Edgar, M., Petersen, P. E., Rugg-Gunn, A., Villa, A., Woodward, M., Eds.; WHO Press: Geneva, Switzerland, 2009; pp 127–136.
- (132) Whitford, G. M. Fluoride in Dental Products: Safety Considerations. *J. Dent. Res.* **1987**, *66*, 1056–1060.
- (133) Pollick, H. F. Salt Fluoridation: A Review. *J. Calif. Dent. Assoc.* **2013**, *41*, 395–404.
- (134) Pollick, H. The Role of Fluoride in the Prevention of Tooth Decay. *Pediatr. Clin. North Am.* **2018**, *65*, 923–940.
- (135) Fejerskov, O.; Thylstrup, A.; Larsen, M. J. Rational Use of Fluorides in Caries Prevention. A Concept Based on Possible Cariostatic Mechanisms. *Acta Odontol. Scand.* **1981**, *39*, 241–249.
- (136) Aoba, T.; Fejerskov, O. Dental Fluorosis: Chemistry and Biology. *Crit. Rev. Oral Biol. Med.* **2002**, *13*, 155–170.
- (137) Whelton, H. Fluoride in the Prevention of Dental Decay. In *Encyclopedia of Food Sciences and Nutrition*, 2nd ed.; Caballero, B., Trugo, L. C., Finglas, P. M., Eds.; Academic Press: San Diego, United States, 2003; pp 1754–1760.
- (138) Walsh, T.; Worthington, H. V.; Glenney, A. M.; Marinho, V. C. C.; Jeronic, A. Fluoride Toothpastes of Different Concentrations for Preventing Dental Caries. *Cochrane Database Syst. Rev.* **2019**, CD007868.
- (139) Robinson, P. G.; Marshman, Z. Dental Public Health. In *Oxford Textbook of Global Public Health*; Detels, R., Gulliford, M., Karim, Q. A., Tan, C. C., Eds.; Oxford University Press: Oxford, United Kingdom, 2015; pp 1028–1045.
- (140) Nicholson, J. W.; Czarnecka, B. Fluoride in Dentistry and Dental Restoratives. In *Fluorine and Health, Molecular Imaging, Biomedical Materials and Pharmaceuticals*; Tressaud, A., Haufe, G., Eds.; Elsevier: Amsterdam, The Netherlands, 2008; pp 333–378.
- (141) Marinho, V. C. C.; Worthington, H. V.; Walsh, T.; Clarkson, J. E. Fluoride Varnishes for Preventing Dental Caries in Children and Adolescents (Review). *Cochrane Database Syst. Rev.* **2013**, CD002279.
- (142) Tressaud, A. *Fluorine - A Paradoxical Element*; Elsevier: Amsterdam, The Netherlands, 2018.
- (143) European Food Safety Authority. Scientific Opinion on Dietary Reference Values for Fluoride. *EFSA J.* **2013**, *11*, 3332–3378.
- (144) Institute of Medicine. *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*; National Academy Press: Washington, D.C., 1997.
- (145) Dean, H. T.; Jay, P.; Arnold, F. A., Jr.; Elvove, E. Domestic Water and Dental Caries. *Pub. Health Rep.* **1942**, *57*, 1155–1194.
- (146) McClure, F. J. Ingestion of Fluoride and Dental Caries. *AMA Am. J. Dis. Child.* **1943**, *66*, 362–369.
- (147) Burt, B. A. The Changing Patterns of Systemic Fluoride Intake. *J. Dent. Res.* **1992**, *71*, 1228–1237.
- (148) World Health Organization. *Air Quality Guidelines for Europe*, 2nd ed.; World Health Organization: Geneva, 2000.
- (149) Li, L.; Luo, K.; Tang, Y.; Liu, Y. The Daily Fluorine and Arsenic Intake for Residents with Different Diets and Fluorosis Risk in Coal-Burning Fluorosis Area, Yunnan, Southwest China. *Environ. Sci. Pollut. Res.* **2015**, *22*, 2031–2040.
- (150) World Health Organization. *Environmental Health Criteria 36, Fluorine and Fluorides*; World Health Organization: Geneva, Switzerland, 2002.
- (151) Erdal, S.; Buchanan, S. N. A Quantitative Look at Fluorosis, Fluoride Exposure, and Intake in Children Using a Health Risk Assessment Approach. *Environ. Health Perspect.* **2005**, *113*, 111–117.
- (152) Maguire, A.; Zohoori, F. V.; Hindmarch, P. N.; Hatts, J.; Moynihan, P. J. Fluoride Intake and Urinary Excretion in 6- to 7-Year-Old Children Living in Optimally, Sub-Optimally and Non-Fluoridated Areas. *Community Dent. Oral Epidemiol.* **2007**, *35*, 479–488.
- (153) Miziara, A. P. B.; Philippi, S. T.; Levy, F. M.; Buzalaf, M. A. R. Fluoride Ingestion from Food Items and Dentifrice in 2–6-Year-Old Brazilian Children Living in a Fluoridated Area Using a Semi-quantitative Food Frequency Questionnaire. *Community Dent. Oral Epidemiol.* **2009**, *37*, 305–315.
- (154) Levy, F. M.; Kaneshiro Olympio, K. P.; Philippi, S. P.; Buzalaf, M. A. R. Fluoride Intake from Food Items in 2- to 6-Year-Old Brazilian Children Living in a Non-Fluoridated Area Using a Semiquantitative Food Frequency Questionnaire. *Int. J. Paediatr. Dent.* **2013**, *23*, 444–451.
- (155) Zohoori, F. V.; Buzalaf, M. A. R.; Cardoso, C. A. B.; Olympio, K. P. K.; Levy, F. M.; Grizzo, L. T.; Manguera, D. F. B.; Sampaio, F. C.; Maguire, A. Total Fluoride Intake and Excretion in Children up to 4 Years of Age Living in Fluoridated and Non-Fluoridated Areas. *Eur. J. Oral Sci.* **2013**, *121*, 457–464.
- (156) Abuhaloob, L.; Maguire, A.; Moynihan, P. Total Daily Fluoride Intake and the Relative Contributions of Foods, Drinks and Toothpaste by 3- to 4-Year-Old Children in the Gaza Strip - Palestine. *Int. J. Paediatr. Dent.* **2015**, *25*, 127–135.

- (157) Lima, C. V.; Cury, J. A.; Vale, G. C.; Lima, M. D.M.; Moura, L. d. F. A.D.; de Moura, M. S. Total Fluoride Intake by Children from a Tropical Brazilian City. *Caries Res.* **2016**, *49*, 640–646.
- (158) Kebede, A.; Retta, N.; Abuye, C.; Whiting, S. J.; Kassaw, M.; Zeru, T.; Tessema, M.; Kjellevoid, M. Dietary Fluoride Intake and Associated Skeletal and Dental Fluorosis in School Age Children in Rural Ethiopian Rift Valley. *Int. J. Environ. Res. Public Health* **2016**, *13*, 756.
- (159) Omid, N.; Maguire, A.; O'Hare, W. T.; Zohoori, F. V. Total Daily Fluoride Intake and Fractional Urinary Fluoride Excretion in 4- to 6-Year-Old Children Living in a Fluoridated Area: Weekly Variation? *Community Dent. Oral Epidemiol.* **2017**, *45*, 12–19.
- (160) Paiola, F. d. G.; Lopes, F. C.; Mazzi-Chaves, J. F.; Pereira, R. D.; Oliveira, H. F.; Queiroz, A. M. d.; Sousa-Neto, M. D. d. Is the Fluoride Intake by Diet and Toothpaste in Children Living in Tropical Semi-Arid City Safe? *Braz. Oral Res.* **2018**, *32*, No. e26.
- (161) Ibiyemi, O.; Zohoori, F. V.; Valentine, R. A.; Maguire, A. Fluoride Intake and Urinary Fluoride Excretion in 4- and 8-Year-Old Children Living in Urban and Rural areas of Southwest Nigeria. *Community Dent. Oral Epidemiol.* **2018**, *46*, 482–491.
- (162) Singer, L.; Ophaug, R. H.; Harland, B. F. Fluoride Intake of Young Male Adults in the United States. *Am. J. Clin. Nutr.* **1980**, *33*, 328–332.
- (163) Singer, L.; Ophaug, R. H.; Harland, B. F. Dietary Fluoride Intake of 15–19-Year-Old Male Adults Residing in the United States. *J. Dent. Res.* **1985**, *64*, 1302–1305.
- (164) Dabeka, R. W.; McKenzie, A. D.; Lacroix, G. M. A. Dietary Intakes of Lead, Cadmium, Arsenic and Fluoride by Canadian Adults: 24 h Duplicate Diet Study. *Food Addit. Contam.* **1987**, *4*, 89–102.
- (165) Haldimann, M.; Zimmerli, B. Evaluation of Ashing Procedures for the Gas Chromatographic Determination of Fluoride in Biological Materials. *Anal. Chim. Acta* **1993**, *282*, 589–601.
- (166) Ponikvar, M.; Stibilj, V.; Žemva, B. Daily Dietary Intake of Fluoride by Slovenian Military Based on Analysis of Total Fluorine in Total Diet Samples Using Fluoride Ion Selective Electrode. *Food Chem.* **2007**, *103*, 369–374.
- (167) San Filippo, P. A.; Battistone, G. C. The Fluoride Content of a Representative Diet of the Young Adult Man. *Clin. Chim. Acta* **1971**, *31*, 453–457.
- (168) Dabeka, R. W.; McKenzie, A. D. Survey of Lead, Cadmium, Fluoride, Nickel, and Cobalt in Food Composites and Estimation of Dietary Intakes of These Elements by Canadians in 1986–1988. *J. AOAC Int.* **1995**, *78*, 897–909.
- (169) European Commission. *Survey on Members States' Implementation of the EU Salt Reduction Framework*; European Commission: 2012.
- (170) Clader, J. W. The Discovery of Ezetimibe: A View from Outside the Receptor. *J. Med. Chem.* **2004**, *47*, 1–9.
- (171) Penning, T. C.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; et al. Synthesis and Biological Evaluation of the 1,5-Diarylpiperazine Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide (SC-58635, Celecoxib). *J. Med. Chem.* **1997**, *40*, 1347–1365.
- (172) Park, B. K.; Kitteringham, N. R.; O'Neill, P. M. Metabolism of Fluorine-Containing Drugs. *Annu. Rev. Pharmacol. Toxicol.* **2001**, *41*, 443–470.
- (173) Kirk, K. L.; Cantacuzene, D.; Collins, B.; Chen, G. T.; Nimit, Y.; Creveling, C. R. Syntheses and Adrenergic Agonist Properties of Ringfluorinated Isoproterenols. *J. Med. Chem.* **1982**, *25*, 680–684.
- (174) Morgan, P.; Maggs, J. L.; Page, P. C. B.; Park, B. K. Oxidative Dehalogenation of 2-Fluoro-17 α -ethynyoestradiol in vivo. A Distal Structure Metabolism Relationship of 17 α -Ethynylation. *Biochem. Pharmacol.* **1992**, *44*, 1717–1724.
- (175) Obach, R. S.; Walker, G. S.; Brodney, M. A. Biosynthesis of Fluorinated Analogs of Drugs Using Human Cytochrome P450 Enzymes Followed by Deoxyfluorination and Quantitative Nuclear Magnetic Resonance Spectroscopy to Improve Metabolic Stability. *Drug Metab. Dispos.* **2016**, *44*, 634–646.
- (176) Smart, B. E. Fluorine substituent effects (on bioactivity). *J. Fluorine Chem.* **2001**, *109*, 3–11.
- (177) Jeffries, B.; Wang, Z.; Felstead, H. R.; Le Questel, J.-Y.; Scott, J. S.; Chiarparin, E.; Graton, J.; Linclau, B. Systematic Investigation of Lipophilicity Modulation by Aliphatic Fluorination Motifs. *J. Med. Chem.* **2020**, *63*, 1002–1031.
- (178) Huchet, Q. A.; Kuhn, B.; Wagner, B.; Fischer, H.; Kansy, M.; Zimmerli, D.; Carreira, E. M.; Müller, K. On the Polarity of Partially Fluorinated Methyl Groups. *J. Fluorine Chem.* **2013**, *152*, 119–128.
- (179) Bortolozzi, R.; Carta, D.; Pra, M. D.; Antoniazzi, G.; Mattiuzzo, E.; Sturlese, M.; Di Paolo, V.; Calderan, L.; Moro, S.; Hamel, E.; Quintieri, L.; Ronca, R.; Viola, G.; Ferlin, M. G.; et al. Evaluating the Effects of Fluorine on Biological Properties and Metabolic Stability of Some Antitubulin 3-Substituted 7-phenyl-pyrroloquinolinones. *Eur. J. Med. Chem.* **2019**, *178*, 297–314.
- (180) Tingle, M. D.; Clarke, J. B.; Kitteringham, N. R.; Park, B. K. Influence of Glutathione Conjugation on the Immunogenicity of Dinitrophenyl Derivatives in the Rat. *Int. Arch. Allergy Immunol.* **2004**, *91*, 160–165.
- (181) Kitteringham, N. R.; Kenna, J. G.; McLean, C.; Clarke, J. B.; Park, B. K. Conjugation of Dinitrofluorobenzene to Plasma Proteins in vivo in the Rat. *Drug Metab. Dispos.* **1992**, *20*, 625–631.
- (182) Pepin, J.; Milord, F.; Guern, C.; Schechter, P. J. Difluoromethylornithine for Arseno-Resistant *Trypanosoma Brucei Gambiense* Sleeping Sickness. *Lancet* **1987**, *330*, 1431–1433.
- (183) Poulin, R.; Lu, L.; Ackermann, B.; Bey, P.; Pegg, A. E. Mechanism of the Irreversible Inactivation of Mouse Ornithine Decarboxylase by α -Difluoromethylornithine. *J. Biol. Chem.* **1992**, *267*, 150–158.
- (184) Brooks, H. B.; Phillips, M. A. Characterization of the Reaction Mechanism for *Trypanosoma brucei* Ornithine Decarboxylase by Multiwavelength Stopped-Flow Spectroscopy. *Biochemistry* **1997**, *36*, 15147–15155.
- (185) Rietjens, I. M. C. M.; den Besten, C.; Hanzlik, R. P.; van Bladeren, P. J. Cytochrome P450-Catalyzed Oxidation of Halobenzene Derivatives. *Chem. Res. Toxicol.* **1997**, *10*, 629–635.
- (186) Wang, Y.-K.; Xiao, X.-R.; Xu, K.-P.; Li, F. Metabolic Profiling of the Anti-Tumor Drug Regorafenib in Mice. *J. Pharm. Biomed. Anal.* **2018**, *159*, 524–535.
- (187) Harrison, A. C.; Park, B. K.; O'Neill, P. M.; Storr, R. C.; Kitteringham, N. R. Metabolic Defluorination of 5-Fluoro-amodiaquine in the Rat. *Br. J. Clin. Pharmacol.* **1992**, *34*, 148.
- (188) Shah, P.; Westwell, A. D. The role of Fluorine in Medicinal Chemistry. *J. Enzyme Inhib. Med. Chem.* **2007**, *22*, 527–540.
- (189) Dear, G. J.; Ismail, I. M.; Mutch, P. J.; Plumb, R. S.; Davies, L. H.; Sweatman, B. C. Urinary Metabolites of a Novel Quinoxaline Nonnucleoside Reverse Transcriptase Inhibitor in Rabbit, Mouse and Human: Identification of Fluorine NIH Shift Metabolites Using NMR and Tandem MS. *Xenobiotica* **2000**, *30*, 407–426.
- (190) Koerts, J.; Soffers, A. E. M. F.; Vervoort, J.; De Jager, A.; Rietjens, I. M. C. M. Occurrence of the NIH Shift upon the Cytochrome P450-Catalyzed in Vivo and in Vitro Aromatic Ring Hydroxylation of Fluorobenzenes. *Chem. Res. Toxicol.* **1998**, *11*, 503–512.
- (191) Shang, J.; Xu, S.; Teffera, Y.; Doss, G. A.; Stearns, R. A.; Edmonson, S.; Beconi, M. G. Metabolic Activation of a Pentafluorophenylethylamine Derivative: Formation of Glutathione Conjugates in vitro in the Rat. *Xenobiotica* **2005**, *35*, 697–713.
- (192) Samuel, K.; Yin, W.; Stearns, R. A.; Tang, Y. S.; Chaudhary, A. G.; Jewell, J. P.; Lanza Jr, T.; Lin, L. S.; Haggmann, W. K.; Evans, D. C.; Kumar, S. Addressing the Metabolic Activation Potential of Newleads in Drug Discovery: A Case Study Using Ion Trap Mass Spectrometry and Tritium Labeling Techniques. *J. Mass Spectrom.* **2003**, *38*, 211–221.
- (193) Dekant, W.; Lash, L. H.; Anders, M. W. Bioactivation Mechanism of the Cytotoxic and Nephrotoxic S-Conjugate S-(2-Chloro-1,1,2-trifluoroethyl)-L-Cysteine. *Proc. Natl. Acad. Sci. U. S. A.* **1987**, *84*, 7443–7447.

- (194) Dohn, D. R.; Quebbemann, A. J.; Borch, R. F.; Anders, M. W. Enzymatic Reaction of Chlorotrifluoroethene with Glutathione: ^{19}F NMR Evidence for Stereochemical Control of the Reaction. *Biochemistry* **1985**, *24*, 5137–5143.
- (195) Brashear, W. T.; Greene, R. J.; Mahle, D. A. Structural Determination of the Carboxylic Acid Metabolites of Polychlorotrifluoroethylene. *Xenobiotica* **1992**, *22*, 499–506.
- (196) Strunecká, A.; Patočka, J.; Connett, P. Fluorine in Medicine. *J. Appl. Biomed.* **2004**, *2*, 141–150.
- (197) Arellano, M.; Malet-Martino, M.; Martino, R.; Gires, P. The Anti-Cancer Drug 5-Fluorouracil Is Metabolized by the Isolated Perfused Rat Liver and in Rats into Highly Toxic Fluoroacetate. *Br. J. Cancer* **1998**, *77*, 79–86.
- (198) Okeda, R.; Shibutani, M.; Matsuo, T.; Kuroiwa, T.; Shimokawa, R.; Tajima, T. Experimental Neurotoxicity of 5-Fluorouracil and Its Derivatives Is due to Poisoning by the Monofluorinated Organic Metabolites, Monofluoroacetic Acid and α -Fluoro- β -alanine. *Acta Neuropathol.* **1990**, *81*, 66–73.
- (199) Yamashita, K.; Yada, H.; Ariyoshi, T. Experimental Neurotoxicity of 5-Fluorouracil and Its Derivatives Is due to Poisoning by the Monofluorinated Organic Metabolites, Monofluoroacetic Acid and α -Fluoro- β -alanine. *J. Toxicol. Sci.* **2004**, *29*, 155–166.
- (200) Kubota, T. 5-Fluorouracil and Dihydropyrimidine Dehydrogenase. *Int. J. Clin. Oncol.* **2003**, *8*, 127–131.
- (201) van der Kamp, M. W.; McGeagh, J. D.; Mulholland, A. J. Lethal Synthesis of Fluorocitrate by Citrate Synthase Explained through QM/MM Modeling. *Angew. Chem., Int. Ed.* **2011**, *50*, 10349–10351.
- (202) Feldwick, M. G.; Noakes, P. S.; Prause, U.; Mead, R. J.; Kostyniak, P. J. The Biochemical Toxicology of 1,3-Difluoro-2-propanol, the Major Ingredient of the Pesticide Gliflor: The Potential of 4-Methylpyrazole as an Antidote. *J. Biochem. Mol. Toxicol.* **1998**, *12*, 41–52.
- (203) Menon, K. I.; Feldwick, M. G.; Noakes, P. S.; Mead, R. J. The Mode of Toxic Action of the Pesticide Gliflor: The Metabolism of 1,3-Difluoroacetone to (–)-Erythro-fluorocitrate. *J. Biochem. Mol. Toxicol.* **2001**, *15*, 47–54.
- (204) Ganesan, K.; Raza, S. K.; Vijayaraghavan, R. Chemical Warfare Agents. *J. Pharm. BioAllied Sci.* **2010**, *2*, 166–178.
- (205) Millard, C. B.; Kryger, G.; Ordentlich, A.; Greenblatt, H. M.; Harel, M.; Raves, M. L.; Segall, Y.; Barak, D.; Shafferman, A.; Silman, L.; Sussman, J. L. Crystal Structures of Aged Phosphorylated Acetylcholinesterase: Nerve Agent Reaction Products at the Atomic Level. *Biochemistry* **1999**, *38*, 7032–7039.
- (206) Benschop, H. P.; De Jong, L. P. A. Nerve Agent Stereoisomers: Analysis, Isolation, and Toxicology. *Acc. Chem. Res.* **1988**, *21*, 368–374.
- (207) Kovarik, Z.; Radić, Z.; Berman, H. A.; Simeon-Rudolf, V.; Reiner, E.; Taylor, P. Acetylcholinesterase Active Centre and Gorge Conformations Analysed by Combinatorial Mutations and Enantiomeric Phosphonates. *Biochem. J.* **2003**, *373*, 33–40.
- (208) Abou-Donia, M. B.; Siracuse, B.; Gupta, N.; Sokol, A. S. Sarin (GB, O-isopropyl methylphosphonofluoridate) Neurotoxicity: Critical Review. *Crit. Rev. Toxicol.* **2016**, *46*, 845–875.
- (209) Stuart, J. A.; Ursano, R. J.; Fullerton, C. S.; Norwood, A. E.; Murray, K. Belief in Exposure to Terrorist Agents: Reported Exposure to Nerve or Mustard Gas by Gulf War Veterans. *J. Nerv. Ment. Dis.* **2003**, *191*, 431–436.
- (210) Nakajima, T.; Ohta, S.; Morita, H.; Midorikawa, Y.; Mimura, S.; Yanagisawa, N. Epidemiological Study of Sarin Poisoning in Matsumoto City, Japan. *J. Epidemiol.* **1998**, *8*, 33–41.
- (211) Okumura, T.; Suzuki, K.; Fukuda, A.; Kohama, A.; Takasu, N.; Ishimatsu, S.; Hinohara, S. The Tokyo Subway Sarin Attack: Disaster Management, Part 1: Community Emergency Response. *Acad. Emerg. Med.* **1998**, *5*, 613–617.
- (212) Okumura, T.; Suzuki, K.; Fukuda, A.; Kohama, A.; Takasu, N.; Ishimatsu, S.; Hinohara, S. The Tokyo Subway Sarin Attack: Disaster Management, Part 2: Hospital Response. *Acad. Emerg. Med.* **1998**, *5*, 618–624.
- (213) Rosman, Y.; Eisenkraft, A.; Milk, N.; Shiyovich, A.; Ophir, N.; Shrot, S.; Kreiss, Y.; Kassirer, M. Lessons Learned From the Syrian Sarin Attack: Evaluation of a Clinical Syndrome Through Social Media. *Ann. Intern. Med.* **2014**, *160*, 644–648.
- (214) Dolgin, E. Syrian Gas Attack Reinforces Need for Better Antisarin Drugs. *Nat. Med.* **2013**, *19*, 1194–1195.
- (215) Kupferschmidt, K. Scientists Clash over Paper on Syrian Sarin Attack. *Science* **2019**, *365*, 1362.
- (216) Stone, R. U.K. Attack Shines Spotlight on Deadly Nerve Agent Developed by Soviet Scientists. *Science* **2018**, *359*, 1314–1315.
- (217) Bidstrup, P. L.; Bonnell, J. A.; Beckett, A. G. Paralysis Following Poisoning by a New Organic Phosphorus Insecticide (Mipafox). *BMJ.* **1953**, *1*, 1068–1072.
- (218) Eddleston, M.; Chowdhury, F. R. Pharmacological Treatment of Organophosphorus Insecticide Poisoning: the Old and the (Possible) New. *Br. J. Clin. Pharmacol.* **2016**, *81*, 462–470.
- (219) Akgür, S. A.; Öztürk, P.; Yemişçigil, A.; Ege, B. Rapid Communication: Postmortem Distribution of Organophosphate Insecticides in Human Autopsy Tissues Following Suicide. *J. Toxicol. Environ. Health, Part A* **2003**, *66*, 2187–2191.
- (220) Akgür, S. A.; Veral, A.; Ege, B. Adult Respiratory Distress Syndrome in Human Organophosphate Poisoning Cases. *Toxicol. Environ. Chem.* **2008**, *90*, 493–499.
- (221) Wang, Y.; Ming, X.-X.; Zhang, C. P. Fluorine-Containing Inhalation Anesthetics: Chemistry, Properties, and Pharmacology. *Curr. Med. Chem.* **2019**, *26*, 1–52.
- (222) Ortíz de Morellano, P. R.; Kunze, K. L.; Beilan, H. S.; Wheeler, C. Destruction of Cytochrome P-450 by Vinyl Fluoride, Fluorene, and Acetylene. Evidence for a Radical Intermediate in Olefin Oxidation. *Biochemistry* **1982**, *21*, 1331–1339.
- (223) Brown, A. P.; Gandolfi, A. J. Glutathione-S-transferase Is a Target for Covalent Modification by a Halothane Reactive Intermediate in the Guinea Pig Liver. *Toxicology* **1994**, *89*, 35–47.
- (224) Holaday, D. A.; Rudofsky, S.; Treuhaff, P. S.; Leung, R. The metabolic Degradation of Methoxyflurane in Man. *Anesthesiology* **1970**, *33*, 589–593.
- (225) Kharasch, E. D.; Schroeder, J. L.; Liggitt, H. D.; Park, S. B.; Whittington, D.; Sheffels, P. New Insights into the Mechanism of Methoxyflurane Nephrotoxicity and Implications for Anesthetic Development (part 1): Identification of Nephrotoxic Metabolites. *Anesthesiology* **2006**, *105*, 726–736.
- (226) Burke, T. R., Jr; Pohl, L. R. Synthesis of Deuterated and Tritiated Derivatives of Enflurane. *J. Labelled Compd. Radiopharm.* **1981**, *18*, 663–670.
- (227) Santos, L. H. M. L. M.; Araújo, A. N.; Fachini, A.; Pena, A.; Delerue-Matos, C.; Montenegro, M. C. B. S. M. Ecotoxicological Aspects Related to the Presence of Pharmaceuticals in the Aquatic Environment. *J. Hazard. Mater.* **2010**, *175*, 45–95.
- (228) Painter, M. M.; Buerkley, M. A.; Julius, M. L.; Vajda, A. M.; Norris, D. O.; Barber, L. B.; Furlong, E. T.; Schultz, M. M.; Schoenfuss, H. L. Antidepressants at Environmentally Relevant Concentrations Affect Predator Avoidance Behaviour of Larval Fathead Minnows (*Pimephales Promelas*). *Environ. Toxicol. Chem.* **2009**, *28*, 2677–2684.
- (229) Conners, D. E.; Rogers, E. D.; Armbrust, K. L.; Kwon, J.-W.; Black, M. C. Growth and Development of Tadpoles (*Xenopus Laevis*) Exposed to Selective Serotonin Reuptake Inhibitors, Fluoxetine and Sertraline, throughout Metamorphosis. *Environ. Toxicol. Chem.* **2009**, *28*, 2671–2676.
- (230) Kim, K. H.; Shon, Z.-H.; Nguyen, H. T.; Jeon, E.-C. A Review of Major Chlorofluorocarbons and Their Halocarbon Alternatives in the Air. *Atmos. Environ.* **2011**, *45*, 1369–1382.
- (231) Molina, M.; Rowland, F. S. Stratospheric Sink for Chlorofluoromethanes: Chlorine Atom Catalyzed Destruction of Ozone. *Nature* **1974**, *249*, 810–812.
- (232) Dorgerloh, U.; Becker, R.; Kaiser, M. Evidence for the Formation of Difluoroacetic Acid in Chlorofluorocarbon-Contaminated Ground Water. *Molecules* **2019**, *24*, 1039–1044.
- (233) Ramanathan, V.; Feng, Y. Air pollution, Greenhouse Gases and Climate Change: Global and Regional Perspectives. *Atmos. Environ.* **2009**, *43*, 37–50.

- (234) Zierkiewicz, W. Reaction of Volatile Anaesthetic Desflurane with Chlorine Atom. *Chem. Phys. Lett.* **2013**, *555*, 72–78.
- (235) Grodin, W. K.; Epstein, M. A.; Epstein, R. A.; Miller, R. D. Soda Lime Adsorption of Isoflurane and Enflurane. *Anesthesiology* **1985**, *62*, 60–64.
- (236) Mehrata, M.; Moralejo, C.; Anderson, W. A. Adsorbent Comparisons for Anesthetic Gas Capture in Hospital Air Emissions. *J. Environ. Sci. Health, Part A: Toxic/Hazard. Subst. Environ. Eng.* **2016**, *51*, 805–809.
- (237) Fluoropolymers: Research, Production Issues, and New Applications. Opportunities in Fluoropolymers: Synthesis, Processing and Simulations. *Fascinating Fluoropolymers and Applications*; Ameduri, B.; Fomin, S., Eds.; Progress in Fluorine Science, Elsevier, 2020; Vols. 1 and 2.
- (238) Hamid, H.; Li, L. Y.; Grace, J. R. Review of the Fate and Transformation of Per- and Polyfluoroalkyl Substances (PFASs) in Landfills. *Environ. Pollut.* **2018**, *235*, 74–84.
- (239) Lau, C.; Anitole, K.; Hodes, C.; Lai, D.; Pfahles-Hutchens, A.; Seed, J. Perfluoroalkyl Acids: A Review of Monitoring and Toxicological Findings. *Toxicol. Sci.* **2007**, *99*, 366–394.
- (240) Houde, M.; Martin, J. W.; Letcher, R. J.; Solomon, K. R.; Muir, D. C. G. Biological Monitoring of Polyfluoroalkyl Substances: A Review. *Environ. Sci. Technol.* **2006**, *40*, 3463–3473.
- (241) Suja, F.; Pramanik, B. K.; Zain, S. M. Contamination, Bioaccumulation and Toxic Effects of Perfluorinated Chemicals (PFCs) in the Water Environment: a Review Paper. *Water Sci. Technol.* **2009**, *60*, 1533–1544.
- (242) Wang, Z.; DeWitt, J. C.; Higgins, C. P.; Cousins, I. T. A Never-Ending Story of Per- and Polyfluoroalkyl Substances (PFASs)? *Environ. Sci. Technol.* **2017**, *51*, 2508–2518.
- (243) Conder, J. M.; Hoke, R. A.; de Wolf, W.; Russell, M. H.; Buck, R. C. Are PFCs Bioaccumulative? A Critical Review and Comparison with Regulatory Criteria and Persistent Lipophilic Compounds. *Environ. Sci. Technol.* **2008**, *42*, 995–1003.
- (244) Eggers Pedersen, K.; Basu, N.; Letcher, R.; Greaves, A. K.; Sonne, C.; Dietz, R.; Styrisshave, B. Brain Region-Specific Perfluoroalkylated Sulfonate (PFSA) and Carboxylic Acid (PFCA) Accumulation and Neurochemical Biomarker Responses in East Greenland Polar Bears (*Ursus maritimus*). *Environ. Res.* **2015**, *138*, 22–31.
- (245) Wu, J.-Y.; Liu, W.-X.; He, W.; Xu, F.-L. Comparisons of Tissue Distributions and Health Risks of Perfluoroalkyl Acids (PFAAs) in Two Fish Species with Different Trophic Levels from Lake Chaohu, China. *Ecotoxicol. Environ. Saf.* **2019**, *185*, 109666–109674.
- (246) Olsen, G. W.; Burris, J. M.; Ehresman, D. J.; Froehlich, J. W.; Seacat, A. M.; Butenhoff, J. L.; Zobel, L. R. Half-life of Serum Elimination of Perfluorooctanesulfonate, Perfluorohexanesulfonate and Perfluorooctanoate in Retired Fluorochemical Production Workers. *Environ. Health Perspect.* **2007**, *115*, 1298–1305.
- (247) Lilienthal, H.; Dieter, H. H.; Hölzer, J.; Wilhelm, M. Recent Experimental Results of Effects of Perfluoroalkyl Substances in Laboratory Animals - Relation to Current Regulations and Guidance Values. *Int. J. Hyg. Environ. Health* **2017**, *220*, 766–775.
- (248) Li, Y.; Cheng, Y.; Xie, Z.; Zeng, F. Perfluorinated Alkyl Substances in Serum of the Southern Chinese General Population and Potential Impact on Thyroid Hormones. *Sci. Rep.* **2017**, *7*, 43380.
- (249) Iwai, H.; Hoberman, A. M. Oral (Gavage) Combined Developmental and Perinatal/Postnatal Reproduction Toxicity Study of Ammonium Salt of Perfluorinated Hexanoic Acid in Mice. *Int. J. Toxicol.* **2014**, *33*, 219–237.
- (250) Fai Tse, W. K.; Li, J. W.; Kwan Tse, A. C.; Chan, T. F.; Hin Ho, J. C.; Sun Wu, R. S.; Chu Wong, C. K.; Lai, K. P. Fatty Liver Disease Induced by Perfluorooctane Sulfonate: Novel Insight from Transcriptome Analysis. *Chemosphere* **2016**, *159*, 166–177.
- (251) Wang, Y.; Wang, L.; Chang, W.; Zhang, Y.; Zhang, Y.; Liu, W. Neurotoxic Effects of Perfluoroalkyl Acids: Neurobehavioral Deficit and Its Molecular Mechanism. *Toxicol. Lett.* **2019**, *305*, 65–72.
- (252) Zeng, Z.; Song, B.; Xiao, R.; Zeng, G.; Gong, J.; Chen, M.; Xu, P.; Zhang, P.; Shen, M.; Yi, H. Assessing the Human Health Risks of Perfluorooctane Sulfonate by in vivo and in vitro Studies. *Environ. Int.* **2019**, *126*, 598–610.
- (253) Nicole, W. PFOA and Cancer in a Highly Exposed Community: New Findings from the C8 Science Panel. *Environ. Health Perspect.* **2013**, *121*, A340.
- (254) Girardi, P.; Merler, E. A Mortality Study on Male Subjects Exposed to Polyfluoroalkyl Acids with High Internal Dose of Perfluorooctanoic acid. *Environ. Res.* **2019**, *179*, 108743–108753.
- (255) Hurley, S.; Goldberg, D.; Wang, M.; Park, J.-S.; Petreas, M.; Bernstein, L.; Anton-Culver, H.; Nelson, D. O.; Reynolds, P. Breast Cancer Risk and Serum Levels of per- and poly-Fluoroalkyl Substances: a Case-Control Study Nested in the California Teachers Study. *Environ. Health* **2018**, *17*, 83–102.
- (256) Saejia, P.; Lirdprapamongkol, K.; Svasti, J.; Paricharttanakul, N. M. Perfluorooctanoic Acid Enhances Invasion of Follicular Thyroid Carcinoma Cells through NF- κ B and Matrix Metalloproteinase-2 Activation. *Anticancer Res.* **2019**, *39*, 2429–2435.
- (257) Jain, R. B. Time Trends over 2003–2014 in the Concentrations of Selected Perfluoroalkyl Substances among US Adults Aged > 20 Years: Interpretational Issues. *Sci. Total Environ.* **2018**, *645*, 946–957.
- (258) Luz, A. L.; Anderson, J. K.; Goodrum, P.; Durda, J. Perfluorohexanoic Acid Toxicity, part I: Development of a Chronic Human Health Toxicity Value for Use in Risk Assessment. *Regul. Toxicol. Pharmacol.* **2019**, *103*, 41–55.
- (259) Anderson, J. K.; Luz, A. L.; Goodrum, P.; Durda, J. Perfluorohexanoic Acid Toxicity, part II: Application of Human Health Toxicity Value for Risk Characterizat. *Regul. Toxicol. Pharmacol.* **2019**, *103*, 10–20.
- (260) Siramshetty, V. B.; Nickel, J.; Omieczynski, C.; Gohlke, B. O.; Drwal, M. N.; Preissner, R. WITHDRAWN-A Resource for Withdrawn and Discontinued Drugs. *Nucleic Acids Res.* **2016**, *44*, D1080–D1086.
- (261) Murphy, C. D.; Sandford, G. Recent Advances in Fluorination Techniques and Their Anticipated Impact on Drug Metabolism and Toxicity. *Expert Opin. Drug Metab. Toxicol.* **2015**, *11*, 589–599.
- (262) Ahmed, A.; Daneshtalab, M. Nonclassical Biological Activities of Quinolone Derivatives. *J. Pharm. Pharm. Sci.* **2012**, *15*, 52–72.
- (263) Joule, J. A.; Knovel, K. *Heterocyclic Chemistry*, 4th ed.; Joule, J. A.; Mills, K., Eds.; Blackwell Science: Malden, MA, 2000; pp 133–134.
- (264) Gould, R. G.; Jacobs, W. A. The Synthesis of Certain Substituted Quinolines and 5,6-Benzoquinolines. *J. Am. Chem. Soc.* **1939**, *61*, 2890–2895.
- (265) Abdel-Aal, M. A. A.; Abdel-Aziz, S. A.; Shaykoon, M. Sh. A.; Abu-Rahma, G. E. A. Towards Anticancer Fluoroquinolones: A Review Article. *Arch. Pharm.* **2019**, *352*, 1800376.
- (266) Andersson, M. I.; MacGowan, A. P. Development of the Quinolones. *J. Antimicrob. Chemoth.* **2003**, *51*, 1–11.
- (267) Hooper, D. C.; Wolfson, J. S. The Fluoroquinolones: Pharmacology, Clinical Uses, and Toxicities in Humans. *Antimicrob. Agents Chemother.* **1985**, *28*, 716–721.
- (268) Charushin, V. N.; Nosova, E. V.; Lipunova, G. N.; Chupakhin, O. N. Fluoroquinolones: Synthesis and Application. In *Fluorine in Heterocyclic Chemistry*; Nenajdenko, V., Ed.; Springer, 2014; Vol. 2.
- (269) Duque, A. F.; Hasan, S. A.; Bessa, V. S.; Carvalho, M. F.; Samin, G.; Janssen, D. B.; Castro, P. M. Isolation and Characterization of a Rhodococcus Strain Able to Degrade 2-Fluorophenol. *Appl. Microbiol. Biotechnol.* **2012**, *95*, 511–520.
- (270) Kim, E. J.; Jeon, J. R.; Kim, Y. M.; Murugesan, K.; Chang, Y. S. Mineralization and Transformation of Monofluorophenols by Pseudonocardia Benzenivorans. *Appl. Microbiol. Biotechnol.* **2010**, *87*, 1569–1577.
- (271) Murphy, C. D.; Palmer-Brown, W.; Quinn, L.; Saccomanno, M. Microbial Metabolism of Fluorinated Drugs. In *Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals. Progress in Fluorine Science Series*; Elsevier, 2019; Chapter 7, pp 281–299.
- (272) Stahlmann, R.; Lode, H. Toxicity of Quinolones. *Drugs* **1999**, *58*, 37–42.
- (273) Rubinstein, E. History of Quinolones and Their Side Effects. *Chemotherapy* **2001**, *47*, 3–8.

- (274) Wiedemann, B.; Heisig, P. Antibacterial Activity of Grepafloxacin. *J. Antimicrob. Chemother.* **1997**, *40*, 19–25.
- (275) Lode, H.; Vogel, F.; Elies, W. Grepafloxacin: A Review of Its Safety Profile Based on Clinical Trials and Postmarketing Surveillance. *Clin. Ther.* **1999**, *21*, 61–74.
- (276) El-Shafie, A. S.; Khashan, A. W.; Hussein, Y. H. A.; El-Azazy, M. Application of a Definitive Screening Design for the Synthesis of a Charge-Transfer Complex of Sparfloxacin with Tetracyanoethylene: Spectroscopic, Thermodynamic, Kinetics, and DFT Computational Studies. *RSC Adv.* **2019**, *9*, 24722–24732.
- (277) Singh, J.; Dwivedi, A.; Ray, L.; Chopra, D.; Dubey, D.; Srivastava, A. K.; Kumari, S.; Yadav, R. K.; Amar, S. K.; Haldar, C.; Ray, R. S. PLGA Nanoformulation of Sparfloxacin Enhanced Antibacterial Activity with Photoprotective Potential under Ambient UV-R Exposure. *Int. J. Pharm.* **2018**, *541*, 173–187.
- (278) Al-Abdullah, E. S. *Profiles of Drug Substances, Excipients and Related Methodology*; Elsevier, 2012; pp 183–243, Vol. 37, Chapter 5.
- (279) Saraya, A.; Yokokura, M.; Gono, T.; Seino, S. Effects of Fluoroquinolones on Insulin Secretion and beta Cell ATP Sensitive K⁺ Channels. *Eur. J. Pharmacol.* **2004**, *497*, 111–117.
- (280) Zvonar, R. Gatifloxacin-Induced Dysglycemia. *Am. J. Health-Syst. Pharm.* **2006**, *63*, 2087–2092.
- (281) Garey, K. W.; Amsden, G. W. Trovafloxacin: An Overview. *Pharmacotherapy* **1999**, *19*, 21–34.
- (282) Gales, B. J.; Sulak, L. B. Severe Thrombocytopenia Associated with Alatrofloxacin. *Ann. Pharmacother.* **2000**, *34*, 330–334.
- (283) Lucena, M. I.; Andrade, R. J.; Rodrigo, L.; Salmerón, J.; Álvarez, A.; López-Garrido, M. J.; Camargo, R.; Alcantara, R. Trovafloxacin-Induced Acute Hepatitis. *Clin. Infect. Dis.* **2000**, *30*, 400–401.
- (284) Isnard, R.; Lechat, P.; Pousset, F.; Carayon, A.; Kalotka, H.; Chikr, H.; Salloum, J.; Thomas, D.; Komajda, M. Hemodynamic and Neurohormonal Effects of Flosequinan in Patients with Heart Failure. *Fundam. Clin. Pharmacol.* **1997**, *11*, 83–89.
- (285) Kashiya, E.; Yokoi, T.; Odomi, M.; Funae, Y.; Inoue, K.; Kamataki, T. Cytochrome P450 Responsible for the Stereoselective S-Oxidation of Flosequinan in Hepatic Microsomes from Rats and Humans. *Drug Metab. Dispos.* **1997**, *25*, 716–724.
- (286) Mayall, S. J.; Banerjee, A. K. Therapeutic Risk Management of Medicines. In *Therapeutic Risk Management of Medicines*, 1st ed.; Elsevier, 2014; Chapter 3, pp 25–59.
- (287) Graham, D. J.; Staffa, J. A.; Shatin, D.; Andrade, S. E.; Schech, S. D.; Grenade, L. L.; Gurwitz, J. H.; Chan, K. A.; Goodman, M. J.; Platt, R. Incidence of Hospitalized Rhabdomyolysis in Patients Treated with Lipid-Lowering Drugs. *JAMA* **2004**, *292*, 2585–2590.
- (288) Furberg, C. D.; Pitt, B. Withdrawal of Cerivastatin from the World Market. *Curr. Control Trials Cardiovasc. Med.* **2001**, *2*, 205–207.
- (289) Bannwarth, B.; Berenbaum, F. Clinical Pharmacology of Lumiracoxib, a Second-generation Cyclooxygenase 2 Selective Inhibitor. *Expert Opin. Invest. Drugs* **2005**, *14*, 521–533.
- (290) Jeger, R. V.; Greenberg, J. D.; Ramanathan, K.; Farkouh, M. E. Lumiracoxib, a Highly Selective COX-2 Inhibitor. *Expert Rev. Clin. Immunol.* **2005**, *1*, 37–45.
- (291) Mei, T. S.; Wang, D. H.; Yu, J. Q. Expedient Drug Synthesis and Diversification via ortho-C-H Iodination Using Recyclable PdI₂ as the Precatalyst. *Org. Lett.* **2010**, *12*, 3140–3143.
- (292) Lewis, J. H.; Stine, J. G. Nonsteroidal Antiinflammatory Drugs and Leukotriene Receptor Antagonists. *Drug-Induced Liver Disease*, 3rd ed.; Elsevier, 2013; Chapter 22, pp 369–401.
- (293) Reddy, V. P. Organofluorine Pharmaceuticals. In *Organofluorine Compounds in Biology and Medicine*; Elsevier, 2015; Chapter 5, pp 133–178.
- (294) Tack, J.; Camilleri, M.; Chang, L.; Chey, W. D.; Galligan, J. J.; Lacy, B. E.; Müller-Lissner, S.; Quigley, E. M. M.; Schuurkes, J.; De Maeyer, J. H.; Stanghellini, V. Systematic Review: Cardiovascular Safety Profile of 5-HT₄ Agonists Developed for Gastrointestinal Disorders. *Aliment. Pharmacol. Ther.* **2012**, *35*, 745–767.
- (295) Gray, N. M.; Young, J. W. Methods for Treating Gastrointestinal Motility Dysfunction Using Optically Pure (+) Cisapride. 1999, US 5955478A.
- (296) Van Daele, G. H. P.; De Bruyn, M. F. L.; Sommen, F. M.; Janssen, M.; Van Nueten, J. M.; Schuurkes, J. A. J.; Niemegeers, C. J. E.; Leysen, J. E. Synthesis of Cisapride, a Gastrointestinal Stimulant Derived From Cis-4-Amino-3-Methoxypropylamine. *Drug Dev. Res.* **1986**, *8*, 225–232.
- (297) Cossy, J.; Molina, J. L.; Desmurs, J.-R. A Short Synthesis of Cisapride: a Gastrointestinal Stimulant Derived from cis-4-Amino-3-methoxypropylamine. *Tetrahedron Lett.* **2001**, *42*, 5713–5715.
- (298) Davies, S. G.; Huckvale, R.; Lorkin, T. J. A.; Roberts, P. M.; Thomson, J. E. Concise, Efficient and Highly Selective Asymmetric Synthesis of (+)-(3S,4R)-Cisapride. *Tetrahedron: Asymmetry* **2011**, *22*, 1591–1593.
- (299) Vlaar, T.; Cioc, R. C.; Mampuy, P.; Maes, B. U. W.; Orru, R. V. A.; Ruijter, E. Sustainable Synthesis of Diverse Privileged Heterocycles by Palladium-Catalyzed Aerobic Oxidative Isocyanide Insertion. *Angew. Chem., Int. Ed.* **2012**, *51*, 13058–13061.
- (300) Janssens, F.; Luyckx, M.; Stokbroekx, R.; Torremans, J. Heterocyclized-4-piperidinamines and Pharmaceutical Compositions Comprising Them. 1979, EP 5318A1.
- (301) García-Quiroz, J.; Camacho, J. Astemizole: an Old Antihistamine as a New Promising Anti-cancer Drug. *Anti-Cancer Agents Med. Chem.* **2011**, *11*, 307–314.
- (302) Tiwari, S. The Date Rape Predator Drug: Rohypnol. *Res. J. Pharm., Biol. Chem. Sci.* **2017**, *8*, 1901–1905.
- (303) Katselou, M.; Papoutsis, I.; Nikolaou, P.; Spiliopoulou, C.; Athanasis, S. Metabolites Replace the Parent Drug in the Drug Arena. The Cases of Fonazepam and Nifoxipam. *Forensic Toxicol.* **2017**, *35*, 1–10.
- (304) Druid, H.; Holmgren, P.; Ahlner, J. Flunitrazepam: an Evaluation of Use, Abuse and Toxicity. *Forensic Sci. Int.* **2001**, *122*, 136–141.
- (305) Billups, S. J.; Carter, B. L. Mibefradil: A New Class of Calcium-Channel Antagonists. *Ann. Pharmacother.* **1998**, *32*, 659–671.
- (306) Cramer, Y.; Foricher, J.; Hengartner, U.; Jenny, C.-J.; Kienzle, F.; Ramuz, H.; Scalone, M.; Schlageter, M.; Schmid, R.; Wang, S. Asymmetric Hydrogenation vs. Resolution in the Synthesis of POSICOR, a New Type of Calcium Antagonist. *Chimia* **1997**, *51*, 303–305.
- (307) SoRelle, R. Withdrawal of Posicor from Market. *Circulation* **1998**, *98*, 831–832.
- (308) Li, P.; Rubaiy, H. N.; Chen, G. L.; Hallett, T.; Zaibi, N.; Zeng, B.; Saurabh, R.; Xu, S. Z. Mibefradil, a T-type Ca²⁺ Channel Blocker also Blocks Orai Channels by Action at the Extracellular Surface. *Br. J. Pharmacol.* **2019**, *176*, 3845–3856.
- (309) Krouse, A. J.; Gray, L.; Macdonald, T.; McCray, J. Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study. *Assay Drug Dev. Technol.* **2015**, *13*, 650–653.
- (310) Kroc, A.; Debicka, M.; Wierzbička, A.; Wolkow, L.; Jernajczyk, W.; Wichniak, A. Sertindole: EEG Analysis, Tolerability, and Clinical Efficacy. *Pharmacopsychiatry* **2018**, *51*, 144–147.
- (311) Sunil Kumar, I. V.; Anjaneyulu, G. S. R.; Hima Bindu, V. Identification and Synthesis of Impurities Formed during Sertindole Preparation. *Beilstein J. Org. Chem.* **2011**, *7*, 29–33.
- (312) Nielsen, J.; Andersen, M. P.; Graff, C.; Kanters, J. K.; Hardahl, T.; Dybbro, J.; Struijk, J. J.; Meyer, J. M.; Toft, E. The Effect of Sertindole on QTd and TPTE. *Acta Psychiatr. Scand.* **2010**, *121*, 385–388.
- (313) Moore, N. Higher Cardiovascular Mortality with Sertindole in ADROIT: a Signal not Confirmed. *Int. J. Psychiatry Clin. Pract.* **2002**, *6*, 3–9.
- (314) Spina, E.; De Leon, J. Metabolic Drug Interactions with Newer Antipsychotics: a Comparative Review. *Basic Clin. Pharmacol. Toxicol.* **2007**, *100*, 4–22.
- (315) Zoccali, R. A.; Bruno, A.; Muscatello, M. R. A. Efficacy and Safety of Sertindole in Schizophrenia. A Clinical Review. *J. Clin. Psychopharmacol.* **2015**, *35*, 286–295.
- (316) Setola, V.; Roth, B. L. Screening the Receptorome Reveals Molecular Targets Responsible for Drug-Induced Side Effects: Focus on 'fen-phen'. *Expert Opin. Drug Metab. Toxicol.* **2005**, *1*, 377–387.

- (317) Goument, B.; Duhamel, L.; Mauge, R. Asymmetric Syntheses of (S)-Fenfluramine using Sharpless Epoxidation Methods. *Tetrahedron* **1994**, *50*, 171–188.
- (318) Wellman, P. J.; Maher, T. J. Synergistic interactions between Fenfluramine and Phentermine. *Int. J. Obes.* **1999**, *23*, 723–732.
- (319) Harvey, N. C.; Judge, A. Benfluorex and Mortality: A Fresh Perspective. Hindawi Publishing Corporation. *Epidemiol. Res. Int.* **2013**, *2013*, 490309.
- (320) Xu, Y. Method for Preparation of 2-({1-Methyl-2-[3-(trifluoromethyl)-phenyl]-ethyl}amino) Ethyl Benzoate Hydrochloride from Benzoyl Ethanolamine Hydrochloride and 1-[3-(Trifluoromethyl)-phenyl]-2-acetone. 2010, CN 101880238 A.
- (321) Szymanski, C.; Andréjak, M.; Peltier, M.; Maréchaux, S.; Tribouilloy, C. Adverse Effects of Benfluorex on Heart Valves and Pulmonary Circulation. *Pharmacoevid. Drug Saf.* **2014**, *23*, 679–686.
- (322) Wrobel, J.; Millen, J.; Sredy, J.; Dietrich, A.; Kelly, J. M.; Gorham, B. J.; Sestan, K. Orally Active Aldose Reductase Inhibitors Derived from Bioisosteric Substitutions on Tolrestat. *J. Med. Chem.* **1989**, *32*, 2493–2500.
- (323) Singh Grewal, A.; Bhardwaj, S.; Pandita, D.; Lather, V.; Singh Sekhon, B. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases. *Mini-Rev. Med. Chem.* **2015**, *16*, 120–162.
- (324) Ryder, S.; Sarokhan, B.; Shand, D. G.; Mullane, J. F. Human Safety Profile of Tolrestat: An Aldose Reductase Inhibitor. *Drug Dev. Res.* **1987**, *11*, 131–143.
- (325) Sestan, K.; Bellini, F.; Fung, S.; Abraham, N.; Treasurywala, A.; Humber, L.; Simard-Dequesne, N.; Dvornik, D. N-[[5-(Trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-JV-methylglycine (Tolrestat), a Potent, Orally Active Aldose Reductase Inhibitor. *J. Med. Chem.* **1984**, *27*, 255–256.
- (326) Malamas, M. S.; Sestan, K.; Millen, J. Synthesis and Biological Evaluation of Tolrestat Metabolites. *Eur. J. Med. Chem.* **1991**, *26*, 197–200.
- (327) Santiago, J. V.; Sonksen, P. H.; Boulton, A. J. M.; Macleod, A.; Beg, M.; Bochenek, W.; Graepel, G. J.; Gonen, B. Withdrawal of the Aldose Reductase Inhibitor Tolrestat in Patients with Diabetic Neuropathy: Effect on Nerve Function. *J. Diab. Comp.* **1993**, *7*, 170–178.
- (328) Schultz, T. C.; Valenzano, J. P.; Verzella, J. L.; Umland, E. M. Odanacatib: an Emerging Novel Treatment Alternative for Postmenopausal Osteoporosis. *Womens Health* **2015**, *11*, 805–814.
- (329) Boggild, M. K.; Gajic-Veljanoski, O.; McDonald-Blumer, H.; Ridout, R.; Tile, L.; Josse, R.; Cheung, A. M. Odanacatib for the Treatment of Osteoporosis. *Expert Opin. Pharmacother.* **2015**, *16*, 1717–1726.
- (330) O'Shea, P. D.; Chen, C.; Gauvreau, D.; Gosselin, F.; Hughes, G.; Nadeau, C.; Volante, R. P. A Practical Enantioselective Synthesis of Odanacatib, a Potent Cathepsin K Inhibitor, via Triflate Displacement of an α -Trifluoromethylbenzyl Triflate. *J. Org. Chem.* **2009**, *74*, 1605–1610.
- (331) Jia, Q.; Deng, Y.; Qing, Y. Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond β -Amyloid: Insights from Clinical Trials. *BioMed. Res. Int.* **2014**, *2014*, 837157.
- (332) Haass, C.; Selkoe, D. J. Soluble Protein Oligomers in Neurodegeneration: Lessons from the Alzheimer's Amyloid β -Peptide. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 101–112.
- (333) Verdier, Y.; Zaránci, M.; Penke, B. Amyloid β -Peptide Interactions with Neuronal and Glial Cell Plasma Membrane: Binding Sites and Implications for Alzheimer's Disease. *J. Pept. Sci.* **2004**, *10*, 229–248.
- (334) Mayer, S. C.; Kreft, A. F.; Harrison, B.; Abou-Gharbia, M.; Antane, M.; Aschmies, S.; Atchison, K.; Chlenov, M.; Cole, D. C.; Comery, T.; et al. Discovery of Begacestat, a Notch-1-Sparing γ -Secretase Inhibitor for the Treatment of Alzheimer's Disease. *J. Med. Chem.* **2008**, *51*, 7348–7351.
- (335) Martinez-Mier, E. A. Fluoride: Its Metabolism, Toxicity, and Role in Dental Health. *J. Evidence-Based Complementary Altern. Med.* **2012**, *17*, 28–32.
- (336) Gutknecht, J.; Walter, A. Hydrofluoric and Nitric Acid Transport Through Lipid Bilayer Membranes. *Biochim. Biophys. Acta, Biomembr.* **1981**, *644*, 153–156.
- (337) Whitford, G. M.; Pashley, D. H. Fluoride Absorption: The Influence of Gastric Acidity. *Calcif. Tissue Int.* **1984**, *36*, 302–307.
- (338) Nopakun, J.; Messer, H. H. Mechanism of Fluoride Absorption from the Rat Small Intestine. *Nutr. Res. (N. Y., NY, U. S.)* **1990**, *10*, 771–779.
- (339) Nopakun, J.; Messer, H. H.; Voller, V. Fluoride Absorption from the Gastrointestinal Tract of Rats. *J. Nutr.* **1989**, *119*, 1411–1417.
- (340) Cerklewski, F. L. Fluoride Bioavailability - Nutritional and Clinical Aspects. *Nutr. Res. (N. Y., NY, U. S.)* **1997**, *17*, 907–929.
- (341) Ekstrand, J.; Ehrnebo, M.; Boréus, L. O. Fluoride Bioavailability after Intravenous and Oral Administration: Importance of Renal Clearance and Urine Flow. *Clin. Pharmacol. Ther.* **1978**, *23*, 329–337.
- (342) Spak, C. J.; Ekstrand, J.; Zylberstein, D. Bioavailability of Fluoride Added to Baby Formula and Milk. *Caries Res.* **1982**, *16*, 249–256.
- (343) Trautner, K.; Siebert, G. An Experimental Study of Bioavailability of Fluoride from Dietary Sources in Man. *Arch. Oral Biol.* **1986**, *31*, 223–228.
- (344) Trautner, K.; Einwag, J. Influence of Milk and Food on Fluoride Bioavailability from NaF and Na₂FPO₃ in Man. *J. Dent. Res.* **1989**, *68*, 72–77.
- (345) Shulman, E. R.; Vallejo, M. Effect of Gastric Contents on the Bioavailability of Fluoride in Humans. *Pediatr. Dent.* **1990**, *12*, 237–240.
- (346) Goyal, A.; Gauba, K.; Tewari, A. Bioavailability of Fluoride in Humans from Commonly Consumed Diets in India. *J. Indian Soc. Pedod. Prev. Dent.* **1998**, *16*, 1–6.
- (347) Whitford, G. M. The Metabolism and Toxicity of Fluoride. *Monogr. Oral Sci.* **1996**, *16*, 1–153.
- (348) Singer, L.; Ophaug, R.; Myers, H. M. Ionic and Nonionic Fluoride in Plasma (Or Serum). *Crit. Rev. Clin. Lab. Sci.* **1982**, *18*, 111–140.
- (349) Zohoori, F. V.; Duckworth, R. M. Fluoride: Intake and Metabolism, Therapeutic and Toxicological Consequences. In *Molecular, Genetic, and Nutritional Aspects of Major and Trace Minerals*; Collins, J. F., Ed.; Elsevier: Amsterdam, The Netherlands, 2017; pp 539–550.
- (350) Whitford, G. M.; Williams, J. L. Fluoride Absorption: Independence from Plasma Fluoride Levels. *Exp. Biol. Med.* **1986**, *181*, 550–554.
- (351) Kaminsky, L. S.; Mahoney, M. C.; Leach, J.; Melius, J.; Miller, M. J. Fluoride: Benefits and Risks of Exposure. *Crit. Rev. Oral Biol. Med.* **1990**, *1*, 261–281.
- (352) Spak, C. J.; Berg, U.; Ekstrand, J. Renal Clearance of Fluoride in Children and Adolescents. *Pediatr.* **1985**, *75*, 575–579.
- (353) Whitford, G. M. Intake and Metabolism of Fluoride. *Adv. Dent. Res.* **1994**, *8*, 5–14.
- (354) Villa, A.; Anabalon, M.; Zohouri, V.; Maguire, A.; Franco, A. M.; Rugg-Gunn, A. Relationships between Fluoride Intake, Urinary Fluoride Excretion and Fluoride Retention in Children and Adults: An Analysis of Available Data. *Caries Res.* **2010**, *44*, 60–68.
- (355) Ekstrand, J.; Fomon, S. J.; Ziegler, E. E.; Nelson, S. E. Fluoride Pharmacokinetics in Infancy. *Pediatr. Res.* **1994**, *35*, 157–163.
- (356) Ekstrand, J.; Ziegler, E. E.; Nelson, S. E.; Fomon, S. J. Absorption and Retention of Dietary and Supplemental Fluoride by Infants. *Adv. Dent. Res.* **1994**, *8*, 175–180.
- (357) Ponikvar, M. Exposure of Humans to Fluorine and Its Assessment. In *Fluorine and Health, Molecular Imaging, Biomedical Materials and Pharmaceuticals*; Tressaud, A., Haufe, G., Eds.; Elsevier: Amsterdam, Netherlands, 2008; pp 487–549.
- (358) Barbier, O.; Arreola-Mendoza, L.; Del Razo, L. M. Molecular Mechanisms of Fluoride Toxicity. *Chem.-Biol. Interact.* **2010**, *188*, 319–333.

- (359) Adamek, E.; Pawłowska-Góral, K.; Bober, K. In Vitro and In Vivo Effects of Fluoride Ions on Enzyme Activity. *Ann. Acad. Med. Stetin.* **2005**, *51*, 69–85.
- (360) Strunecka, A.; Patocka, J.; Blaylock, R. L.; Chinoy, N. J. Fluoride Interactions: From Molecules to Disease. *Curr. Signal Transduction Ther.* **2007**, *2*, 190–213.
- (361) Agalakova, N. I.; Gusev, G. P. Molecular Mechanisms of Cytotoxicity and Apoptosis Induced by Inorganic Fluoride. *ISRN Cell Biol.* **2012**, *2012*, 1–16.
- (362) Perumal, E.; Paul, V.; Govindarajan, V.; Panneerselvam, L. A Brief Review on Experimental Fluorosis. *Toxicol. Lett.* **2013**, *223*, 236–251.
- (363) Green, D. R.; Llambi, F. Cell Death Signaling. *Cold Spring Harbor Perspect. Biol.* **2015**, *7*, No. a006080.
- (364) Zuo, H.; Chen, L.; Kong, M.; Qiu, L.; Lü, P.; Wu, P.; Yang, Y.; Chen, K. Toxic Effects of Fluoride on Organisms. *Life Sci.* **2018**, *198*, 18–24.
- (365) Wei, W.; Pang, S.; Sun, D. The Pathogenesis of Endemic Fluorosis: Research Progress in the Last 5 Years. *J. Cell. Mol. Med.* **2019**, *23*, 2333–2342.
- (366) Ghosh, J.; Das, J.; Manna, P.; Sil, P. C. Cytoprotective Effect of Arjunolic Acid in Response to Sodium Fluoride Mediated Oxidative Stress and Cell Death via Necrotic Pathway. *Toxicol. In Vitro* **2008**, *22*, 1918–1926.
- (367) Elmore, S. Apoptosis: A Review of Programmed Cell Death. *Toxicol. Pathol.* **2007**, *35*, 495–516.
- (368) Ribeiro, D. A.; Cardoso, C. M.; Yujra, V. Q.; De Barros Viana, M.; Aguiar, O. Jr.; Pisani, L. P.; Oshima, C. T. F. Fluoride Induces Apoptosis in Mammalian Cells: In Vitro and In Vivo Studies. *Anticancer Res.* **2017**, *37*, 4767–4777.
- (369) Galluzzi, L.; Vitale, I.; Aaronson, S. A.; Abrams, J. M.; Adam, D.; Agostinis, P.; Alnemri, E. S.; Altucci, L.; Amelio, I.; Andrews, D. W.; et al. Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ.* **2018**, *25*, 486–541.
- (370) Strunecka, A.; Strunecky, O.; Patocka, J. Fluoride Plus Aluminum: Useful Tools in Laboratory Investigations, but Messengers of False Information. *Physiol. Res.* **2002**, *51*, 557–564.
- (371) Sternweis, P. C.; Gilman, A. G. Aluminum: A Requirement for Activation of the Regulatory Component of Adenylate Cyclase by Fluoride. *Proc. Natl. Acad. Sci. U. S. A.* **1982**, *79*, 4888–4891.
- (372) Bigay, J.; Deterre, P.; Pfister, C.; Chabre, M. Fluoroaluminates Activate Transducin-GDP by Mimicking the γ -Phosphate of GTP in its Binding Site. *FEBS Lett.* **1985**, *191*, 181–185.
- (373) Antonny, B.; Sukumar, M.; Bigay, J.; Chabre, M.; Higashijima, T. The Mechanism of Aluminum-independent G-protein Activation by Fluoride and Magnesium. *J. Biol. Chem.* **1993**, *268*, 2393–2402.
- (374) Martin, B. R. Ternary Complexes of Al^{3+} and F^- with a Third Ligand. *Coord. Chem. Rev.* **1996**, *149*, 23–32.
- (375) Sondek, J.; Lambright, D. G.; Noel, J. P.; Hamm, H. E.; Sigler, P. B. GTPase Mechanism of Gproteins from the 1.7-Å Crystal Structure of Transducin α -GDP· AlF_4^- . *Nature* **1994**, *372*, 276–279.
- (376) Chabre, M. Aluminofluoride and Berylliofluoride Complexes: New Phosphate Analogs in Enzymology. *Trends Biochem. Sci.* **1990**, *15*, 6–10.
- (377) Li, L. The Biochemistry and Physiology of Metallic Fluoride: Action, Mechanism, and Implications. *Crit. Rev. Oral Biol. Med.* **2003**, *14*, 100–114.
- (378) Takai, Y.; Sasaki, T.; Matozaki, T. Small GTP-Binding Proteins. *Physiol. Rev.* **2001**, *81*, 153–208.
- (379) Burgstahler, A. W. Paradoxical Dose-Response Effects of Fluoride. *Fluoride* **2002**, *35*, 143–147.
- (380) Strunecka, A.; Strunecky, O. Chronic Fluoride Exposure and the Risk of Autism Spectrum Disorder. *Int. J. Environ. Res. Public Health* **2019**, *16*, 3431.
- (381) Vieira, A. P. G. F.; Hanocock, R.; Eggertsson, H.; Everett, E. T.; Grynypas, M. D. Tooth Quality in Dental Fluorosis: Genetic and Environmental Factors. *Calcif. Tissue Int.* **2005**, *76*, 17–25.
- (382) Everett, E. T. Fluoride's Effects on the Formation of Teeth and Bones, and the Influence of Genetics. *J. Dent. Res.* **2011**, *90*, 552–560.
- (383) Pramanik, S.; Saha, D. The Genetic Influence in Fluorosis. *Environ. Toxicol. Pharmacol.* **2017**, *56*, 157–162.
- (384) Akinawa, K. Re-Examination of Acute Toxicity of Fluoride. *Fluoride* **1997**, *30*, 89–104.
- (385) European Food Safety Authority Panel on Dietetic Products, Nutrition, and Allergies. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a Request from the Commission Related to the Tolerable Upper Intake Level of Fluoride. *EFSA J.* **2005**, *192*, 1–65.
- (386) Whitford, G. M. Acute Toxicity of Ingested Fluoride. *Monogr. Oral Sci.* **2011**, *22*, 66–80.
- (387) Hodge, H. C.; Smith, F. A. Biological Effects of Inorganic Fluorides. In *Fluorine Chemistry*; Simons, J. H., Ed.; Academic Press: New York, U.S.A., 1965; pp 1–364.
- (388) Susheela, A. K. Fluoride and Fluorosis Mitigation: Indian Contributions and Its Impact. In *Water and Sanitation in the New Millennium*; Nath, K. J., Sharma, V. P., Eds.; Springer: New Delhi, India, 2017; pp 97–105.
- (389) Jia, B.; Zong, L.; Lee, J. Y.; Lei, J.; Zhu, Y.; Xie, H.; Clemens, J. L.; Feller, M. C.; Na, Q.; Dong, J.; McLane, M. W.; Jones-Beatty, K.; Burd, I. Maternal Supplementation of Low Dose Fluoride Alleviates Adverse Perinatal Outcomes Following Exposure to Intrauterine Inflammation. *Sci. Rep.* **2019**, *9*, 2575.
- (390) DenBesten, P.; Li, W. Chronic Fluoride Toxicity: Dental Fluorosis. *Monogr. Oral Sci.* **2011**, *22*, 81–96.
- (391) Sierant, M. L.; Bartlett, J. D. A Potential Mechanism for the Development of Dental Fluorosis. In *Interface Oral Health Science*; Sasaki, K., Ed.; Springer Verlag: Tokyo, Japan, 2011; pp 408–412.
- (392) DenBesten, P. K. Biological Mechanisms of Dental Fluorosis Relevant to the Use of Fluoride Supplements. *Community Dent. Oral Epidemiol.* **1999**, *27*, 41–47.
- (393) Bronckers, A. L. J. J.; Lyaruu, D. M.; DenBesten, P. K. The Impact of Fluoride on Ameloblasts and the Mechanisms of Enamel Fluorosis. *J. Dent. Res.* **2009**, *88*, 877–893.
- (394) Porto, I. M.; Saiani, R. A.; Chan, K. L. A.; Kazarian, S. G.; Gerlach, R. F.; Bachmann, L. Organic and Inorganic Content of Fluorotic Rat Incisors Measured by FTIR Spectroscopy. *Spectrochim. Acta, Part A* **2010**, *77*, 59–63.
- (395) Fejerskov, O.; Larsen, M. J.; Richards, A.; Baelum, V. Dental Tissue Effects of Fluoride. *Adv. Dent. Res.* **1994**, *8*, 15–31.
- (396) Warren, J. J.; Levy, S. M.; Broffitt, B.; Cavanaugh, J. E.; Kanellis, M. J.; Weber-Gasparoni, K. Considerations on Optimal Fluoride Intake Using Dental Fluorosis and Dental Caries Outcomes-A Longitudinal Study. *J. Public Health Dent.* **2009**, *69*, 111–115.
- (397) Dean, H. T.: The Investigation of Physiological Effects by the Epidemiological Method. In *Fluorine and Dental Health*; Moulton, F. R., Ed.; American Association for the Advancement of Science: Washington, D.C., U.S.A., 1942; pp 23–31.
- (398) Thylstrup, A.; Fejerskov, O. Clinical Appearance of Dental Fluorosis in Permanent Teeth in Relation to Histologic Changes. *Community Dent. Oral Epidemiol.* **1978**, *6*, 315–328.
- (399) Fomon, S. J.; Ekstrand, J.; Ziegler, E. E. Fluoride Intake and Prevalence of Dental Fluorosis: Trends in Fluoride Intake with Special Attention to Infants. *J. Public Health Dent.* **2000**, *60*, 131–139.
- (400) Beltrán-Aguilar, E. D.; Barker, L.; Dye, B. A. Prevalence and Severity of Dental Fluorosis in the United States, 1999–2004. *NCHS Data Brief* **2010**, *53*, 1–7.
- (401) Neurath, C.; Limeback, H.; Osmunson, B.; Connett, M.; Kanter, V.; Wells, C. R. Dental Fluorosis Trends in US Oral Health Surveys: 1986 to 2012. *JDR Clin. Trans. Res.* **2019**, *4*, 298–308.
- (402) Qin, X.; Wang, S.; Yu, M.; Zhang, L.; Li, X.; Zuo, Z.; Zhang, X.; Wang, L. Child Skeletal Fluorosis from Indoor Burning of Coal in Southwestern China. *J. Environ. Public Health* **2009**, 969764.
- (403) Chen, Y.; Yan, W.; Hui, X. Treatment and Prevention of Skeletal Fluorosis. *Biomed. Environ. Sci.* **2017**, *30*, 147–149.
- (404) World Health Organization. *Fluoride in Drinking Water*; World Health Organization: Geneva, 2004.

- (405) Khandare, A. L.; Harikumar, R.; Sivakumar, B. Severe Bone Deformities in Young Children Residing from Vitamin D Deficiency and Fluorosis in Bihar-India. *Calcif. Tissue Int.* **2005**, *76*, 412–418.
- (406) Shulman, J. D.; Wells, L. M. Acute Fluoride Toxicity from Ingesting Home-use Dental Products in Children, Birth to 6 Years of Age. *J. Public Health Dent.* **1997**, *57*, 150–158.
- (407) National Research Council. *Fluoride in Drinking Water: A Scientific Review of EPA's Standards*; The National Academies Press: Washington, D.C., 2006.
- (408) Hagenauer, D.; Shea, B.; Tugwell, P.; Wells, G. A.; Welch, V. Fluoride for Treating Postmenopausal Osteoporosis. *Cochrane Database Syst. Rev.* **2000**, CD002825.
- (409) Davenport, H. W. Salicylate Damage to Gastric Mucosal Barrier. *N. Engl. J. Med.* **1967**, *276*, 1307–1312.
- (410) Das, T. K.; Susheela, A. K.; Gupta, I. P.; Dasarathy, S.; Tandon, R. K. Toxic Effects of Chronic Fluoride Ingestion on the Upper Gastrointestinal Tract. *J. Clin. Gastroenterol.* **1994**, *18*, 194–199.
- (411) Gharzouli, K.; Amira, S.; Khenouf, S.; Gharzouli, A. Effects of Sodium Fluoride on Water and Acid Secretion, Soluble Mucus and Adherent Mucus of the Rat Stomach. *Can. J. Gastroenterol.* **2000**, *14*, 493–498.
- (412) Ludlow, M.; Luxton, G.; Mathew, T. Effects of Fluoridation of Community Water Supplies for People with Chronic Kidney Disease. *Nephrol., Dial., Transplant.* **2007**, *22*, 2763–2767.
- (413) Schiff, H. Fluoridation of Drinking Water and Chronic Kidney Disease: Absence of Evidence Is not Evidence of Absence. *Nephrol., Dial., Transplant.* **2007**, *23*, 411.
- (414) Arnala, I.; Alhava, E. M.; Kauranen, P. Effects of Fluoride on Bone in Finland: Histomorphometry of Cadaver Bone from Low and High Fluoride Areas. *Acta Orthop. Scand.* **1985**, *56*, 161–166.
- (415) Naidu, M. R. C.; Sastry, K. V. R.; Reddy, K.; Reddy, D. R. Skeletal Fluorosis. Secondary to Occult Renal Disease. *Fluoride* **1986**, *19*, 166–168.
- (416) Dharmaratne, R. W. Exploring the Role of Excess Fluoride in Chronic Kidney Disease: A Review. *Hum. Exp. Toxicol.* **2019**, *38*, 269–279.
- (417) Quadri, J. A.; Sarwar, S.; Sinha, A.; Kalavani, M.; Dinda, A. K.; Bagga, A.; Roy, R. S.; Das, T. K.; Shariff, A. Fluoride-Associated Ultrastructural Changes and Apoptosis in Human Renal Tubule: A Pilot Study. *Hum. Exp. Toxicol.* **2018**, *37*, 1199–1206.
- (418) Liu, J. L.; Xia, T.; Yu, Y. Y.; Sun, X. Z.; Zhu, Q.; He, W.; Zhang, M.; Wang, A. The Dose-Effect Relationship of Water Fluoride Levels and Renal Damage in Children. *Wei Sheng Yan Jiu* **2005**, *34*, 287–288.
- (419) Singh, P. P.; Barjatiya, M. K.; Dhing, S.; Bhatnagar, R.; Kothari, S.; Dhar, V. Evidence Suggesting that High Intake of Fluoride Provokes Nephrolithiasis in Tribal populations. *Urol. Res.* **2001**, *29*, 238–244.
- (420) Wimalawansa, S. J. Does Fluoride Cause the Mysterious Chronic Kidney Disease of Multifactorial Origin? *Environ. Geochem. Health* **2020**, *42*, 3035–3057.
- (421) Barbosa da Silva Pereira, H. A.; Dionizio, A. S.; Araujo, T. T.; Fernandes, M. S.; Iano, F. G.; Buzalaf, M. A. R. Proposed Mechanism for Understanding the Dose- and Time-Dependency of the Effects of Fluoride in the Liver. *Toxicol. Appl. Pharmacol.* **2018**, *358*, 68–75.
- (422) Perera, T.; Ranasinghe, S.; Alles, N.; Waduge, R. Effect of Fluoride on Major Organs with the Different Time of Exposure in Rats. *Environ. Health Prev. Med.* **2018**, *23*, 17.
- (423) Xiong, X.; Liu, J.; Hea, W.; Xia, T.; He, P.; Chen, X.; Yang, K.; Wang, A. Dose-Effect Relationship between Drinking Water Fluoride Levels and Damage to Liver and Kidney Functions in Children. *Environ. Res.* **2007**, *103*, 112–116.
- (424) Malin, A. J.; Lesseur, C.; Busgang, S. A.; Curtin, P.; Wright, R. O.; Sanders, A. P. Fluoride Exposure and Kidney and Liver Function Among Adolescents in the United States: NHANES, 2013–2016. *Environ. Int.* **2019**, *132*, 1050122.
- (425) Mazze, R. I.; Raja, S. N. Methoxyflurane Revisited. *Anesthesiology* **2006**, *105*, 843–846.
- (426) Susheela, A. K.; Kharb, P. Aortic Calcification in Chronic Fluoride Poisoning: Biochemical and Electronmicroscopic Evidence. *Exp. Mol. Pathol.* **1990**, *53*, 72–80.
- (427) Janssen, T.; Bannas, P.; Herrmann, J.; Veldhoen, S.; Busch, J. D.; Treszl, A.; Münster, S.; Mester, J.; Derlin, T. Association of Linear ¹⁸F-Sodium Fluoride Accumulation in Femoral Arteries as a Measure of Diffuse Calcification with Cardiovascular Risk Factors: A PET/CT Study. *J. Nucl. Cardiol.* **2013**, *20*, 569–577.
- (428) Sun, L.; Gao, Y.; Liu, H.; Zhang, W.; Ding, Y.; Li, B.; Li, M.; Sun, D. An Assessment of the Relationship between Excess Fluoride Intake from Drinking Water and Essential Hypertension in Adults Residing in Fluoride Endemic Areas. *Sci. Total Environ.* **2013**, *443*, 864–869.
- (429) Masaki, T. Historical Review: Endothelin. *Trends Pharmacol. Sci.* **2004**, *25*, 219–224.
- (430) Khimji, A.; Rockey, D. C. Endothelin-Biology and Disease. *Cell. Signalling* **2010**, *22*, 1615–1625.
- (431) Jimenez-Cordova, M. I.; Gonzalez-Horta, C.; Ayllon-Vergara, J. C.; Arreola-Mendoza, L.; Aguilar-Madrid, G.; Villareal-Vega, E. E.; Barrera-Hernandez, A.; Barbier, O. C.; Del Razo, L. M. Evaluation of Vascular and Kidney Injury Biomarkers in Mexican Children Exposed to Inorganic Fluoride. *Environ. Res.* **2019**, *169*, 220–228.
- (432) Karademir, S.; Akçam, M.; Kuybulu, A. E.; Olgar, S.; Öktem, F. Effects of Fluorosis on QT Dispersion, Heart Rate Variability and Echocardiographic Parameters in Children. *Anadolu Kardiyol. Derg.* **2011**, *1*, 150–155.
- (433) Xu, R.; Xu, R. Electrocardiogram Analysis of Patients with Skeletal Fluorosis. *Fluoride* **1997**, *30*, 16–18.
- (434) Varol, E.; Akçay, S.; Hakký Ersoy, Y.; Özyaydın, M.; Köroğlu, B. K.; Varol, S. Electrocardiographic Evaluation in Patients with Endemic Fluorosis without Clinically Evident Heart Disease. *S.D.Ü. Tıp Fak. Derg.* **2010**, *17*, 9–14.
- (435) Varol, E.; Akçay, S.; Ersoy, I. H.; Ozaydin, M.; Koroglu, B. K.; Varol, S. Aortic Elasticity is Impaired in Patients with Endemic Fluorosis. *Biol. Trace Elem. Res.* **2010**, *133*, 121–127.
- (436) Varol, E.; Akçay, S.; Ersoy, I. H.; Koroglu, B. K.; Varol, S. Impact of Chronic Fluorosis on Left Ventricular Diastolic and Global Functions. *Sci. Total Environ.* **2010**, *408*, 2295–2298.
- (437) Liu, H.; Gao, Y.; Sun, L.; Li, M.; Li, B.; Sun, D. Assessment of Relationship on Excess Fluoride Intake from Drinking Water and Carotid Atherosclerosis Development in Adults in Fluoride Endemic Areas, China. *Int. J. Hyg. Environ. Health* **2014**, *217*, 413–420.
- (438) Amini, H.; Taghavi Shahri, S. M.; Amini, M.; Ramezani Mehriani, M.; Mokhayeri, Y.; Yunesian, M. Drinking Water Fluoride and Blood Pressure? An Environmental Study. *Biol. Trace Elem. Res.* **2011**, *144*, 157–163.
- (439) Yousefi, M.; Yaseri, M.; Nabizadeh, R.; Hooshmand, E.; Jalilzadeh, M.; Mahvi, A. H.; Mohammadi, A. A. Association of Hypertension, Body Mass Index, and Waist Circumference with Fluoride Intake; Water Drinking in Residents of Fluoride Endemic Areas, Iran. *Biol. Trace Elem. Res.* **2018**, *185*, 282–288.
- (440) Kaipio, J.; Näyhä, A.; Valtonen, V. Fluoride in the Drinking Water and the Geographical Variation of Coronary Heart Disease in Finland. *Eur. J. Cardiovasc. Prev. Rehabil.* **2004**, *11*, 56–62.
- (441) Nasman, P.; Granath, F.; Ekstrand, J.; Ekblom, A.; Sandborgh-Englund, G.; Fored, C. M. Natural Fluoride in Drinking Water and Myocardial Infarction: A Cohort Study in Sweden. *Sci. Total Environ.* **2016**, *562*, 305–311.
- (442) Varol, E.; Varol, S. Water-Borne Fluoride and Primary Hypertension. *Fluoride* **2013**, *46*, 3–6.
- (443) Knust, K. S.; Leung, A. M. Iodine: Basic Nutritional Aspects. In *Molecular, Genetic, and Nutritional Aspects of Major and Trace Minerals*; Collins, J. F., Ed.; Elsevier: Amsterdam, The Netherlands, 2017; pp 133–157.
- (444) Carter, P. H.; Schipani, E. The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics. *Endocr., Metab. Immune Disord.: Drug Targets* **2006**, *6*, 59–76.
- (445) Galletti, P. M.; Joyet, G. Effect of Fluorine on Thyroidal Iodine Metabolism in Hyperthyroidism. *J. Clin. Endocrinol. Metab.* **1958**, *18*, 1102–1110.

- (446) Waugh, D. T. Fluoride Exposure Induces Inhibition of Sodium/Iodide Symporter (NIS) Contributing to Impaired Iodine Absorption and Iodine Deficiency: Molecular Mechanisms of Inhibition and Implications for Public Health. *Int. J. Environ. Res. Public Health* **2019**, *16*, 1086.
- (447) Day, T. K.; Powell-Jackson, P. R. Fluoride, Water Hardness, and Endemic Goitre. *Lancet* **1972**, *299*, 1135–1138.
- (448) Xu, Y.; Lu, C.; Zhang, X. The Effect of Fluoride on the Level of Intelligence in Children. *Endem. Dis. Bull.* **1994**, *9*, 83–84.
- (449) Peckham, S.; Lowery, D.; Spencer, S. Are Fluoride Levels in Drinking Water Associated with Hypothyroidism Prevalence in England? A Large Observational Study of GP Practice Data and Fluoride Levels in Drinking Water. *J. Epidemiol. Community Health* **2015**, *0*, 1–6.
- (450) Kheradpisheh, Z.; Mirzaei, M.; Mahvi, A. H.; Mokhtari, M.; Azizi, R.; Fallahzadeh, H.; Ehrampoush, M. H. Impact of Drinking Water Fluoride on Human Thyroid Hormones: A Case- Control Study. *Sci. Rep.* **2018**, *8*, 2674.
- (451) Barberio, A. M.; Hosein, F. S.; Quiñonez, C.; McLaren, L. Fluoride Exposure and Indicators of Thyroid Functioning in the Canadian Population: Implications for Community Water Fluoridation. *J. Epidemiol. Community Health* **2017**, *71*, 1019–1025.
- (452) Malin, A. J.; Riddell, J.; McCague, H.; Till, C. Fluoride Exposure and Thyroid Function Among Adults Living in Canada: Effect Modification by Iodine Status. *Environ. Int.* **2018**, *121*, 667–674.
- (453) Puranik, C. P.; Ryan, K. A.; Yin, Z.; Martinez-Mier, E. A.; Preisser, J. S.; Everrett, E. T. Fluoride Modulates Parathyroid Hormone Secretion in vivo and in vitro. *Cells Tissues Organs* **2015**, *200*, 413–423.
- (454) Wang, Y.; Duan, X.; Zhao, Z.; Zhang, X.; Wang, H.; Liu, D.; Li, G.; Jing, L. Fluoride Affects Calcium Homeostasis by Regulating Parathyroid Hormone, PTH-Related Peptide, and Calcium-Sensing Receptor Expression. *Biol. Trace Elem. Res.* **2015**, *165*, 159–166.
- (455) Koroglu, B. K.; Ersoy, I. H.; Koroglu, M.; Balkarli, A.; Ersoy, S.; Varol, S.; Tamer, M. N. Serum Parathyroid Hormone Levels in Chronic Endemic Fluorosis. *Biol. Trace Elem. Res.* **2011**, *143*, 79–86.
- (456) Grandjean, P.; Landrigan, P. J. Neurobehavioural Effects of Developmental Toxicity. *Lancet Neurol.* **2014**, *13*, 330–338.
- (457) Gelinis, J.; Allukian, M. Jr. Neurodevelopmental Toxicity: Still More Questions Than Answers. *Lancet Neurol.* **2014**, *13*, 647–648.
- (458) Grandjean, P.; Landrigan, P. J. Neurodevelopmental Toxicity: Still More Questions than Answers - Authors' Response. *Lancet Neurol.* **2014**, *13*, 648–649.
- (459) Shen, Y. W.; Taves, D. R. Fluoride Concentrations in the Human Placenta and Maternal and Cord Blood. *Am. J. Obstet. Gynecol.* **1974**, *119*, 205–207.
- (460) Ron, M.; Singer, L.; Menczel, J.; Kidroni, G. Fluoride Concentration in Amniotic Fluid and Fetal Cord and Maternal Plasma. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **1986**, *21*, 213–218.
- (461) Varner, J. A.; Jensen, K. F.; Horvath, W.; Isaacson, R. L. Chronic Administration of Aluminum-Fluoride or Sodium-Fluoride to Rats in Drinking Water: Alterations in Neuronal and Cerebrovascular Integrity. *Brain Res.* **1998**, *784*, 284–298.
- (462) Blaylock, R. L. Excitotoxicity: A Possible Central Mechanism in Fluoride Neurotoxicity. *Fluoride* **2004**, *37*, 301–314.
- (463) Tang, Q.; Du, J.; Ma, H.; Jiang, S.; Zhou, X. Fluoride and Children's Intelligence: A Meta-analysis. *Biol. Trace Elem. Res.* **2008**, *126*, 115–120.
- (464) Choi, A. L.; Sun, G.; Zhang, Y.; Grandjean, P. Developmental Fluoride Neurotoxicity: A Systematic Review and Meta-Analysis. *Environ. Health Perspect.* **2012**, *120*, 1362–1368.
- (465) Duan, Q.; Jiao, J.; Chen, X.; Wang, X. Association between Water Fluoride and the Level of Children's Intelligence: A Dose-Response Meta-analysis. *Public Health* **2018**, *154*, 87–97.
- (466) Bashash, M.; Thomas, D.; Hu, H.; Angeles Martinez-Mier, E.; Sanchez, B. N.; Basu, N.; Peterson, K. E.; Ettinger, A. S.; Wright, R.; Zhang, Z.; Liu, Y.; Schnaas, L.; Mercado-Garcia, A.; Maria Tellez-Rojo, M.; Hernandez-Avila, M.; et al. Prenatal Fluoride Exposure and Cognitive Outcomes in Children at 4 and 6–12 Years of Age in Mexico. *Environ. Health Perspect.* **2017**, *125*, 097017.
- (467) Bashash, M.; Marchand, M.; Hu, H.; Till, C.; Martinez-Mier, E. A.; Sanchez, B. N.; Basu, N.; Peterson, K. E.; Green, R.; Schnaas, L.; Mercado-Garcia, A.; Hernandez-Avila, M.; Tellez-Rojo, M. M.; et al. Prenatal Fluoride Exposure and Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Children at 6–12 Years of Age in Mexico City. *Environ. Int.* **2018**, *121*, 658–666.
- (468) Green, R.; Lanphear, B.; Hornung, R.; Flora, D.; Martinez-Mier, E. A.; Neufeld, R.; Ayotte, P.; Muckle, G.; Till, C. Association Between Maternal Fluoride Exposure During Pregnancy and IQ Scores in Offspring in Canada. *JAMA Pediatr.* **2019**, *173*, 940–948.
- (469) Till, C.; Green, R.; Flora, D.; Hornung, R.; Martinez-Mier, E. A.; Blazer, M.; Farmus, L.; Ayotte, P.; Muckle, G.; Lanphear, B. Fluoride Exposure from Infant Formula and Child IQ in a Canadian Birth Cohort. *Environ. Int.* **2020**, *134*, 105315.
- (470) Riddell, J. K.; Malin, A. J.; Flora, D.; McCague, H.; Till, C. Association of Water Fluoride and Urinary Fluoride Concentrations with Attention Deficit Hyperactivity Disorder in Canadian Youth. *Environ. Int.* **2019**, *133*, 105190.
- (471) Barberio, A. M.; Quiñonez, C.; Hosein, F. S.; McLaren, L. Fluoride Exposure and Reported Learning Disability Diagnosis among Canadian Children: Implications for Community Water Fluoridation. *Can. J. Public Health* **2017**, *108*, No. e229–e239.
- (472) Still, C. N.; Kelley, P. On the Incidence of Primary Degenerative Dementia vs Water Fluoride Content in South Carolina. *Neurotoxicology* **1980**, *1*, 125–131.
- (473) Russ, T. C.; Killin, L. O. J.; Hannah, J.; Batty, G. D.; Deary, I. J.; Starr, J. M. Aluminium and Fluoride in Drinking Water in Relation to Later Dementia Risk. *Br. J. Psychiatry* **2020**, *216*, 29–34.
- (474) Radicchi, F. In Science There is no Bad Publicity: Papers Criticized in Comments Have High Scientific Impact. *Sci. Rep.* **2012**, *2*, 815.
- (475) Sapède, D.; Cau, E. The Pineal Gland from Development to Function. In *Current Topics in Developmental Biology*; Thomas, P., Ed.; Elsevier: Amsterdam, The Netherlands, 2013; Vol. 106, pp 171–215.
- (476) Luke, J. Fluoride Deposition in the Aged Human Pineal Gland. *Caries Res.* **2001**, *35*, 125–128.
- (477) Mrvelj, A.; Womble, M. D. Fluoride-Free Diet Stimulates Pineal Growth in Aged Male Rats. *Biol. Trace Elem. Res.* **2020**, *197*, 175–183.
- (478) Schlesinger, E. R.; Overton, D. E.; Chase, H. C.; Cantwell, K. T. Newburgh-Kingston Caries-Fluorine Study X III. Pediatric Findings after Ten Years. *J. Am. Dent. Assoc., JADA* **1956**, *52*, 296–306.
- (479) Farkas, G.; Fazekas, A.; Szekeres, E. The Fluoride Content of Drinking Water and the Menarcheal Age. *Acta Biol. Szeged.* **1983**, *29*, 1–4.
- (480) Liu, Y.; Téllez-Rojo, M.; Hu, H.; Sánchez, B. N.; Martinez-Mier, E. A.; Basu, N.; Mercado-García, A.; Solano-González, M.; Peterson, K. E. *Environ. Health* **2019**, *18*, 26.
- (481) Sun, Z.; Niu, R.; Wang, B.; Jiao, Z.; Wang, J.; Zhang, J.; Wang, S.; Wang, J. Fluoride-Induced Apoptosis and Gene Expression Profiling in Mice Sperm in Vivo. *Arch. Toxicol.* **2011**, *85*, 1441–1552.
- (482) Yang, Y.; Huang, H.; Ba, Y.; Cheng, Y.; Cui, L. Effect of Oxidative Stress on Fluoride-Induced Apoptosis in Primary Cultured Sertoli Cells of rats. *Int. J. Int. J. Environ. Health Res.* **2015**, *1*, 1–9.
- (483) Niu, R.; Wang, J.; Sun, Z.; Xue, X.; Yan, X.; Wang, J.; Zhang, J.; Wang, J. Transcriptional Regulatory Dynamics of the Hypothalamic-Pituitary-Testicular Axis in Male Mice Exposed to fluoride. *Environ. Toxicol. Pharmacol.* **2015**, *40*, 557–562.
- (484) Lu, Z.; Wang, S.; Sun, Z.; Niu, R.; Wang, J. In Vivo Influence of Sodium Fluoride on Sperm Chemotaxis in Male Mice. *Arch. Toxicol.* **2014**, *88*, 533–539.
- (485) Kumar, N.; Sood, S.; Arora, B.; Singh, M.; Beena. Effect of Duration of Fluoride Exposure on the Reproductive System in Male Rabbits. *J. Hum. Reprod. Sci.* **2010**, *3*, 148–152.
- (486) Han, H.; Sun, Z.; Luo, G.; Wang, C.; Wei, W.; Wang, J. Fluoride Exposure Changed the Structure and the Expressions of Reproductive Related Genes in the Hypothalamus-Pituitary-Testicular Axis of Male Mice. *Chemosphere* **2015**, *135*, 297–303.

- (487) Sun, Z.; Xue, X.; Zhang, Y.; Niu, R.; Wang, J. Effect of Sodium Fluoride on the Sperm Mitochondrial DNA in Mice. *Biochem. Biophys. Res. Commun.* **2017**, *492*, 295–299.
- (488) Zhou, Y.; Zhang, H.; He, J.; Chen, X.; Ding, Y.; Wang, Y.; Liu, X. Effects of Sodium Fluoride on Reproductive Function in Female Rats. *Food Chem. Toxicol.* **2013**, *56*, 297–303.
- (489) Fu, M.; Wu, X.; He, J.; Zhang, Y.; Hua, S. Sodium Fluoride Influences Methylation Modifications and Induces Apoptosis in Mouse Early Embryos. *Environ. Sci. Technol.* **2014**, *48*, 10398–10405.
- (490) Zhu, J.; Si, Y.; Cheng, L.; Xu, B.; Wang, Q.; Zhang, X.; Wang, H.; Liu, Z. Sodium Fluoride Disrupts DNA Methylation of H19 and Peg3 Imprinted Genes During the Early Development of Mouse Embryo. *Arch. Toxicol.* **2014**, *88*, 241–248.
- (491) Liang, S.; Zhao, M.; Ock, S. A.; Kim, N.; Cui, X. Fluoride Impairs Oocyte Maturation and Subsequent Embryonic Development in Mice. *Environ. Toxicol.* **2016**, *31*, 1486–1495.
- (492) Liang, S.; Nie, Z.; Zhao, M.; Niu, Y.; Shin, K.; Cui, X. Sodium Fluoride Exposure Exerts Toxic Effects on Porcine Oocyte Maturation. *Sci. Rep.* **2017**, *7*, 17082.
- (493) Liu, X.; Nie, Z.; Gao, Y.; Chen, L.; Yin, S.; Zhang, X.; Hao, C.; Miao, Y. Sodium Fluoride Disturbs DNA Methylation of NNAT and Declines Oocyte Quality by Impairing Glucose Transport in Porcine Oocytes. *Environ. Mol. Mutagen.* **2018**, *59*, 223–233.
- (494) Freni, S. C. Exposure to High Fluoride Concentrations in Drinking Water is Associated with Decreased Birth Rates. *J. Toxicol. Environ. Health* **1994**, *42*, 109–121.
- (495) Susheela, A. K.; Jethanandani, P. Circulating Testosterone Levels in Skeletal Fluorosis Patients. *J. Toxicol., Clin. Toxicol.* **1996**, *34*, 183–189.
- (496) Ortiz-Pérez, D.; Rodríguez-Martínez, M.; Martínez, F.; Borja-Aburto, V. H.; Castelo, J.; Grimaldo, J. I.; de la Cruz, E.; Carrizales, L.; Diaz-Barriga, F. Fluoride-Induced Disruption of Reproductive Hormones in Men. *Environ. Res.* **2003**, *93*, 20–30.
- (497) Hao, P.; Ma, X.; Cheng, X.; Ba, Y.; Zhu, J.; Cui, L. Effect of Fluoride on Human Hypothalamus-Hypophysis-Testis Axis Hormones. *Wei Sheng Yan Jiu* **2010**, *39*, 53–55.
- (498) Duan, L.; Zhu, J.; Wang, K.; Zhou, G.; Yang, Y.; Cui, L.; Huang, H.; Cheng, X.; Ba, Y. Does Fluoride Affect Serum Testosterone and Androgen Binding Protein with Age-Specificity? A Population-Based Cross-Sectional Study in Chinese Male Farmers. *Biol. Trace Elem. Res.* **2016**, *174*, 294–299.
- (499) Ma, Q.; Huang, H.; Sun, L.; Zhou, T.; Zhu, J.; Cheng, X.; Duan, L.; Li, Z.; Cui, L.; Ba, Y. Gene-Environment Interaction: Does Fluoride Influence the Reproductive Hormones in Male Farmers Modified by ERA Gene Polymorphisms? *Chemosphere* **2017**, *188*, 525–531.
- (500) Zhao, M.; Zhou, G.; Zhu, J.; Gong, B.; Hou, J.; Zhou, T.; Duan, L.; Ding, Z.; Cui, L.; Ba, Y. Fluoride Exposure, Follicle Stimulating Hormone Receptor Gene Polymorphism and Hypothalamus-pituitary-ovarian Axis Hormones in Chinese Women. *Biomed. Environ. Sci.* **2015**, *28*, 696–700.
- (501) Bayless, J. M.; Tinanoff, N. Diagnosis and Treatment of Acute Fluoride Toxicity. *J. Am. Dent. Assoc., JADA* **1985**, *110*, 209–211.
- (502) McIvor, M. E. Acute Fluoride Toxicity. *Drug Saf.* **1990**, *5*, 79–85.
- (503) Mumtaz, N. A Study on Integrated Fluorosis Mitigation Plan for Endemic Fluorosis - An Indian Perspective. *Int. J. Civ. Eng. Technol.* **2017**, *8*, 94–91.
- (504) Susheela, A. K.; Mondal, N. K.; Tripathi, N.; Gupta, R. Early Diagnosis and Complete Recovery from Fluorosis Through Practice of Interventions. *J. Assoc. Physicians India* **2014**, *62*, 572–579.
- (505) Thangapandiyar, S.; Miltonprabu, S. Molecular Mechanism of Fluoride Induced Oxidative Stress and Its Possible Reversal by Chelation Therapy. *Res. Rev. J. Toxicol.* **2013**, *3*, 1–19.
- (506) Susheela, A. K.; Toteja, G. S. Prevention & Control of Fluorosis & Linked Disorders: Developments in the 21st Century - Reaching Out to Patients in the Community & Hospital Settings for Recovery. *Indian J. Med. Res.* **2018**, *148*, 539–547.
- (507) United States National Research Council. *Biologic Markers in Reproductive Toxicology*; The National Academies Press: Washington, D.C., 1989.
- (508) World Health Organization. *Biomarkers and Risk Assessment: Concepts and Principles, Environmental Health Criteria 155*; World Health Organization: Geneva, 1993.
- (509) Pessan, J. P.; Buzalaf, M. A. R. Historical and Recent Biological Markers of Exposure to Fluoride. *Monogr. Oral Sci.* **2011**, *22*, 52–65.
- (510) Rugg-Gunn, M. A. R.; Villa, A. E.; Buzalaf, M. A. R. Contemporary Biological Markers of Exposure to Fluoride. *Monogr. Oral Sci.* **2011**, *22*, 37–51.
- (511) World Health Organization. *Basic Methods for Assessment of Renal Fluoride Excretion in Community Prevention Programmes for Oral Health*; World Health Organization: Geneva, 2014.
- (512) Mehta, A. Biomarkers of Fluoride Exposure in Human Body. *Indian J. Dent.* **2013**, *4*, 207–210.
- (513) Agali, R. C.; Shintre, S. B. Biological Markers of Fluoride Exposure: A Review Article. *IJSS Rep. Rev.* **2016**, *2*, 49–52.
- (514) Oliveby, A.; Lagerlof, F.; Ekstrand, J.; Dawes, C. Influence of Flow Rate, pH, Plasma Fluoride Concentrations on Fluoride Concentration in Human Parotid Saliva. *Arch. Oral Biol.* **1989**, *34*, 191–194.
- (515) Oliveby, A.; Lagerlof, F.; Ekstrand, J.; Dawes, C. Studies on Fluoride Concentrations in Human Submandibular/Sublingual Saliva and their Relation to Flow Rate and Plasma Fluoride Levels. *J. Dent. Res.* **1989**, *68*, 146–149.
- (516) Sener, Y.; Tosuna, G.; Kahvecioğlu, F.; Gökalp, A.; Koç, H. Fluoride Levels of Human Plasma and Breast Milk. *Eur. J. Dent.* **2007**, *1*, 21–24.
- (517) Campus, G.; Congiu, G.; Cocco, F.; Sale, S.; Cagetti, M. G.; Sanna, G.; Lingström, P.; Garcia-Godoy, F. Fluoride Content in Breast Milk After the Use of Fluoridated Food Supplement: A Randomized Clinical Trial. *Am. J. Dent.* **2014**, *27*, 199–202.
- (518) Poureslami, H.; Khazaeli, P.; Mahvi, A. H.; Poureslami, K.; Poureslami, P.; Haghani, J.; Aghaei, M. Fluoride Level in the Breast Milk in Koohbanan, a City with Endemic Dental fluorosis. *Fluoride* **2016**, *49*, 485–494.
- (519) Spittle, B. Fluoride in Human Breast Milk. *Fluoride* **2016**, *49*, 471.
- (520) Whitford, G. M. *The Metabolism and Toxicology of Fluoride*, 2nd ed.; Karger: Basel, 1996.
- (521) Hopps, H. C. The Biologic Bases for Using Hair and Nail for Analyses of Trace Elements. *Sci. Total Environ.* **1977**, *7*, 71–89.
- (522) Fukushima, R.; Rigolizzo, D. S.; Maia, L. P.; Sampaio, F. C.; Lauris, J. R. P.; Buzalaf, M. A. R. Environmental and Individual Factors Associated with Nail Fluoride Concentration. *Caries Res.* **2009**, *43*, 147–154.
- (523) Buzalaf, M. A. R.; Pessan, J. P.; Alves, K. M. R. P. Influence of Growth Rate and Length on Fluoride Detection in Human Nails. *Caries Res.* **2006**, *40*, 231–238.
- (524) Whitford, G. M.; Sampaio, F. C.; Arneberg, P.; von der Fehr, F. R. Fingernail Fluoride: A Method for Monitoring Fluoride Exposure. *Caries Res.* **1999**, *33*, 462–467.
- (525) Whitford, G. M. Monitoring Fluoride Exposure with Fingernail Clippings. *Schweiz. Monatsschr. Zahnmed.* **2005**, *115*, 685–689.
- (526) Elekdag-Turk, S.; Almuzian, M.; Turk, T.; Buzalaf, M. A. R.; Alnuaimi, A.; Dalci, O.; Darendeliler, M. A. Big Toenail and Hair Samples as Biomarkers for Fluoride Exposure - A Pilot Study. *BMC Oral Health* **2019**, *19*, 82.
- (527) Czarnowski, W.; Krechniak, J. Fluoride in the Urine, Hair, and Nails of Phosphate Fertiliser Workers. *Br. J. Ind. Med.* **1990**, *47*, 349–351.
- (528) Schamschula, R. G.; Sugar, E.; Un, P. S. H.; Toth, K.; Barmes, D. E.; Adkins, B. L. Physiological Indicators of Fluoride Exposure and Utilization: An Epidemiological Study. *Community Dent. Oral Epidemiol.* **1985**, *13*, 104–117.
- (529) Mandinic, Z.; Curcic, M.; Antonijevic, B.; Carevic, M.; Mandic, J.; Djukic-Cosic, D.; Lekic, C. P. Fluoride in Drinking Water and Dental Fluorosis. *Sci. Total Environ.* **2010**, *408*, 3507–3512.

- (530) Parimi, N.; Viswanath, V.; Kashyap, B.; Patil, P. U. Hair as Biomarker of Fluoride Exposure in a Fluoride Endemic Area and a Low Fluoridated Area. *Int. J. Trichology* **2013**, *5*, 148–150.
- (531) Łukomska, A.; Stachowska, E.; Rebacz-Maron, E.; Maciejewska, D.; Jakubczyk, K.; Baranowska-Bosiacka, I.; Ryterska, K.; Czerwińska, M.; Banaszczak, M.; Budrewicz, S.; et al. Fluoride Content in Hair in Dependence of the Place of Residence, Sex, Dietary habits and Anthropometric Data. *J. Elem.* **2018**, *23*, 901–911.
- (532) Joshi, N. A.; Ajithkrishnan, C. G. Scalp Hair as Biomarker for Chronic Fluoride Exposure among Fluoride Endemic and Low Fluoride Areas: A Comparative Study. *Int. J. Trichology* **2018**, *10*, 71–75.
- (533) Czarnowski, W.; Stolarska, K.; Brzezinska, B.; Krechniak, P. Fluoride in Urine, Hair and Nails of Phosphate Fertilizer Workers. *Fluoride* **1993**, *29*, 163–165.
- (534) Kokot, Z.; Drzewiecki, D. Fluoride Levels in Hair of Exposed and Unexposed Populations in Poland. *Fluoride* **2000**, *33*, 196–204.
- (535) Ophaug, R. Determination of Fluorine in Biological Materials: Reaction Paper. *Adv. Dent. Res.* **1994**, *8*, 87–91.
- (536) Rao, H. V.; Beliles, R. P.; Whitford, G. M.; Turner, C. H. A Physiologically Based Pharmacokinetic Model for Fluoride Uptake by Bone. *Regul. Toxicol. Pharmacol.* **1995**, *22*, 30–42.
- (537) Fluoride Concentrations in Human Bones. *Nutr. Rev.* **1959**, *17*, 133–136.
- (538) Allolio, B.; Lehmann, R. Drinking Water Fluoridation and Bone. *Exp. Clin. Endocrinol. Diabetes* **1999**, *107*, 12–20.
- (539) Dela Cruz, G. G.; Rozier, R. G.; Bawden, J. W. Fluoride Concentration in Dentin of Exfoliated Primary Teeth as a Biomarker for Cumulative Fluoride Exposure. *Caries Res.* **2008**, *42*, 419–428.
- (540) Vieira, A. P. G. F.; Hancock, R.; Limeback, H.; Maia, R.; Grynpas, M. D. Is Fluoride Concentration in Dentin and Enamel a Good Indicator of Dental Fluorosis? *J. Dent. Res.* **2004**, *83*, 76–80.
- (541) Vieira, A. P. G. F.; Mousny, M.; Maia, R.; Hancock, R.; Everett, E. T.; Grynpas, M. D. Assessment of Teeth as Biomarkers for Skeletal Fluoride Exposure. *Osteoporosis Int.* **2005**, *16*, 1576–1582.